Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3392233,plasma concentration at steady state,The mean plasma concentration at steady state was 1.0 ng/mL.,Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392233/),[ng] / [ml],1.0,195,DB01115,Nifedipine
,3219150,detection limit,"After methanol deproteinization and ethyl ether extraction under alkaline conditions as pretreatment, the detection limit for KW-3049 in plasma was 0.2 ng/ml using 0.5 ml of sample.",Sensitive radioreceptor assay of the calcium antagonist benidipine hydrochloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219150/),[ng] / [ml],0.2,1738,DB01115,Nifedipine
,3219150,detection limit,"For the urine, 0.05 ml of urine sample was directly added to the assay system, and detection limit of drug was 1 ng/ml.",Sensitive radioreceptor assay of the calcium antagonist benidipine hydrochloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219150/),[ng] / [ml],1,1739,DB01115,Nifedipine
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB01115,Nifedipine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],105,2145,DB01115,Nifedipine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[h·μg] / [l],111,2146,DB01115,Nifedipine
,1958451,AUC,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[h·μg] / [l],211,2147,DB01115,Nifedipine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],33,2148,DB01115,Nifedipine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],39,2149,DB01115,Nifedipine
,1958451,Cmax,"Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively.",The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958451/),[μg] / [l],76,2150,DB01115,Nifedipine
,3196403,half-lives,Elimination from most of the organs occurred quite uniformly with half-lives of 40-70 h.,Pharmacokinetics of nisoldipine. Distribution to and elimination from tissues and organs following single or repeated administration of [14C]nisoldipine to rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196403/),h,40-70,2430,DB01115,Nifedipine
,3196403,terminal half-life,The residues in the body after repeated administration were eliminated with a terminal half-life of about 10 days.,Pharmacokinetics of nisoldipine. Distribution to and elimination from tissues and organs following single or repeated administration of [14C]nisoldipine to rats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196403/),d,10,2431,DB01115,Nifedipine
excess,1587055,t 1/2 beta,Amlodipine is an exception with a t 1/2 beta in excess of 30h.,Clinical pharmacokinetics of calcium antagonists. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587055/),h,30,2483,DB01115,Nifedipine
,3958904,1.0 V,The limit of quantitation for nicardipine at 1.0 V versus Ag/AgCl was 8 ng/mL and the linear dynamic range was 15-150 ng/mL.,Intranasal delivery of nicardipine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[ng] / [ml],8,4745,DB01115,Nifedipine
,3958904,linear dynamic,The limit of quantitation for nicardipine at 1.0 V versus Ag/AgCl was 8 ng/mL and the linear dynamic range was 15-150 ng/mL.,Intranasal delivery of nicardipine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[ng] / [ml],15-150,4746,DB01115,Nifedipine
,3958904,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 5110 ng . min/mL as compared to 3730 ng . min/mL following intranasal dosing.,Intranasal delivery of nicardipine in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[min·ng] / [ml],5110,4747,DB01115,Nifedipine
,3958904,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 5110 ng . min/mL as compared to 3730 ng . min/mL following intranasal dosing.,Intranasal delivery of nicardipine in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),[min·ng] / [ml],3730,4748,DB01115,Nifedipine
,3958904,bioavailability,This corresponds to a bioavailability of 73%.,Intranasal delivery of nicardipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958904/),%,73,4749,DB01115,Nifedipine
,24903704,50% inhibition concentration (IC50 ),Licochalcone A inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC50 ) of 5.9 μm.,Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24903704/),μm,5.9,5719,DB01115,Nifedipine
,15108221,terminal half-life,"After intravenous dosing, the plasma concentration of mebudipine declined biexponentially with a terminal half-life of 2.84 h.","Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),h,2.84,6043,DB01115,Nifedipine
,15108221,blood clearance,The blood clearance was 1.67 l/h/kg and the volume of distribution at steady state was found to be 6.26 l/kg.,"Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),[l] / [h·kg],1.67,6044,DB01115,Nifedipine
,15108221,volume of distribution at steady state,The blood clearance was 1.67 l/h/kg and the volume of distribution at steady state was found to be 6.26 l/kg.,"Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),[l] / [kg],6.26,6045,DB01115,Nifedipine
,15108221,C(max),"After oral dosing (10 mg/kg), the C(max) of mebudipine was 25.9+/-9.79 ng/ml.","Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),[ng] / [ml],25.9,6046,DB01115,Nifedipine
<,15108221,oral bioavailability,The oral bioavailability was low (< 2%) suggesting a marked first-pass effect.,"Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15108221/),%,2,6047,DB01115,Nifedipine
,2142447,elimination half-life,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,58,6787,DB01115,Nifedipine
,2142447,elimination half-life,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,42,6788,DB01115,Nifedipine
,2142447,clearance,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),[l] / [h],19,6789,DB01115,Nifedipine
,2142447,clearance,"After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01).","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),[l] / [h],25,6790,DB01115,Nifedipine
,2142447,half-life,"After a 3-months oral treatment washout period, half-life tended to be prolonged in the elderly patients (69 +/- 20 hours for the elderly patients versus 53 +/- 14 hours for the young patients; difference not significant) and was not markedly different from the short-term intravenous measurement.","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,69,6791,DB01115,Nifedipine
,2142447,half-life,"After a 3-months oral treatment washout period, half-life tended to be prolonged in the elderly patients (69 +/- 20 hours for the elderly patients versus 53 +/- 14 hours for the young patients; difference not significant) and was not markedly different from the short-term intravenous measurement.","Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142447/),h,53,6792,DB01115,Nifedipine
,2702799,AUC,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[μg] / [h·ml],48.2,7447,DB01115,Nifedipine
,2702799,AUC,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[μg] / [h·ml],28.6,7448,DB01115,Nifedipine
,2702799,CL,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[ml] / [min],94.4,7449,DB01115,Nifedipine
,2702799,CL,"The patient's AUC and CL were 48.2 micrograms/ml.hr (Q) versus 28.6 micrograms/ml.hr (N + Q) and 94.4 ml/min (Q) versus 159.1 ml/min (N + Q), respectively.",Elucidation of the nifedipine-quinidine interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702799/),[ml] / [min],159.1,7450,DB01115,Nifedipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,3,9816,DB01115,Nifedipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,10,9817,DB01115,Nifedipine
,9126675,elimination half-lives,"The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5-2 hours), and their elimination half-lives range from 2 to 7 hours.",Pharmacological aspects of calcium channel blockers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),h,2 to 7,9818,DB01115,Nifedipine
,12814453,area under the plasma nifedipine concentration-time curve (AUC0-alpha),The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001).,Evidence of an interaction between nifedipine and nafcillin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[μg] / [h·l],80.9,10400,DB01115,Nifedipine
,12814453,area under the plasma nifedipine concentration-time curve (AUC0-alpha),The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001).,Evidence of an interaction between nifedipine and nafcillin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[μg] / [h·l],216.4,10401,DB01115,Nifedipine
,12814453,Total plasma clearance of nifedipine (CL/F),Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).,Evidence of an interaction between nifedipine and nafcillin in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[l] / [h],138.5,10402,DB01115,Nifedipine
,12814453,Total plasma clearance of nifedipine (CL/F),Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).,Evidence of an interaction between nifedipine and nafcillin in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[l] / [h],56.5,10403,DB01115,Nifedipine
,3766146,half-lives,Both myocardial accumulation and disposition pharmacokinetics of the drug showed one-compartment characteristics with half-lives of about 97 min.,"Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766146/),min,97,10987,DB01115,Nifedipine
,3766146,Apparent Vd,"Apparent Vd was about 480 ml/g myocardial tissue, which expresses a very pronounced binding and accumulation of felodipine in the rabbit myocardium in vitro.","Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766146/),[ml] / [g],480,10988,DB01115,Nifedipine
,2471001,systemic clearance,"In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg.",Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471001/),[l] / [min],1.02,11580,DB01115,Nifedipine
,2471001,terminal half-life (t1/2),"In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg.",Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471001/),h,15.4,11581,DB01115,Nifedipine
,2471001,volume of distribution,"In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg.",Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471001/),[l] / [kg],5.9,11582,DB01115,Nifedipine
,4054203,terminal elimination half-life,The terminal elimination half-life in plasma was similar for both drugs with a mean of 2 h.,The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054203/),h,2,14468,DB01115,Nifedipine
,1951561,Peak serum concentrations,Peak serum concentrations of 18 +/- 2.1 micrograms/L occurred 40 minutes after ingestion of nifedipine (10 mg).,Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1951561/),[μg] / [l],18,15409,DB01115,Nifedipine
,1951561,terminal elimination half-life,"The terminal elimination half-life (mean = 1.35 +/- 0.3 hours) was found to be shorter than that reported for normotensive volunteers or nonpregnant hypertensive women (mean, 3.4 +/- 0.4 hours).",Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1951561/),h,1.35,15410,DB01115,Nifedipine
,1951561,terminal elimination half-life,"The terminal elimination half-life (mean = 1.35 +/- 0.3 hours) was found to be shorter than that reported for normotensive volunteers or nonpregnant hypertensive women (mean, 3.4 +/- 0.4 hours).",Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1951561/),h,3.4,15411,DB01115,Nifedipine
,1951561,apparent oral elimination clearance,"A mean apparent oral elimination clearance of 3.3 +/- 1.3 L/hr/kg was more rapid than that found in normal volunteers (mean, 0.49 +/- 0.09 L/hr/kg) or in women with pregnancy-induced hypertension in the third trimester (mean, 2.0 +/- 0.8 L/hr/kg).",Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1951561/),[l] / [h·kg],3.3,15412,DB01115,Nifedipine
,1951561,apparent oral elimination clearance,"A mean apparent oral elimination clearance of 3.3 +/- 1.3 L/hr/kg was more rapid than that found in normal volunteers (mean, 0.49 +/- 0.09 L/hr/kg) or in women with pregnancy-induced hypertension in the third trimester (mean, 2.0 +/- 0.8 L/hr/kg).",Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1951561/),[l] / [h·kg],0.49,15413,DB01115,Nifedipine
,1951561,apparent oral elimination clearance,"A mean apparent oral elimination clearance of 3.3 +/- 1.3 L/hr/kg was more rapid than that found in normal volunteers (mean, 0.49 +/- 0.09 L/hr/kg) or in women with pregnancy-induced hypertension in the third trimester (mean, 2.0 +/- 0.8 L/hr/kg).",Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1951561/),[l] / [h·kg],2.0,15414,DB01115,Nifedipine
,3433803,oral bioavailability,2. Nilvadipine was rapidly and almost completely absorbed after oral dosing in both species; oral bioavailability was 4.3% in rats and 37.0% in dogs due to extensive first-pass metabolism.,"Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),%,4.3,15530,DB01115,Nifedipine
,3433803,oral bioavailability,2. Nilvadipine was rapidly and almost completely absorbed after oral dosing in both species; oral bioavailability was 4.3% in rats and 37.0% in dogs due to extensive first-pass metabolism.,"Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),%,37.0,15531,DB01115,Nifedipine
,3433803,half-lives,"The half-lives of radioactivity in plasma after i.v. and oral dosing were similar, i.e. 8-10 h in rats, estimated from 2 to 24 h after dosing and 1.5 d in dogs, estimated from 1 to 3 d.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),h,8-10,15532,DB01115,Nifedipine
,3433803,half-lives,"The half-lives of radioactivity in plasma after i.v. and oral dosing were similar, i.e. 8-10 h in rats, estimated from 2 to 24 h after dosing and 1.5 d in dogs, estimated from 1 to 3 d.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),h,2 to 24,15533,DB01115,Nifedipine
,3433803,half-lives,"The half-lives of radioactivity in plasma after i.v. and oral dosing were similar, i.e. 8-10 h in rats, estimated from 2 to 24 h after dosing and 1.5 d in dogs, estimated from 1 to 3 d.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),d,1.5,15534,DB01115,Nifedipine
,3433803,half-lives,"The half-lives of radioactivity in plasma after i.v. and oral dosing were similar, i.e. 8-10 h in rats, estimated from 2 to 24 h after dosing and 1.5 d in dogs, estimated from 1 to 3 d.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),d,1 to 3,15535,DB01115,Nifedipine
,3433803,terminal phase half-lives,"In contrast, plasma concentrations of unchanged drug after i.v. dosing declined biexponentially with terminal phase half-lives of 1.2 h in rats and 4.4 h in dogs.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),h,1.2,15536,DB01115,Nifedipine
,3433803,terminal phase half-lives,"In contrast, plasma concentrations of unchanged drug after i.v. dosing declined biexponentially with terminal phase half-lives of 1.2 h in rats and 4.4 h in dogs.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),h,4.4,15537,DB01115,Nifedipine
,3433803,urinary excretion,"4. With both routes of dosing, urinary excretion of radioactivity was 21-24% dose in rats and 56-61% in dogs, mainly in 24 h.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),%,21-24,15538,DB01115,Nifedipine
,3433803,urinary excretion,"4. With both routes of dosing, urinary excretion of radioactivity was 21-24% dose in rats and 56-61% in dogs, mainly in 24 h.","Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433803/),%,56-61,15539,DB01115,Nifedipine
,12235445,inhibition constant [K(i)],"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μg] / [ml],35.9,15936,DB01115,Nifedipine
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],87.0,15937,DB01115,Nifedipine
,12235445,K(i),"Peppermint oil (inhibition constant [K(i)] = 35.9 +/- 3.3 microg/mL, mean +/- SEM) and 2 constituents, menthol (K(i) = 87.0 +/- 7.0 micromol/L), and menthyl acetate (K(i) = 124.0 +/- 7.0 micromol/L), produced reversible inhibition of nifedipine oxidation.",Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],124.0,15938,DB01115,Nifedipine
,12235445,K(i),Ascorbyl palmitate was more potent (K(i) = 12.3 +/- 0.5 micromol/L).,Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235445/),[μM] / [l],12.3,15939,DB01115,Nifedipine
,6502496,extraction efficiencies,"The extraction efficiencies for nicardipine and its pyridine metabolite II from 1 mL of plasma were 77.4 and 81.1%, respectively.",A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502496/),%,77.4,15940,DB01115,Nifedipine
,6502496,extraction efficiencies,"The extraction efficiencies for nicardipine and its pyridine metabolite II from 1 mL of plasma were 77.4 and 81.1%, respectively.",A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502496/),%,81.1,15941,DB01115,Nifedipine
,2873232,tmax,"Mean bioavailability parameters included a tmax of 2.9 h, a Cmax of 33.3 ng ml-1 and a AUC0-8 h of 113.3 ng h ml-1.",Accumulation of nifedipine after multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),h,2.9,16090,DB01115,Nifedipine
,2873232,Cmax,"Mean bioavailability parameters included a tmax of 2.9 h, a Cmax of 33.3 ng ml-1 and a AUC0-8 h of 113.3 ng h ml-1.",Accumulation of nifedipine after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),[ng] / [ml],33.3,16091,DB01115,Nifedipine
,2873232,AUC0-8 h,"Mean bioavailability parameters included a tmax of 2.9 h, a Cmax of 33.3 ng ml-1 and a AUC0-8 h of 113.3 ng h ml-1.",Accumulation of nifedipine after multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),[h·ng] / [ml],113.3,16092,DB01115,Nifedipine
,2873232,tmax at steady state,"After multiple dosing with either 10 or 20 mg every 8 h for 10 days the mean tmax at steady state was 2.1 h while the mean dose-corrected (to 10 mg) Cmax and AUC0-8 h were 51.9 ng ml-1 and 146.9 ng h ml-1, respectively.",Accumulation of nifedipine after multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),h,2.1,16093,DB01115,Nifedipine
,2873232,Cmax,"After multiple dosing with either 10 or 20 mg every 8 h for 10 days the mean tmax at steady state was 2.1 h while the mean dose-corrected (to 10 mg) Cmax and AUC0-8 h were 51.9 ng ml-1 and 146.9 ng h ml-1, respectively.",Accumulation of nifedipine after multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),[ng] / [ml],51.9,16094,DB01115,Nifedipine
,2873232,AUC0-8 h,"After multiple dosing with either 10 or 20 mg every 8 h for 10 days the mean tmax at steady state was 2.1 h while the mean dose-corrected (to 10 mg) Cmax and AUC0-8 h were 51.9 ng ml-1 and 146.9 ng h ml-1, respectively.",Accumulation of nifedipine after multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),[h·ng] / [ml],146.9,16095,DB01115,Nifedipine
,2873232,elimination rate constant,The mean elimination rate constant was 0.173 h-1 after both single and multiple doses.,Accumulation of nifedipine after multiple doses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),1/[h],0.173,16096,DB01115,Nifedipine
,2873232,ratio of AUC0-8 h (steady state)/AUC0-8 h,"The mean extent of accumulation of nifedipine, defined as the ratio of AUC0-8 h (steady state)/AUC0-8 h (single dose), was 1.3; we concluded that nifedipine accumulates in the body when it is administered every 8 h.",Accumulation of nifedipine after multiple doses. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873232/),,1.3,16097,DB01115,Nifedipine
,23624178,zeta potential,NI-lipid nanoparticle (LN) suspensions with a mean particle size of 48.0 nm and a zeta potential of -57.2 mV were prepared by co-grinding combined with a high-pressure homogenization process.,Lipid nanoparticles with no surfactant improve oral absorption rate of poorly water-soluble drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624178/),m,57.2,16457,DB01115,Nifedipine
,23624178,area under the curve (AUC),"The oral administration of NI-LN suspensions to rats led to a significant increase in the NI plasma concentration, and the area under the curve (AUC) value was found to be 108 min μg mL⁻¹, indicating a 4-fold increase relative to the NI suspensions.",Lipid nanoparticles with no surfactant improve oral absorption rate of poorly water-soluble drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624178/),min·ml⁻¹·μg,108,16458,DB01115,Nifedipine
,23624178,bioavailability,"A comparison of the pharmacokinetic parameters of the NI-LN suspensions with those of the NI solution prepared using only the surfactant polysorbate 80 revealed that although the AUC and bioavailability (59%) values were almost identical, a rapid absorption rate was still observed in the NI-LN suspensions.",Lipid nanoparticles with no surfactant improve oral absorption rate of poorly water-soluble drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624178/),%,59,16459,DB01115,Nifedipine
,2618708,K,The pellet-released drug fitted to a first-order process (K = 0.23 h-1) as wall as Higuchi's function (K = 37.05 h-1/2).,[Studies on the controlled-release pellets of nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618708/),1/[h],0.23,17161,DB01115,Nifedipine
,2618708,K,The pellet-released drug fitted to a first-order process (K = 0.23 h-1) as wall as Higuchi's function (K = 37.05 h-1/2).,[Studies on the controlled-release pellets of nifedipine]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618708/),1/[2·h],37.05,17162,DB01115,Nifedipine
,2618708,t1/2 beta,"The pharmacokinetic character of nifedipine has primarily been explored in this article, and corresponds with a two-compartment model (t1/2 beta = 3.5 h).",[Studies on the controlled-release pellets of nifedipine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618708/),h,3.5,17163,DB01115,Nifedipine
,3437389,systemic availability,"The systemic availability of nifedipine after intraduodenal administration was on the average between 52% and 57%, indicating that nifedipine is extensively metabolized during first passage through the liver.","Moment analysis of intravenous, intraduodenal, buccal, rectal and percutaneous nifedipine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437389/),%,52,17709,DB01115,Nifedipine
,3437389,systemic availability,"The systemic availability of nifedipine after intraduodenal administration was on the average between 52% and 57%, indicating that nifedipine is extensively metabolized during first passage through the liver.","Moment analysis of intravenous, intraduodenal, buccal, rectal and percutaneous nifedipine in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437389/),%,57,17710,DB01115,Nifedipine
,3690906,concentration at steady state,The mean nifedipine concentration at steady state was 17.2 +/- 4.2 ng/ml and mean elimination T 1/2 3.57 +/- 2.70 h.,Nifedipine infusion in acute myocardial infarction: experience in twelve patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690906/),[ng] / [ml],17.2,18509,DB01115,Nifedipine
,3690906,elimination T 1/2,The mean nifedipine concentration at steady state was 17.2 +/- 4.2 ng/ml and mean elimination T 1/2 3.57 +/- 2.70 h.,Nifedipine infusion in acute myocardial infarction: experience in twelve patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690906/),h,3.57,18510,DB01115,Nifedipine
,1387475,terminal elimination half life,The most notable pharmacokinetic features were a prolonged terminal elimination half life of 48 +/- 16 hours and a delayed tmax of 7.3 +/- 1.3 hours.,An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387475/),h,48,18649,DB01115,Nifedipine
,1387475,tmax,The most notable pharmacokinetic features were a prolonged terminal elimination half life of 48 +/- 16 hours and a delayed tmax of 7.3 +/- 1.3 hours.,An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1387475/),h,7.3,18650,DB01115,Nifedipine
greater,12907265,Recovery,Recovery for nifedipine was greater than 93.9% and for internal standard nitrendipine was 96.1%.,Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907265/),%,93.9,20191,DB01115,Nifedipine
,12907265,Recovery,Recovery for nifedipine was greater than 93.9% and for internal standard nitrendipine was 96.1%.,Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907265/),%,96.1,20192,DB01115,Nifedipine
,2088764,peak plasma nifedipine concentration,"The mean peak plasma nifedipine concentration was 27.6 ng/ml at a maximum time of 24 h, after tablet ingestion.",Pharmacokinetics of nifedipine derived from a new retard tablet formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088764/),[ng] / [ml],27.6,20275,DB01115,Nifedipine
,2088764,maximum time,"The mean peak plasma nifedipine concentration was 27.6 ng/ml at a maximum time of 24 h, after tablet ingestion.",Pharmacokinetics of nifedipine derived from a new retard tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088764/),h,24,20276,DB01115,Nifedipine
,2088764,elimination half-life,The mean apparent nifedipine elimination half-life was 16.0 +/- 7.5 h and the mean area under the plasma concentration time curve (0-24 h) 404.1 +/- 134.0 ng/ml.h.,Pharmacokinetics of nifedipine derived from a new retard tablet formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088764/),h,16.0,20277,DB01115,Nifedipine
,2088764,area under the plasma concentration time curve (0-24 h),The mean apparent nifedipine elimination half-life was 16.0 +/- 7.5 h and the mean area under the plasma concentration time curve (0-24 h) 404.1 +/- 134.0 ng/ml.h.,Pharmacokinetics of nifedipine derived from a new retard tablet formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088764/),[ng] / [h·ml],404.1,20278,DB01115,Nifedipine
,7426117,terminal half-life,The terminal half-life of the drug after i.v. administration to humans was about 1 h.,"Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426117/),h,1,20935,DB01115,Nifedipine
,2577014,relative bioavailability,The relative bioavailability of the other products was: tablets (Adalat); 93%; dragées (Niphedipine): 92%; dragées (Corinfar 86%).,[The bioavailability of nifedipine in different solid pharmaceutical preparations for oral use]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2577014/),%,93,21861,DB01115,Nifedipine
,2577014,relative bioavailability,The relative bioavailability of the other products was: tablets (Adalat); 93%; dragées (Niphedipine): 92%; dragées (Corinfar 86%).,[The bioavailability of nifedipine in different solid pharmaceutical preparations for oral use]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2577014/),%,92,21862,DB01115,Nifedipine
,2577014,relative bioavailability,The relative bioavailability of the other products was: tablets (Adalat); 93%; dragées (Niphedipine): 92%; dragées (Corinfar 86%).,[The bioavailability of nifedipine in different solid pharmaceutical preparations for oral use]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2577014/),%,86,21863,DB01115,Nifedipine
,11243202,minimal detectable concentration,The minimal detectable concentration in plasma was 1 ng.,[Determination of nifedipine in human plasma by gas chromatography and its pharmacokinetic study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243202/),ng,1,22793,DB01115,Nifedipine
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],17.4,23022,DB01115,Nifedipine
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],0.6,23023,DB01115,Nifedipine
,2624612,Maximal nifedipine plasma concentrations (Cmax),"Maximal nifedipine plasma concentrations (Cmax) measured at tmax (0.6 h, median) for P averaged 87.5 +/- 32.7 micrograms/l, corresponding values for R were 95.4 +/- 41.1 micrograms/l and 0.46 h.",[The bioequivalence of two nifedipine fluid capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),[μg] / [l],87.5,23061,DB01115,Nifedipine
,2624612,Maximal nifedipine plasma concentrations (Cmax),"Maximal nifedipine plasma concentrations (Cmax) measured at tmax (0.6 h, median) for P averaged 87.5 +/- 32.7 micrograms/l, corresponding values for R were 95.4 +/- 41.1 micrograms/l and 0.46 h.",[The bioequivalence of two nifedipine fluid capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),[μg] / [l],95.4,23062,DB01115,Nifedipine
,2624612,Maximal nifedipine plasma concentrations (Cmax),"Maximal nifedipine plasma concentrations (Cmax) measured at tmax (0.6 h, median) for P averaged 87.5 +/- 32.7 micrograms/l, corresponding values for R were 95.4 +/- 41.1 micrograms/l and 0.46 h.",[The bioequivalence of two nifedipine fluid capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),h,0.46,23063,DB01115,Nifedipine
,2624612,tmax,"Maximal nifedipine plasma concentrations (Cmax) measured at tmax (0.6 h, median) for P averaged 87.5 +/- 32.7 micrograms/l, corresponding values for R were 95.4 +/- 41.1 micrograms/l and 0.46 h.",[The bioequivalence of two nifedipine fluid capsules]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),[μg] / [l],87.5,23064,DB01115,Nifedipine
,2624612,tmax,"Maximal nifedipine plasma concentrations (Cmax) measured at tmax (0.6 h, median) for P averaged 87.5 +/- 32.7 micrograms/l, corresponding values for R were 95.4 +/- 41.1 micrograms/l and 0.46 h.",[The bioequivalence of two nifedipine fluid capsules]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),[μg] / [l],95.4,23065,DB01115,Nifedipine
,2624612,areas under the curves AUC(0-10 h),Mean areas under the curves AUC(0-10 h) were 128.7 +/- 59.9 micrograms.h/h after p and 123.3 +/- 49.3 micrograms.h/l after R (n.s.).,[The bioequivalence of two nifedipine fluid capsules]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),[h·μg] / [h],128.7,23066,DB01115,Nifedipine
,2624612,areas under the curves AUC(0-10 h),Mean areas under the curves AUC(0-10 h) were 128.7 +/- 59.9 micrograms.h/h after p and 123.3 +/- 49.3 micrograms.h/l after R (n.s.).,[The bioequivalence of two nifedipine fluid capsules]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624612/),[h·μg] / [l],123.3,23067,DB01115,Nifedipine
,3219152,biological half-lives,"After oral administration of 14C-KW-3049 to rats, the plasma radioactivity reached the maximum at 0.5 h, showed the second peak at 4 h and decreased biphasically with the biological half-lives of about 6 h and 38 h.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),h,6,23326,DB01115,Nifedipine
,3219152,biological half-lives,"After oral administration of 14C-KW-3049 to rats, the plasma radioactivity reached the maximum at 0.5 h, showed the second peak at 4 h and decreased biphasically with the biological half-lives of about 6 h and 38 h.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),h,38,23327,DB01115,Nifedipine
,3219152,biological half-lives,"2. After oral administration of 14C-KW-3049 to dogs, the plasma radioactivity reached the maximum at 1 h and decreased biphasically with the biological half-lives of about 2 h and 25 h.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),h,2,23328,DB01115,Nifedipine
,3219152,biological half-lives,"2. After oral administration of 14C-KW-3049 to dogs, the plasma radioactivity reached the maximum at 1 h and decreased biphasically with the biological half-lives of about 2 h and 25 h.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),h,25,23329,DB01115,Nifedipine
,3219152,excretion,"3. After oral administration to rats and dogs, the excretion of the radioactivity in feces and urine during 72 h (rats) and 96 h (dogs) were 74% and 19%, 66% and 25%, respectively.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),%,74,23330,DB01115,Nifedipine
,3219152,excretion,"3. After oral administration to rats and dogs, the excretion of the radioactivity in feces and urine during 72 h (rats) and 96 h (dogs) were 74% and 19%, 66% and 25%, respectively.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),%,19,23331,DB01115,Nifedipine
,3219152,excretion,"3. After oral administration to rats and dogs, the excretion of the radioactivity in feces and urine during 72 h (rats) and 96 h (dogs) were 74% and 19%, 66% and 25%, respectively.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),%,66,23332,DB01115,Nifedipine
,3219152,excretion,"3. After oral administration to rats and dogs, the excretion of the radioactivity in feces and urine during 72 h (rats) and 96 h (dogs) were 74% and 19%, 66% and 25%, respectively.","Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),%,25,23333,DB01115,Nifedipine
,3219152,radioactivity,The radioactivity excreted in the bile was 34% during 48 h and was followed by partial reabsorption from the gastrointestinal tract.,"Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),%,34,23334,DB01115,Nifedipine
,3219152,excreted,The radioactivity excreted in the bile was 34% during 48 h and was followed by partial reabsorption from the gastrointestinal tract.,"Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219152/),%,34,23335,DB01115,Nifedipine
,22131238,time required,The time required for reduction in systolic and diastolic blood pressure was shorter for oral nifedipine group (24.0 ± 10.0 min) than intravenus Hydralazine group (34.8 ± 18.8 min) (P ≤ 0.016).,Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22131238/),min,24.0,25656,DB01115,Nifedipine
,22131238,time required,The time required for reduction in systolic and diastolic blood pressure was shorter for oral nifedipine group (24.0 ± 10.0 min) than intravenus Hydralazine group (34.8 ± 18.8 min) (P ≤ 0.016).,Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22131238/),min,34.8,25657,DB01115,Nifedipine
,3731682,peak expiratory flow rate (PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],336,26251,DB01115,Nifedipine
,3731682,peak expiratory flow rate (PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],349,26252,DB01115,Nifedipine
,3731682,PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],393,26253,DB01115,Nifedipine
,3731682,PEFR,"Nifedipine did not significantly affect the mean (+/- SD) morning peak expiratory flow rate (PEFR; 336 +/- 130 L/min for drug vs. 349 +/- 92 L/min for placebo), evening PEFR (393 +/- 69 L/min for drug vs. 367 +/- 66 L/min for placebo), symptom score (27.4% +/- 22.9% for drug vs. 33.8% +/- 26.4% for placebo), or the number of albuterol inhalations per day (5.8 +/- 3.5 for drug vs. 6.2 +/- 4.1 for placebo).",Effect of nifedipine and theophylline in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[l] / [min],367,26254,DB01115,Nifedipine
,3731682,steady-state serum,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[mg] / [ml],9.1,26255,DB01115,Nifedipine
,3731682,trough levels,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[mg] / [ml],9.1,26256,DB01115,Nifedipine
,3731682,trough levels,"Nifedipine did not significantly affect the steady-state serum theophylline trough levels (9.1 +/- 2.2 mg/ml for drug vs. 10.2 +/- 1.9 micrograms/ml for placebo) or the theophylline pharmacokinetic parameters, such as the elimination t1/2, peak serum concentration, time to peak, and AUC(0-24).",Effect of nifedipine and theophylline in asthma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731682/),[μg] / [ml],10.2,26257,DB01115,Nifedipine
,25750535,peak plasma concentration,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),[ng] / [ml],1.66-23.06,29970,DB01115,Nifedipine
,25750535,time to peak plasma concentration,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),h,2.6-4.0,29971,DB01115,Nifedipine
,25750535,area under the plasma concentration versus time curve from time 0 hour to 96 hours,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),[ng] / [h·ml],17.9-429,29972,DB01115,Nifedipine
,25750535,elimination half-life,"In Chinese healthy volunteers, a single-dose oral administration of azelnidipine 8-16 mg had a peak plasma concentration of 1.66-23.06 ng/mL and time to peak plasma concentration was 2.6-4.0 hours and the area under the plasma concentration versus time curve from time 0 hour to 96 hours was 17.9-429 ng/mL·h and elimination half-life was 16.0-28.0 hours.",Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25750535/),h,16.0-28.0,29973,DB01115,Nifedipine
,8737759,Absolute bioavailability,"Absorption was less rapid from the colon than from the upper part of the gut, but this was not associated with a decrease in absorption and/or bioavailability: Absolute bioavailability, calculated from the normalised AUC values, ranged from 42 to 56%, and bioavailability relative to oral solution was 100 to 126% (medians of the application sites).",Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737759/),%,42 to 56,31889,DB01115,Nifedipine
,8737759,bioavailability,"Absorption was less rapid from the colon than from the upper part of the gut, but this was not associated with a decrease in absorption and/or bioavailability: Absolute bioavailability, calculated from the normalised AUC values, ranged from 42 to 56%, and bioavailability relative to oral solution was 100 to 126% (medians of the application sites).",Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737759/),%,100 to 126,31890,DB01115,Nifedipine
,8846626,GI transit time,"For example, the median GI transit time for both oxprenolol and metoprolol Oros drug delivery systems has been reported as 27.4 hours, with individual times ranging from 5.1 to 58.3 hours.","The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846626/),h,27.4,33421,DB01115,Nifedipine
,2467122,half-life,"It is water soluble and photostable, and has a long half-life of 35-50 h.",Pharmacokinetics of calcium antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467122/),h,35-50,33986,DB01115,Nifedipine
,31947655,elimination half-life (T1/2β),The elimination half-life (T1/2β) of nifedipine was increased from 1.6 h to 6.6 h.,A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31947655/),h,1.6,34548,DB01115,Nifedipine
,31947655,elimination half-life (T1/2β),The elimination half-life (T1/2β) of nifedipine was increased from 1.6 h to 6.6 h.,A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31947655/),h,6.6,34549,DB01115,Nifedipine
,34290611,C0/D,"In group I (n = 43), the C0/D of CONF was significantly higher than in Controls [225.2 ± 66.3 vs. 155.1 ± 34.6 ng/ml/(mg/kg); p = 0.002].",CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34290611/),[ml·ng] / [kg·mg],225.2,34737,DB01115,Nifedipine
,34290611,C0/D,"In group I (n = 43), the C0/D of CONF was significantly higher than in Controls [225.2 ± 66.3 vs. 155.1 ± 34.6 ng/ml/(mg/kg); p = 0.002].",CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34290611/),[ml·ng] / [kg·mg],155.1,34738,DB01115,Nifedipine
,28049915,zeta potential,"The mean particle size, polydispersity index (PDI), zeta potential, solubility and encapsulation efficiency (EE) values of the SPI- and NI-loaded cubosomes were determined to be 90.4 nm, 0.187, -13.4 mV, 163 µg/mL and 90.2%, and 91.3 nm, 0.168, -12.8 mV, 189 µg/mL and 93.0%, respectively, which were almost identical to those of the blank cubosome.",Enhancing the Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs Using Monoolein Cubosomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28049915/),m,0.187,35732,DB01115,Nifedipine
,28049915,solubility,"The mean particle size, polydispersity index (PDI), zeta potential, solubility and encapsulation efficiency (EE) values of the SPI- and NI-loaded cubosomes were determined to be 90.4 nm, 0.187, -13.4 mV, 163 µg/mL and 90.2%, and 91.3 nm, 0.168, -12.8 mV, 189 µg/mL and 93.0%, respectively, which were almost identical to those of the blank cubosome.",Enhancing the Solubility and Oral Bioavailability of Poorly Water-Soluble Drugs Using Monoolein Cubosomes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28049915/),m,0.187,35733,DB01115,Nifedipine
,9892074,absolute recoveries,"The absolute recoveries evaluated over the whole concentration range were 95+/-2% and 95+/-4% for NIF and DNIF, respectively.",Simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892074/),%,95,36219,DB01115,Nifedipine
,9892074,absolute recoveries,"The absolute recoveries evaluated over the whole concentration range were 95+/-2% and 95+/-4% for NIF and DNIF, respectively.",Simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892074/),%,95,36220,DB01115,Nifedipine
,2604495,F,"The F value was 44.5 + 7.5% and 48.7 + 8.3% for the swallowed and sublingual routes respectively; however, during the sublingual administration the mean Cmax was larger (92.9 +/- ng/ml), and mean tmax greater (1 h), than the data obtained following the swallowed administration (134.1 +/- 17.7 ng/ml and 0.5 h respectively; p less than 0.05).",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),%,44.5,37562,DB01115,Nifedipine
,2604495,F,"The F value was 44.5 + 7.5% and 48.7 + 8.3% for the swallowed and sublingual routes respectively; however, during the sublingual administration the mean Cmax was larger (92.9 +/- ng/ml), and mean tmax greater (1 h), than the data obtained following the swallowed administration (134.1 +/- 17.7 ng/ml and 0.5 h respectively; p less than 0.05).",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),%,48.7,37563,DB01115,Nifedipine
,2604495,Cmax,"The F value was 44.5 + 7.5% and 48.7 + 8.3% for the swallowed and sublingual routes respectively; however, during the sublingual administration the mean Cmax was larger (92.9 +/- ng/ml), and mean tmax greater (1 h), than the data obtained following the swallowed administration (134.1 +/- 17.7 ng/ml and 0.5 h respectively; p less than 0.05).",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),[ng] / [ml],92.9,37564,DB01115,Nifedipine
greater,2604495,tmax,"The F value was 44.5 + 7.5% and 48.7 + 8.3% for the swallowed and sublingual routes respectively; however, during the sublingual administration the mean Cmax was larger (92.9 +/- ng/ml), and mean tmax greater (1 h), than the data obtained following the swallowed administration (134.1 +/- 17.7 ng/ml and 0.5 h respectively; p less than 0.05).",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),h,1,37565,DB01115,Nifedipine
,2604495,tmax,"The F value was 44.5 + 7.5% and 48.7 + 8.3% for the swallowed and sublingual routes respectively; however, during the sublingual administration the mean Cmax was larger (92.9 +/- ng/ml), and mean tmax greater (1 h), than the data obtained following the swallowed administration (134.1 +/- 17.7 ng/ml and 0.5 h respectively; p less than 0.05).",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),[ng] / [ml],134.1,37566,DB01115,Nifedipine
,2604495,tmax,"The F value was 44.5 + 7.5% and 48.7 + 8.3% for the swallowed and sublingual routes respectively; however, during the sublingual administration the mean Cmax was larger (92.9 +/- ng/ml), and mean tmax greater (1 h), than the data obtained following the swallowed administration (134.1 +/- 17.7 ng/ml and 0.5 h respectively; p less than 0.05).",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),h,0.5,37567,DB01115,Nifedipine
,2604495,t1/2 beta,"When nifedipine was administered intravenously the mean t1/2 beta was 2.063 +/- 0.24 h, the mean CL was 0.234 + 0.017 l/h.kg, and the mean V1 was 0.278 + 0.027 l/kg; these data did nat show the great individual variability reported by other authors.",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),h,2.063,37568,DB01115,Nifedipine
,2604495,CL,"When nifedipine was administered intravenously the mean t1/2 beta was 2.063 +/- 0.24 h, the mean CL was 0.234 + 0.017 l/h.kg, and the mean V1 was 0.278 + 0.027 l/kg; these data did nat show the great individual variability reported by other authors.",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),[l] / [h·kg],0.234,37569,DB01115,Nifedipine
,2604495,V1,"When nifedipine was administered intravenously the mean t1/2 beta was 2.063 +/- 0.24 h, the mean CL was 0.234 + 0.017 l/h.kg, and the mean V1 was 0.278 + 0.027 l/kg; these data did nat show the great individual variability reported by other authors.",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),[l] / [kg],0.278,37570,DB01115,Nifedipine
less,2604495,AUC,"Due to the mean AUC, less than 450 ng.h/ml, the group of volunteers of this trial could be classified as rapid metabolizers.",Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2604495/),[h·ng] / [ml],450,37571,DB01115,Nifedipine
,2054269,nonrenal clearance,"3. Population pharmacokinetic parameters of quinidine (assuming 100% bioavailability of oral quinidine sulphate) were: nonrenal clearance for patients without severe heart and liver failure 12.6 l h-1, reduction in patients with severe heart or liver failure to 6.8 l h-1, renal clearance (l h-1) related to creatinine clearance (ml min-1), proportionality constant 0.0566, volume of distribution of the central compartment 161 l, maximum serum drug concentration 1.4 h after administration of quinidine sulphate and 6.0 h after administration of quinidine bisulphate.",Population pharmacokinetics of quinidine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054269/),[l] / [h],12.6,37741,DB01115,Nifedipine
,2054269,nonrenal clearance,"3. Population pharmacokinetic parameters of quinidine (assuming 100% bioavailability of oral quinidine sulphate) were: nonrenal clearance for patients without severe heart and liver failure 12.6 l h-1, reduction in patients with severe heart or liver failure to 6.8 l h-1, renal clearance (l h-1) related to creatinine clearance (ml min-1), proportionality constant 0.0566, volume of distribution of the central compartment 161 l, maximum serum drug concentration 1.4 h after administration of quinidine sulphate and 6.0 h after administration of quinidine bisulphate.",Population pharmacokinetics of quinidine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054269/),[l] / [h],6.8,37742,DB01115,Nifedipine
,2054269,volume of distribution of the central compartment,"3. Population pharmacokinetic parameters of quinidine (assuming 100% bioavailability of oral quinidine sulphate) were: nonrenal clearance for patients without severe heart and liver failure 12.6 l h-1, reduction in patients with severe heart or liver failure to 6.8 l h-1, renal clearance (l h-1) related to creatinine clearance (ml min-1), proportionality constant 0.0566, volume of distribution of the central compartment 161 l, maximum serum drug concentration 1.4 h after administration of quinidine sulphate and 6.0 h after administration of quinidine bisulphate.",Population pharmacokinetics of quinidine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054269/),l,161,37743,DB01115,Nifedipine
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],1430,38324,DB01115,Nifedipine
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],1134,38325,DB01115,Nifedipine
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],957,38326,DB01115,Nifedipine
,32974907,AUC ratio,"The kinetic disposition of VEN was enantioselective (phase 1) with VEN S-(+)/R-(-) AUC ratio median of 2.83 (AUC0-∞ , 526 vs 195 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),,2.83,39446,DB01115,Nifedipine
,32974907,AUC0-∞,"The kinetic disposition of VEN was enantioselective (phase 1) with VEN S-(+)/R-(-) AUC ratio median of 2.83 (AUC0-∞ , 526 vs 195 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],526,39447,DB01115,Nifedipine
,32974907,AUC0-∞,"The kinetic disposition of VEN was enantioselective (phase 1) with VEN S-(+)/R-(-) AUC ratio median of 2.83 (AUC0-∞ , 526 vs 195 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],195,39448,DB01115,Nifedipine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],1971,39449,DB01115,Nifedipine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],2226,39450,DB01115,Nifedipine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],199,39451,DB01115,Nifedipine
,32974907,AUC,"However, AUC median did not differ between enantiomers for the metabolites ODV (1971 vs 2226 ng·h/mL) and DDV (199 vs 151 ng·h/mL).","Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32974907/),[h·ng] / [ml],151,39452,DB01115,Nifedipine
,7336949,half-lives,"The mean half-lives of the alpha-phase of distribution and of the beta-phase of disposition were about 1.2 and 6.5 min., respectively.",Myocardial pharmacokinetics and pharmacodynamics of nifedipine in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7336949/),min,1.2,40642,DB01115,Nifedipine
,7336949,half-lives,"The mean half-lives of the alpha-phase of distribution and of the beta-phase of disposition were about 1.2 and 6.5 min., respectively.",Myocardial pharmacokinetics and pharmacodynamics of nifedipine in the isolated rabbit heart. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7336949/),min,6.5,40643,DB01115,Nifedipine
,18534803,flow rate,"The analysis was carried out on an Acquity UPLC BEH C18 column (50 mm x 2.1 mm, 1.7 microm) with flow rate of 0.28 ml/min.",Ultra-performance liquid chromatography-tandem mass spectrometry for the determination of lacidipine in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534803/),[ml] / [min],0.28,42069,DB01115,Nifedipine
,3345623,elimination half-life (t1/2),"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),h,4.0,42272,DB01115,Nifedipine
,3345623,systemic clearance (CL),"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),[l] / [min],0.83,42273,DB01115,Nifedipine
,3345623,volume of distribution,"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),[l] / [kg],1.6,42274,DB01115,Nifedipine
,3345623,t1/2,"After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),h,3.8,42275,DB01115,Nifedipine
,3345623,systemic availability,"After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),%,3.9,42276,DB01115,Nifedipine
,3345623,Systemic availability,Systemic availability increased to 5.7% +/- 2.8%.,Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),%,5.7,42277,DB01115,Nifedipine
,2898337,elimination half-life,The mean elimination half-life was approximately 6 hr after both iv and oral doses.,Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898337/),h,6,43256,DB01115,Nifedipine
,2898337,absolute bioavailability,"The absolute bioavailability of nilvadipine decreased from 67 to 27% after increasing oral doses (6 and 24 mg), probably because of reduced drug absorption from the gastrointestinal tract.",Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898337/),%,67,43257,DB01115,Nifedipine
,2898337,absolute bioavailability,"The absolute bioavailability of nilvadipine decreased from 67 to 27% after increasing oral doses (6 and 24 mg), probably because of reduced drug absorption from the gastrointestinal tract.",Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898337/),%,27,43258,DB01115,Nifedipine
,21644845,area under the curve,The mean nifedipine area under the curve in 20 pregnant women was 86.1±61.1 ng/ml/h.,A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21644845/),[ng] / [h·ml],86.1,43923,DB01115,Nifedipine
,2757680,maximum concentrations,Both preparations led to mean maximum concentrations of nifedipine in plasma of 110 mg/ml about 0.5 h p.a.; the mean termial half-lives were 1.8 h (test preparation) and 1.7 h (reference preparation).,[Bioavailability and pharmacokinetics of a new nifedipine preparation in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757680/),[mg] / [ml],110,43997,DB01115,Nifedipine
,2757680,half-lives,Both preparations led to mean maximum concentrations of nifedipine in plasma of 110 mg/ml about 0.5 h p.a.; the mean termial half-lives were 1.8 h (test preparation) and 1.7 h (reference preparation).,[Bioavailability and pharmacokinetics of a new nifedipine preparation in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757680/),h,1.8,43998,DB01115,Nifedipine
,2757680,half-lives,Both preparations led to mean maximum concentrations of nifedipine in plasma of 110 mg/ml about 0.5 h p.a.; the mean termial half-lives were 1.8 h (test preparation) and 1.7 h (reference preparation).,[Bioavailability and pharmacokinetics of a new nifedipine preparation in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2757680/),h,1.7,43999,DB01115,Nifedipine
,17339138,ch,The method had a chromatographic running time of approximately 2.5 min and linear calibration curves over the concentrations of 0.5-100 ng/mL for NIF and DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44539,DB01115,Nifedipine
,17339138,running time,The method had a chromatographic running time of approximately 2.5 min and linear calibration curves over the concentrations of 0.5-100 ng/mL for NIF and DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44540,DB01115,Nifedipine
,17339138,recoveries,The recoveries of the one-step liquid extraction method were 81.3-89.1% for NIF and 71.6-80.4% for DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),%,81.3-89.1,44541,DB01115,Nifedipine
,17339138,recoveries,The recoveries of the one-step liquid extraction method were 81.3-89.1% for NIF and 71.6-80.4% for DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),%,71.6-80.4,44542,DB01115,Nifedipine
,17339138,running time,These results indicated that the developed LC/MS/MS method was efficient with a significantly shorter running time (2.5 min) for NIF and DNIF compared to those methods previously reported in the literature.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44543,DB01115,Nifedipine
,15175561,peak concentration,"Following capsule administration, there was a rapid rise in plasma concentration of drug achieving a peak concentration of 196(35) ng/mL (mean and coefficient of variation) within 0.7 (105) hours and an AUC(infinity) of 973(39) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],196,46540,DB01115,Nifedipine
,15175561,AUC(infinity),"Following capsule administration, there was a rapid rise in plasma concentration of drug achieving a peak concentration of 196(35) ng/mL (mean and coefficient of variation) within 0.7 (105) hours and an AUC(infinity) of 973(39) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[h·ng] / [ml],973,46541,DB01115,Nifedipine
,15175561,Cmax,After nifedipine PA there was also a rapid rise in plasma concentration of drug achieving a Cmax of 85.5 (36) ng/mL with a tmax of 1.7(58) hours and an AUC(infinity) of 879(46) ng.hr/mL.,Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],85.5,46542,DB01115,Nifedipine
,15175561,tmax,After nifedipine PA there was also a rapid rise in plasma concentration of drug achieving a Cmax of 85.5 (36) ng/mL with a tmax of 1.7(58) hours and an AUC(infinity) of 879(46) ng.hr/mL.,Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),h,1.7,46543,DB01115,Nifedipine
,15175561,AUC(infinity),After nifedipine PA there was also a rapid rise in plasma concentration of drug achieving a Cmax of 85.5 (36) ng/mL with a tmax of 1.7(58) hours and an AUC(infinity) of 879(46) ng.hr/mL.,Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[h·ng] / [ml],879,46544,DB01115,Nifedipine
,15175561,Cmax,"For the nifedipine GITS formulation, there was a lag in the plasma concentration time profile for approximately 2 to 3 hours, then it rose gradually achieving a Cmax of of 686(54) 30.5(63) ng/mL with a tmax of 15.0(50) hours and an AUC(infinity) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],686,46545,DB01115,Nifedipine
,15175561,Cmax,"For the nifedipine GITS formulation, there was a lag in the plasma concentration time profile for approximately 2 to 3 hours, then it rose gradually achieving a Cmax of of 686(54) 30.5(63) ng/mL with a tmax of 15.0(50) hours and an AUC(infinity) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),[ng] / [ml],30.5,46546,DB01115,Nifedipine
,15175561,tmax,"For the nifedipine GITS formulation, there was a lag in the plasma concentration time profile for approximately 2 to 3 hours, then it rose gradually achieving a Cmax of of 686(54) 30.5(63) ng/mL with a tmax of 15.0(50) hours and an AUC(infinity) ng.hr/mL.",Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175561/),h,15.0,46547,DB01115,Nifedipine
,1666430,half-life,"Of these agents, amlodipine has by far the longest half-life (30-40 h) allowing the benefit of once-daily administration; it has the additional property of a slow association and dissociation with the calcium channel binding site.",Profiles of calcium antagonists in cardiovascular disease with special reference to second-generation agents and amlodipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1666430/),h,30-40,47183,DB01115,Nifedipine
,25407260,half-life,"Nifedipine slow-release had a half-life of 2 - 5 hours, a mean distribution volume of 6.2 ± 1.9 L/kg (calculated while using a fixed biological availability of 0.45 taken from the literature due to lack of intravenous data in this population) compared to a half-life of 6 - 11 hours, and a distribution volume of 1.2 - 1.3 L/kg described in non-pregnant subjects in the literature.",Pharmacokinetics of nifedipine slow-release during sustained tocolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25407260/),h,2 - 5,47898,DB01115,Nifedipine
,25407260,distribution volume,"Nifedipine slow-release had a half-life of 2 - 5 hours, a mean distribution volume of 6.2 ± 1.9 L/kg (calculated while using a fixed biological availability of 0.45 taken from the literature due to lack of intravenous data in this population) compared to a half-life of 6 - 11 hours, and a distribution volume of 1.2 - 1.3 L/kg described in non-pregnant subjects in the literature.",Pharmacokinetics of nifedipine slow-release during sustained tocolysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25407260/),[l] / [kg],6.2,47899,DB01115,Nifedipine
,25407260,biological availability,"Nifedipine slow-release had a half-life of 2 - 5 hours, a mean distribution volume of 6.2 ± 1.9 L/kg (calculated while using a fixed biological availability of 0.45 taken from the literature due to lack of intravenous data in this population) compared to a half-life of 6 - 11 hours, and a distribution volume of 1.2 - 1.3 L/kg described in non-pregnant subjects in the literature.",Pharmacokinetics of nifedipine slow-release during sustained tocolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25407260/),,0.45,47900,DB01115,Nifedipine
,25407260,half-life,"Nifedipine slow-release had a half-life of 2 - 5 hours, a mean distribution volume of 6.2 ± 1.9 L/kg (calculated while using a fixed biological availability of 0.45 taken from the literature due to lack of intravenous data in this population) compared to a half-life of 6 - 11 hours, and a distribution volume of 1.2 - 1.3 L/kg described in non-pregnant subjects in the literature.",Pharmacokinetics of nifedipine slow-release during sustained tocolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25407260/),h,6 - 11,47901,DB01115,Nifedipine
,25407260,distribution volume,"Nifedipine slow-release had a half-life of 2 - 5 hours, a mean distribution volume of 6.2 ± 1.9 L/kg (calculated while using a fixed biological availability of 0.45 taken from the literature due to lack of intravenous data in this population) compared to a half-life of 6 - 11 hours, and a distribution volume of 1.2 - 1.3 L/kg described in non-pregnant subjects in the literature.",Pharmacokinetics of nifedipine slow-release during sustained tocolysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25407260/),[l] / [kg],1.2 - 1.3,47902,DB01115,Nifedipine
,15525456,half-lives,"The in-vitro half-lives of mebudipine (22 +/- 7.1 min) and dibudipine (40 +/- 9.8 min) were significantly longer than that of nifedipine (5.5 +/- 1.1 min), which was investigated in parallel in this study.",Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525456/),min,22,50262,DB01115,Nifedipine
,15525456,half-lives,"The in-vitro half-lives of mebudipine (22 +/- 7.1 min) and dibudipine (40 +/- 9.8 min) were significantly longer than that of nifedipine (5.5 +/- 1.1 min), which was investigated in parallel in this study.",Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525456/),min,40,50263,DB01115,Nifedipine
,15525456,half-lives,"The in-vitro half-lives of mebudipine (22 +/- 7.1 min) and dibudipine (40 +/- 9.8 min) were significantly longer than that of nifedipine (5.5 +/- 1.1 min), which was investigated in parallel in this study.",Metabolism of the dihydropyridine calcium channel blockers mebudipine and dibudipine by isolated rat hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15525456/),min,5.5,50264,DB01115,Nifedipine
,6748559,Plasma,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],0.64,50577,DB01115,Nifedipine
,6748559,Plasma,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],0.61,50578,DB01115,Nifedipine
,6748559,concentrations,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],13.9,50579,DB01115,Nifedipine
,6748559,concentrations,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],13.7,50580,DB01115,Nifedipine
,1608903,relative bioavailability,"The relative bioavailability of nifedipine, measured as AUC, was increased by 54% (533 vs 346 ng.hr/ml) after the dose of alcohol (P less than 0.0002).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),[h·ng] / [ml],533,52229,DB01115,Nifedipine
,1608903,relative bioavailability,"The relative bioavailability of nifedipine, measured as AUC, was increased by 54% (533 vs 346 ng.hr/ml) after the dose of alcohol (P less than 0.0002).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),[h·ng] / [ml],346,52230,DB01115,Nifedipine
,1608903,time to reach peak heart rate,"Although there was no difference in the systolic and diastolic blood pressure and pulse rate between the two treatment groups, the time to reach peak heart rate was significantly faster in the group treated with alcohol (1.4 vs 2.2 hr).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),h,1.4,52231,DB01115,Nifedipine
,1608903,time to reach peak heart rate,"Although there was no difference in the systolic and diastolic blood pressure and pulse rate between the two treatment groups, the time to reach peak heart rate was significantly faster in the group treated with alcohol (1.4 vs 2.2 hr).",Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608903/),h,2.2,52232,DB01115,Nifedipine
,31746448,Cmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[ng] / [ml],54.46,52568,DB01115,Nifedipine
,31746448,Cmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[ng] / [ml],107.45,52569,DB01115,Nifedipine
,31746448,Tmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),h,2.97,52570,DB01115,Nifedipine
,31746448,Tmax,"Following a single oral administration, SR formulation had a lower Cmax, compared to IR formulation (54.46±17.75 , 107.45±29.85 ng/mL, respectively), and Tmax was significantly longer (2.97 vs. 1.13 h) for the SR and IR formulation, respectively.","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),h,1.13,52571,DB01115,Nifedipine
,31746448,AUC0-last,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],326.7,52572,DB01115,Nifedipine
,31746448,AUC0-last,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],309.27,52573,DB01115,Nifedipine
,31746448,AUC0-∞,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],380.9,52574,DB01115,Nifedipine
,31746448,AUC0-∞,"There was no significant difference between the SR and the IR formulations for AUC0-last and AUC0-∞ (326.7±98.28 vs. 309.27±105.53 ng·h·mL-1 and 380.9 ± 105.24 vs. 334.36±108.1 ng·h·mL-1, respectively).","Pharmacokinetic and Tolerability Comparison of Sustained and Immediate Release Oral Formulations of Nifedipine Tablet Formulations: A Single-Dose, Randomized, Open-Label, Two-Period, Two-Way Crossover Study in Healthy, Fasting Egyptian Male Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31746448/),[h·ng] / [ml],334.36,52575,DB01115,Nifedipine
,1628595,blood,Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,16.7,53367,DB01115,Nifedipine
,1628595,blood,Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,11.2,53368,DB01115,Nifedipine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,22.4,53369,DB01115,Nifedipine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,11.2,53370,DB01115,Nifedipine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,14.7,53371,DB01115,Nifedipine
,3709238,plasma digoxin concentration,Mean plasma digoxin concentration was 0.68 +/- 0.15 ng/ml during control conditions versus 0.74 +/- 0.13 ng/ml (NS) after two weeks of nifedipine coadministration.,Non-interaction between nifedipine and digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[ng] / [ml],0.68,56544,DB01115,Nifedipine
,3709238,plasma digoxin concentration,Mean plasma digoxin concentration was 0.68 +/- 0.15 ng/ml during control conditions versus 0.74 +/- 0.13 ng/ml (NS) after two weeks of nifedipine coadministration.,Non-interaction between nifedipine and digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[ng] / [ml],0.74,56545,DB01115,Nifedipine
,3709238,renal,Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs).,Non-interaction between nifedipine and digoxin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[ml] / [min],173.6,56546,DB01115,Nifedipine
,3709238,renal,Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs).,Non-interaction between nifedipine and digoxin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[ml] / [min],173.1,56547,DB01115,Nifedipine
,3709238,clearance,Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs).,Non-interaction between nifedipine and digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[ml] / [min],173.6,56548,DB01115,Nifedipine
,3709238,clearance,Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs).,Non-interaction between nifedipine and digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[ml] / [min],173.1,56549,DB01115,Nifedipine
,3709238,urinary recovery,Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs).,Non-interaction between nifedipine and digoxin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[μg] / [24·h],164.7,56550,DB01115,Nifedipine
,3709238,urinary recovery,Nifedipine caused no significant changes in either renal digoxin clearance (173.6 +/- 25.9 versus 173.1 +/- 33.2 ml/min) or 24-hour urinary recovery of digoxin (164.7 +/- 25.7 versus 183.8 +/- 29.2 micrograms/24 hrs).,Non-interaction between nifedipine and digoxin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709238/),[μg] / [24·h],183.8,56551,DB01115,Nifedipine
,12878393,half-life drug,In order to avoid sub-therapeutic plasma drug concentrations a modification in classical pharmacokinetic model is proposed and discussed through theoretical calculations for different hypothetical pharmacokinetic situations and a practical single dose pharmacokinetic study with a first order kinetic CRDDS for nifedipine (a short half-life drug; about 2h).,Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878393/),h,2,56967,DB01115,Nifedipine
,2943308,plasma half-life,"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),h,34,57282,DB01115,Nifedipine
,2943308,clearance,"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),[ml] / [kg·min],7,57283,DB01115,Nifedipine
,2943308,apparent volume of distribution,"Intravenous administration of amlodipine (single dose, 10 mg) to 12 volunteers gave a mean plasma half-life of 34 h, mean clearance of 7 ml min-1 kg-1 and a mean apparent volume of distribution of 21 l kg-1.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),[l] / [kg],21,57284,DB01115,Nifedipine
,2943308,systemic availability,"Oral administration (single dose, 10 mg) to the same 12 volunteers gave a mean systemic availability of 64% and a mean plasma half-life of 36 h.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),%,64,57285,DB01115,Nifedipine
,2943308,plasma half-life,"Oral administration (single dose, 10 mg) to the same 12 volunteers gave a mean systemic availability of 64% and a mean plasma half-life of 36 h.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),h,36,57286,DB01115,Nifedipine
,2943308,half-life,"In a second study, repeated oral administration (once daily for 14 days, 15 mg) to 28 volunteers resulted in steady state plasma drug concentration being reached after seven doses, an accumulation of approximately threefold and a mean half-life of 45 h.",The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943308/),h,45,57287,DB01115,Nifedipine
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),mmhg,108,57623,DB01115,Nifedipine
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),mmhg,61,57624,DB01115,Nifedipine
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),mmhg,112,57625,DB01115,Nifedipine
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),,122,57626,DB01115,Nifedipine
,8491245,erect BP,"BP was consistently lower with the combination than with either monotherapy: for example, average erect BP was 108/61 (Group 1) and 112/62 mmHg (Group 2) compared with 122/66 and 116/68 during steady-state monotherapy.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),,116,57627,DB01115,Nifedipine
,8491245,liver blood flow,The introduction of nifedipine in Group 2 was associated with a significant increase in liver blood flow at 1.5 h: 1560 vs 1050 ml.min-1 during monotherapy with doxazosin.,The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),[ml] / [min],1560,57628,DB01115,Nifedipine
,8491245,liver blood flow,The introduction of nifedipine in Group 2 was associated with a significant increase in liver blood flow at 1.5 h: 1560 vs 1050 ml.min-1 during monotherapy with doxazosin.,The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),[ml] / [min],1050,57629,DB01115,Nifedipine
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,257,57630,DB01115,Nifedipine
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,307,57631,DB01115,Nifedipine
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,301,57632,DB01115,Nifedipine
,8491245,steady-state AUC,"In particular, the steady-state AUC of doxazosin was unaffected by the addition of nifedipine: 257, 307, 301, and 256 ng.",The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491245/),ng,256,57633,DB01115,Nifedipine
,3757391,recovery,The recovery in dialysate varied between 0.6 and 0.9% of the amount infused during the period of dialysis.,Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757391/),%,0.6,57792,DB01115,Nifedipine
,3757391,kidney clearance,"Artificial kidney clearance of nifedipine varied between 2.8 and 8.3 ml/min, which was in agreement with in vitro data.",Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757391/),[ml] / [min],2.8 and 8.3,57793,DB01115,Nifedipine
,8004237,minimum quantifiable concentration,The minimum quantifiable concentration of nifedipine was determined to be 5 ng/ml.,Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004237/),[ng] / [ml],5,58412,DB01115,Nifedipine
,8004237,minimum detectable concentration,The minimum detectable concentration was in the order of 1 ng/ml.,Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8004237/),[ng] / [ml],1,58413,DB01115,Nifedipine
,3160527,t1/2,The mean nitrendipine t1/2 was 2.8 +/- 2.1 hours and that of the metabolite was 3.4 +/- 3.9 hours.,Nitrendipine kinetics in normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3160527/),h,2.8,59160,DB01115,Nifedipine
,3160527,t1/2,The mean nitrendipine t1/2 was 2.8 +/- 2.1 hours and that of the metabolite was 3.4 +/- 3.9 hours.,Nitrendipine kinetics in normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3160527/),h,3.4,59161,DB01115,Nifedipine
,6085386,relative bioavailability,"Although relative bioavailability of the tablets ranged from 58.0 to 69.9%, there was no statistically significant difference in the area under the curve among the doses.",Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085386/),%,58.0 to 69.9,60220,DB01115,Nifedipine
,7898101,vascular/cardiac efficacy quotient,"Nilvadipine's higher vasoselectivity is expressed in a vascular/cardiac efficacy quotient of 251, is 9-10 times higher than that of nifedipine.",Nilvadipine: profile of a new calcium antagonist. An overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898101/),,251,60369,DB01115,Nifedipine
,7898101,absolute bioavailability,"Owing to a marked first-pass effect, the absolute bioavailability is 14-19%.",Nilvadipine: profile of a new calcium antagonist. An overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898101/),%,14-19,60370,DB01115,Nifedipine
,7898101,final elimination half-life,"The final elimination half-life is between 15 and 20 h, probably due to slow redistribution from the tissue.",Nilvadipine: profile of a new calcium antagonist. An overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898101/),h,15 and 20,60371,DB01115,Nifedipine
<,7898101,responder rate (,"At a daily dosage of 8-16 mg, the responder rate (RRdiast < 90 mm Hg) is 60-70% in single-drug therapy and up to 80% in combination therapy.",Nilvadipine: profile of a new calcium antagonist. An overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898101/),mm,90,60372,DB01115,Nifedipine
<,7898101,responder rate (,"At a daily dosage of 8-16 mg, the responder rate (RRdiast < 90 mm Hg) is 60-70% in single-drug therapy and up to 80% in combination therapy.",Nilvadipine: profile of a new calcium antagonist. An overview. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898101/),%,60-70,60373,DB01115,Nifedipine
,3503594,total body clearance,"Nifedipine is extensively biotransformed to inactive metabolites, and the total body clearance (450 to 700 ml/minute) is primarily due to hepatic metabolism.",Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3503594/),[ml] / [min],450 to 700,61190,DB01115,Nifedipine
,3503594,steady-state volume of distribution,Nifedipine undergoes significant tissue distribution in that the steady-state volume of distribution (0.62 to 0.77 liter/kg) is more than twice the volume of distribution of the central compartment (0.25 to 0.29 liter/kg).,Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3503594/),[l] / [kg],0.62 to 0.77,61191,DB01115,Nifedipine
,3503594,volume of distribution of the central compartment,Nifedipine undergoes significant tissue distribution in that the steady-state volume of distribution (0.62 to 0.77 liter/kg) is more than twice the volume of distribution of the central compartment (0.25 to 0.29 liter/kg).,Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3503594/),[l] / [kg],0.25 to 0.29,61192,DB01115,Nifedipine
,3503594,oral bioavailability,"Although nifedipine is almost completely absorbed from the gastrointestinal tract, oral bioavailability ranges from 45 to 68 percent because of first-pass metabolism.",Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3503594/),%,45 to 68,61193,DB01115,Nifedipine
,3503594,bioavailability,"Pharmacokinetic studies on the gastrointestinal therapeutic system (GITS) show that the bioavailability of the GITS dosage form (relative to the capsule) is about 65 percent after a single dose, but increases to about 86 percent at steady-state because of residual absorption more than 24 hours after dosing.",Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3503594/),%,65,61194,DB01115,Nifedipine
,3503594,bioavailability,"Pharmacokinetic studies on the gastrointestinal therapeutic system (GITS) show that the bioavailability of the GITS dosage form (relative to the capsule) is about 65 percent after a single dose, but increases to about 86 percent at steady-state because of residual absorption more than 24 hours after dosing.",Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3503594/),%,86,61195,DB01115,Nifedipine
,8703655,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of nifedipine in Nigerians (808 +/- 250 ng ml-1 h) was significantly higher (P < 0.001) than that in Caucasians (323 +/- 116 ng ml-1 h) and the difference remained significant (P < 0.001) when corrected for body weight.,"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703655/),[h·ng] / [ml],808,61701,DB01115,Nifedipine
,8703655,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of nifedipine in Nigerians (808 +/- 250 ng ml-1 h) was significantly higher (P < 0.001) than that in Caucasians (323 +/- 116 ng ml-1 h) and the difference remained significant (P < 0.001) when corrected for body weight.,"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703655/),[h·ng] / [ml],323,61702,DB01115,Nifedipine
,8703655,elimination half-life,The elimination half-life was also significantly higher (P < 0.01) in Nigerians (5.03 +/- 1.96 h) than in Caucasians (2.78 +/- 1.11 h).,"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703655/),h,5.03,61703,DB01115,Nifedipine
,8703655,elimination half-life,The elimination half-life was also significantly higher (P < 0.01) in Nigerians (5.03 +/- 1.96 h) than in Caucasians (2.78 +/- 1.11 h).,"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703655/),h,2.78,61704,DB01115,Nifedipine
,8703655,AUC,The AUC of the nitropyridine metabolite was higher (P < 0.01) in Nigerians (220 +/- 51 ng ml-1 h) compared with that in Caucasians (154 +/- 56 ng ml-1 h) but the difference was not maintained when corrected for body weight.,"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703655/),[h·ng] / [ml],220,61705,DB01115,Nifedipine
,8703655,AUC,The AUC of the nitropyridine metabolite was higher (P < 0.01) in Nigerians (220 +/- 51 ng ml-1 h) compared with that in Caucasians (154 +/- 56 ng ml-1 h) but the difference was not maintained when corrected for body weight.,"Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703655/),[h·ng] / [ml],154,61706,DB01115,Nifedipine
,17667209,Peak plasma concentration,Peak plasma concentration of nifedipine was 127.2 +/- 44 ng/mL at 1.2 +/- 0.1 hours.,Nifedipine pharmacokinetics and plasma levels in the management of preterm labor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667209/),[ng] / [ml],127.2,69665,DB01115,Nifedipine
,17667209,plasma concentrations,Mean plasma concentrations of nifedipine was 67.4 +/- 28.4 ng/mL.,Nifedipine pharmacokinetics and plasma levels in the management of preterm labor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667209/),[ng] / [ml],67.4,69666,DB01115,Nifedipine
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],259.0,70275,DB01115,Nifedipine
,9805816,AUC,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[h·ng] / [ml],326.7,70276,DB01115,Nifedipine
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],34.5,70277,DB01115,Nifedipine
,9805816,Cmax,"The ingestion of a high fat containing breakfast, increased the AUC of nifedipine from 259.0 +/- 101.2 ng h/ml to 326.7 +/- 122.5 ng h/ml and Cmax from 34.5 +/- 15.9 ng/ml to 74.3 +/- 23.9 ng/ml in case of nifedipine 20 mg retard tablet, in agreement with the data of literature.",[Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9805816/),[ng] / [ml],74.3,70278,DB01115,Nifedipine
,1464126,systemic clearance,"The pharmacokinetic studies revealed a systemic clearance of nifedipine of 0.371 +/- 0.101 L.hr-1.kg-1, an apparent volume of distribution of 0.764 +/- 0.288 L.kg-1 and an elimination half-life of 1.4 +/- 0.6 hr.",Intravenous nifedipine for prevention of myocardial ischaemia after coronary revascularization. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464126/),[l] / [h·kg],0.371,74699,DB01115,Nifedipine
,1464126,apparent volume of distribution,"The pharmacokinetic studies revealed a systemic clearance of nifedipine of 0.371 +/- 0.101 L.hr-1.kg-1, an apparent volume of distribution of 0.764 +/- 0.288 L.kg-1 and an elimination half-life of 1.4 +/- 0.6 hr.",Intravenous nifedipine for prevention of myocardial ischaemia after coronary revascularization. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464126/),[l] / [kg],0.764,74700,DB01115,Nifedipine
,1464126,elimination half-life,"The pharmacokinetic studies revealed a systemic clearance of nifedipine of 0.371 +/- 0.101 L.hr-1.kg-1, an apparent volume of distribution of 0.764 +/- 0.288 L.kg-1 and an elimination half-life of 1.4 +/- 0.6 hr.",Intravenous nifedipine for prevention of myocardial ischaemia after coronary revascularization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464126/),h,1.4,74701,DB01115,Nifedipine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,47.0,75129,DB01115,Nifedipine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,5.2,75130,DB01115,Nifedipine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,15.0,75131,DB01115,Nifedipine
,25560574,inhibitory concentration (IC50),"Atorvastatin, fluvastatin, pravastatin and simvastatin inhibited CYP3A4 activities; inhibitory concentration (IC50) values were 47.0, 5.2, 15.0 and 3.3 μM, respectively.",Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25560574/),μM,3.3,75132,DB01115,Nifedipine
less,1726014,Absolute bioavailability,Absolute bioavailability is less than 10%.,Clinical pharmacology of lacidipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1726014/),%,10,76144,DB01115,Nifedipine
,9058533,AUC 0-infinity,"3. When the SR and normal capsules were administered at a dose of 10 mg to six subjects in a crossover design, AUC 0-infinity of unchanged drug, M-3 and 4 in each subject receiving the SR were 97 +/- 15, 85 +/- 31 and 76 +/- 21% respectively of those subjects receiving the normal formulation.","Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058533/),%,97,76383,DB01115,Nifedipine
,9058533,AUC 0-infinity,"3. When the SR and normal capsules were administered at a dose of 10 mg to six subjects in a crossover design, AUC 0-infinity of unchanged drug, M-3 and 4 in each subject receiving the SR were 97 +/- 15, 85 +/- 31 and 76 +/- 21% respectively of those subjects receiving the normal formulation.","Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058533/),%,85,76384,DB01115,Nifedipine
,9058533,AUC 0-infinity,"3. When the SR and normal capsules were administered at a dose of 10 mg to six subjects in a crossover design, AUC 0-infinity of unchanged drug, M-3 and 4 in each subject receiving the SR were 97 +/- 15, 85 +/- 31 and 76 +/- 21% respectively of those subjects receiving the normal formulation.","Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058533/),%,76,76385,DB01115,Nifedipine
,9058533,excretion,The sum of the excretion of urinary metabolites for the SR formulation was 65 +/- 6% of that for the normal formulation.,"Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9058533/),%,65,76386,DB01115,Nifedipine
,9772655,Vd,"After i.v. 1 mg.kg-1, the parameters were: Vd = 0.37 +/- 0.10 L.kg-1, T1/2 alpha = 6.4 +/- 2.9 min, T1/2 beta = 84 +/- 22 min, AUC = 94 +/- 16 mg.min.L-1, Cl = 0.65 +/- 0.13 L.kg-1.h-1.",Pharmacokinetics of m-nifedipine in rabbits after intravenous injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772655/),[l] / [kg],0.37,76494,DB01115,Nifedipine
,9772655,T1/2 alpha,"After i.v. 1 mg.kg-1, the parameters were: Vd = 0.37 +/- 0.10 L.kg-1, T1/2 alpha = 6.4 +/- 2.9 min, T1/2 beta = 84 +/- 22 min, AUC = 94 +/- 16 mg.min.L-1, Cl = 0.65 +/- 0.13 L.kg-1.h-1.",Pharmacokinetics of m-nifedipine in rabbits after intravenous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772655/),min,6.4,76495,DB01115,Nifedipine
,9772655,T1/2 beta,"After i.v. 1 mg.kg-1, the parameters were: Vd = 0.37 +/- 0.10 L.kg-1, T1/2 alpha = 6.4 +/- 2.9 min, T1/2 beta = 84 +/- 22 min, AUC = 94 +/- 16 mg.min.L-1, Cl = 0.65 +/- 0.13 L.kg-1.h-1.",Pharmacokinetics of m-nifedipine in rabbits after intravenous injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772655/),min,84,76496,DB01115,Nifedipine
,9772655,AUC,"After i.v. 1 mg.kg-1, the parameters were: Vd = 0.37 +/- 0.10 L.kg-1, T1/2 alpha = 6.4 +/- 2.9 min, T1/2 beta = 84 +/- 22 min, AUC = 94 +/- 16 mg.min.L-1, Cl = 0.65 +/- 0.13 L.kg-1.h-1.",Pharmacokinetics of m-nifedipine in rabbits after intravenous injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772655/),[mg·min] / [l],94,76497,DB01115,Nifedipine
,9772655,Cl,"After i.v. 1 mg.kg-1, the parameters were: Vd = 0.37 +/- 0.10 L.kg-1, T1/2 alpha = 6.4 +/- 2.9 min, T1/2 beta = 84 +/- 22 min, AUC = 94 +/- 16 mg.min.L-1, Cl = 0.65 +/- 0.13 L.kg-1.h-1.",Pharmacokinetics of m-nifedipine in rabbits after intravenous injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772655/),[l] / [h·kg],0.65,76498,DB01115,Nifedipine
,7699942,Cmax,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),[ng] / [ml],59.1,77484,DB01115,Nifedipine
,7699942,AUC,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),[h·ng] / [ml],288.2,77485,DB01115,Nifedipine
,7699942,Tmax,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),h,3.4,77486,DB01115,Nifedipine
,7699942,t1/2,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),h,5.5,77487,DB01115,Nifedipine
,2153819,IC50,"One of the compounds, 2-[[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6- methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]acetamide (26, UK-51,656), was identified as a potent (IC50 = 4 x 10(-9) M) calcium antagonist which is 20-fold selective for vascular over cardiac tissue and which has a markedly longer duration of action (greater than 5 h) than nifedipine in the anesthetized dog on intravenous administration.","Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153819/),M,4 x 10(-9),78543,DB01115,Nifedipine
,2153819,half-life,The pharmacokinetic half-life of 26 was established as 4.7 h and possible explanations are advanced to account for 26 having a shorter plasma half-life than amlodipine and a longer plasma half-life than felodipine.,"Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153819/),h,4.7,78544,DB01115,Nifedipine
,17495416,maximum concentration,The maximum concentration of nifedipine in plasma after administration into the intestinal loop (0.8 mg/kg) was significantly higher in L. casei-treated rats (3.26 microg/mL) than in those untreated rats (2.33 microg/mL) by 40%.,Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495416/),[μg] / [ml],3.26,78787,DB01115,Nifedipine
,17495416,maximum concentration,The maximum concentration of nifedipine in plasma after administration into the intestinal loop (0.8 mg/kg) was significantly higher in L. casei-treated rats (3.26 microg/mL) than in those untreated rats (2.33 microg/mL) by 40%.,Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495416/),[μg] / [ml],2.33,78788,DB01115,Nifedipine
,21950148,"t(max,ss","The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),h,3.32,78861,DB01115,Nifedipine
,21950148,"CG(max,ss)","The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),[nM] / [l],13.12,78862,DB01115,Nifedipine
,21950148,AUG(tau),"The mean +/- SD t(max,ss,) CG(max,ss) and AUG(tau) of dose normalized to 10 mg felodipine was 3.32 +/- 1.33 h, 13.12 +/- 5.34 nmol/L and 136.33 +/- 63.18 nmol x h/L, respectively.",Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950148/),[h·nM] / [l],136.33,78863,DB01115,Nifedipine
,3987557,volume of distribution,The major fraction of the felodipine dose is localised extravascularly with a volume of distribution of about 10 L/kg.,"Absorption, distribution and elimination of felodipine in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987557/),[l] / [kg],10,79749,DB01115,Nifedipine
greater,3987557,elimination half-life,The mean elimination half-life of felodipine is greater than 10 hours.,"Absorption, distribution and elimination of felodipine in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987557/),h,10,79750,DB01115,Nifedipine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB01115,Nifedipine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB01115,Nifedipine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB01115,Nifedipine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB01115,Nifedipine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB01115,Nifedipine
,2903820,oral bioavailability,"The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions.","Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903820/),%,90,81252,DB01115,Nifedipine
,10725318,oxidation activity,"In microsomes prepared from the intestinal mucosa of animals receiving long-term administration of GJ, NFP oxidation activity (0.21 +/- 0.02 nmol/mg/min) and P-450 content (0.045 +/- 0.009 nmol/mg) were significantly lower than those in untreated rats (0.32 +/- 0.05 nmol/mg/min and 0.060 +/- 0.007 nmol/mg).",Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725318/),[nM] / [mg·min],0.21,81408,DB01115,Nifedipine
,10725318,P-450 content,"In microsomes prepared from the intestinal mucosa of animals receiving long-term administration of GJ, NFP oxidation activity (0.21 +/- 0.02 nmol/mg/min) and P-450 content (0.045 +/- 0.009 nmol/mg) were significantly lower than those in untreated rats (0.32 +/- 0.05 nmol/mg/min and 0.060 +/- 0.007 nmol/mg).",Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725318/),[nM] / [mg],0.045,81409,DB01115,Nifedipine
,10725318,P-450 content,"In microsomes prepared from the intestinal mucosa of animals receiving long-term administration of GJ, NFP oxidation activity (0.21 +/- 0.02 nmol/mg/min) and P-450 content (0.045 +/- 0.009 nmol/mg) were significantly lower than those in untreated rats (0.32 +/- 0.05 nmol/mg/min and 0.060 +/- 0.007 nmol/mg).",Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725318/),[nM] / [mg],0.060,81410,DB01115,Nifedipine
,10725318,oxidation activity,"In hepatic microsomes from the same rats, however, NFP oxidation activity (1.43 +/- 0.17 nmol/mg/min) and P-450 content (0.66 +/- 0.07 nmol/mg) were distinctly greater than those in untreated rats (1.00 +/- 0.06 nmol/mg/min and 0.51 +/- 0.04 nmol/mg).",Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725318/),[nM] / [mg·min],1.43,81411,DB01115,Nifedipine
,10725318,P-450 content,"In hepatic microsomes from the same rats, however, NFP oxidation activity (1.43 +/- 0.17 nmol/mg/min) and P-450 content (0.66 +/- 0.07 nmol/mg) were distinctly greater than those in untreated rats (1.00 +/- 0.06 nmol/mg/min and 0.51 +/- 0.04 nmol/mg).",Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725318/),[nM] / [mg],0.66,81412,DB01115,Nifedipine
,10725318,P-450 content,"In hepatic microsomes from the same rats, however, NFP oxidation activity (1.43 +/- 0.17 nmol/mg/min) and P-450 content (0.66 +/- 0.07 nmol/mg) were distinctly greater than those in untreated rats (1.00 +/- 0.06 nmol/mg/min and 0.51 +/- 0.04 nmol/mg).",Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10725318/),[nM] / [mg],0.51,81413,DB01115,Nifedipine
,2459525,concentrations,Mean (+/- SD) digoxin concentrations of 0.64 +/- 0.19 ng/ml after 2-week digoxin monotherapy and 0.61 +/- 0.23 ng/ml during placebo were not altered by amlodipine (0.60 +/- 0.18 mg/ml).,Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459525/),[ng] / [ml],0.,82344,DB01115,Nifedipine
,2459525,Renal digoxin clearance,Renal digoxin clearance was 202 +/- 44 ml/min on placebo and 207 +/- 55 ml/min during amlodipine coadministration.,Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459525/),[ml] / [min],202,82345,DB01115,Nifedipine
,2459525,Renal digoxin clearance,Renal digoxin clearance was 202 +/- 44 ml/min on placebo and 207 +/- 55 ml/min during amlodipine coadministration.,Effects of amlodipine on steady-state digoxin concentrations and renal digoxin clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2459525/),[ml] / [min],207,82346,DB01115,Nifedipine
,19819100,T(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,2.0,84534,DB01115,Nifedipine
,19819100,T(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,2.5,84535,DB01115,Nifedipine
,19819100,C(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[μg] / [ml],0.084,84536,DB01115,Nifedipine
,19819100,C(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[μg] / [ml],0.076,84537,DB01115,Nifedipine
,19819100,T(1/2),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,84.0,84538,DB01115,Nifedipine
,19819100,T(1/2),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,91.4,84539,DB01115,Nifedipine
,19819100,AUC(0-t),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],4.183,84540,DB01115,Nifedipine
,19819100,AUC(0-t),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],3.467,84541,DB01115,Nifedipine
,19819100,AUC(infinity),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),,5.915,84542,DB01115,Nifedipine
,19819100,AUMC(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],224.073,84543,DB01115,Nifedipine
,19819100,AUMC(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],173.063,84544,DB01115,Nifedipine
,19819100,AUMC(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],776.871,84545,DB01115,Nifedipine
,19819100,AUMC(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],575.038,84546,DB01115,Nifedipine
,19819100,MRT(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],53.608,84547,DB01115,Nifedipine
,19819100,MRT(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],49.538,84548,DB01115,Nifedipine
,19819100,MRT(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],118.194,84549,DB01115,Nifedipine
,19819100,MRT(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],115.246,84550,DB01115,Nifedipine
,19819100,CL(tot),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[l] / [h],0.0375,84551,DB01115,Nifedipine
,19819100,CL(tot),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[l] / [h],0.0433,84552,DB01115,Nifedipine
,19819100,Vd(ss),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),l,3.999,84553,DB01115,Nifedipine
,19819100,Vd(ss),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),l,4.641,84554,DB01115,Nifedipine
,11707062,V1,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],1.83,85950,DB01115,Nifedipine
,11707062,V2,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],22.6,85951,DB01115,Nifedipine
,11707062,Q,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [h·kg],0.629,85952,DB01115,Nifedipine
,10915941,maximal,The values reached their maximal levels (approximately 13 kg for the NP-PEG-HPMC tablet and 8 kg for the PEG tablet) at the compression force of 100 MPa.,Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915941/),kg,13,86112,DB01115,Nifedipine
,10915941,maximal,The values reached their maximal levels (approximately 13 kg for the NP-PEG-HPMC tablet and 8 kg for the PEG tablet) at the compression force of 100 MPa.,Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915941/),kg,8,86113,DB01115,Nifedipine
,2597191,systemic blood clearance,M-0 exhibited a high systemic blood clearance (104 +/- 27 ml/min/kg) (mean +/- SD) which was not significantly influenced by deuterium substitution (125 +/- 13 ml/min/kg).,In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597191/),[ml] / [kg·min],104,86295,DB01115,Nifedipine
,2597191,systemic blood clearance,M-0 exhibited a high systemic blood clearance (104 +/- 27 ml/min/kg) (mean +/- SD) which was not significantly influenced by deuterium substitution (125 +/- 13 ml/min/kg).,In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597191/),[ml] / [kg·min],125,86296,DB01115,Nifedipine
,6529535,bioavailability,Oral administration of nifedipine (20 and 30 mg tablets) to six volunteers was associated with a bioavailability of 0.43 and the presence of its nitropyridine analogue in the plasma.,The first pass metabolism of nifedipine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6529535/),,0.43,86451,DB01115,Nifedipine
,2467130,Bioavailability,"Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),%,63,87599,DB01115,Nifedipine
,2467130,Bioavailability,"Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),%,88,87600,DB01115,Nifedipine
,2467130,Bioavailability,"Bioavailability of unchanged drug after oral administration was high with values of 63, 88, 100, and 100% in humans, dogs, mice, and rats, respectively.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),%,100,87601,DB01115,Nifedipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,35,87602,DB01115,Nifedipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,2,87603,DB01115,Nifedipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,30,87604,DB01115,Nifedipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,3,87605,DB01115,Nifedipine
,2467130,plasma half-life,"Mean plasma half-life values from single-dose studies were 35 h in humans (cf nifedipine, approximately 2 h), 30 h in dogs, 3 h in rats, and 11 h in mice.",The metabolism and pharmacokinetics of amlodipine in humans and animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467130/),h,11,87606,DB01115,Nifedipine
,12906339,relative bioavailability,The relative bioavailability for MOTS was 112%.,Evaluation of monolithic osmotic tablet system for nifedipine delivery in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906339/),%,112,88717,DB01115,Nifedipine
,11143705,bioavailability,"There was no loss in bioavailability of the experimental ethylcellulose microcapsule (drug content 75.8%), even though nifedipine undergoes extensive first pass metabolism.",Assessment of bioavailability of experimental controlled release microcapsules of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11143705/),%,75.8,89088,DB01115,Nifedipine
,9267683,bioavailability,The peroral (p.o.) bioavailability of nifedipine is reported to range from about 45 to 58% in the rat; this compares favourably to human beings.,Extrahepatic first-pass metabolism of nifedipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),%,45 to 58,89346,DB01115,Nifedipine
,9267683,plasma clearance,The geometric mean of systemic nifedipine plasma clearance after i.v. dosing was 10.3 mL min-1 kg-1.,Extrahepatic first-pass metabolism of nifedipine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),[ml] / [kg·min],10.3,89347,DB01115,Nifedipine
,9267683,blood-to-plasma ratio,The nifedipine blood-to-plasma ratio was found to be about 0.59.,Extrahepatic first-pass metabolism of nifedipine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),,0.59,89348,DB01115,Nifedipine
,9267683,systemic blood clearance,"Therefore, the systemic blood clearance of nifedipine was about 17.5 mL min-1 kg-1; which, compared to the hepatic blood flow of rats (55 to 80 mL min-1 kg-1) showed that nifedipine is poorly extracted by the liver (0.22 < or = EH < = 0.32).",Extrahepatic first-pass metabolism of nifedipine in the rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),[ml] / [kg·min],17.5,89349,DB01115,Nifedipine
,9267683,hepatic blood flow,"Therefore, the systemic blood clearance of nifedipine was about 17.5 mL min-1 kg-1; which, compared to the hepatic blood flow of rats (55 to 80 mL min-1 kg-1) showed that nifedipine is poorly extracted by the liver (0.22 < or = EH < = 0.32).",Extrahepatic first-pass metabolism of nifedipine in the rat. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),[ml] / [kg·min],55 to 80,89350,DB01115,Nifedipine
,9267683,absolute bioavailabilities,"The mean absolute bioavailabilities of the p.o., i.p., and i.c. doses were 61, 90, and 100%, respectively.",Extrahepatic first-pass metabolism of nifedipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),%,61,89351,DB01115,Nifedipine
,9267683,absolute bioavailabilities,"The mean absolute bioavailabilities of the p.o., i.p., and i.c. doses were 61, 90, and 100%, respectively.",Extrahepatic first-pass metabolism of nifedipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),%,90,89352,DB01115,Nifedipine
,9267683,absolute bioavailabilities,"The mean absolute bioavailabilities of the p.o., i.p., and i.c. doses were 61, 90, and 100%, respectively.",Extrahepatic first-pass metabolism of nifedipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267683/),%,100,89353,DB01115,Nifedipine
,6374280,Peak serum concentrations,"Peak serum concentrations averaged 45 micrograms/l, attained 2.7 h after dosage.",Nifedipine: kinetics and dynamics after single oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374280/),[μg] / [l],45,89818,DB01115,Nifedipine
,6374280,elimination half-life,The mean elimination half-life was 5.9 h (range: 3-12 h).,Nifedipine: kinetics and dynamics after single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374280/),h,5.9,89819,DB01115,Nifedipine
,1982192,maximum concentrations,"An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found.",[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982192/),[ng] / [ml],158,91838,DB01115,Nifedipine
,1982192,maximum concentrations,"An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found.",[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982192/),[ng] / [ml],68,91839,DB01115,Nifedipine
,1982192,biological half time,"An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found.",[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982192/),h,11.9,91840,DB01115,Nifedipine
,1982192,biological half time,"An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found.",[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982192/),h,2.5,91841,DB01115,Nifedipine
,1982192,area under the curve of the drug concentrations in time,"An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found.",[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982192/),[h·ng] / [ml],450,91842,DB01115,Nifedipine
,1982192,area under the curve of the drug concentrations in time,"An increase in the level of the maximum concentrations (158 ng/ml versus 68 ng/ml), of the biological half time (11.9 hours versus 2.5 hours) and of the area under the curve of the drug concentrations in time (450 ng.ml-1.hour versus 205 ng.ml-1.hour) were found.",[Nifedipine pharmacokinetics in liver cirrhosis patients after the administration of a single oral dose]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982192/),[h·ng] / [ml],205,91843,DB01115,Nifedipine
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],76-324,94436,DB01115,Nifedipine
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],63-229,94437,DB01115,Nifedipine
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],22,94438,DB01115,Nifedipine
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],31,94439,DB01115,Nifedipine
,24399740,IC50,"Administration of nifedipine resulted in inhibition CYP3A4 activity with an IC50 value of 7.8 μM, and nifedipine significantly inhibited P-gp activity in a concentration-dependent manner.",Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399740/),μM,7.8,95337,DB01115,Nifedipine
,24399740,absolute bioavailability (AB),Nifedipine also increased the absolute bioavailability (AB) of repaglinide by 50.0% compared to the oral control group (33.6%).,Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399740/),%,33.6,95338,DB01115,Nifedipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB01115,Nifedipine
,7480098,bioavailability,Administration of the test drugs in combination slightly increased the bioavailability of both--nifedipine [N] to 18% and quinidine [Q] to 16%--and decreased the clearance of both drugs.,Pharmacokinetic interactions of nifedipine and quinidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7480098/),%,18,96483,DB01115,Nifedipine
,7480098,bioavailability,Administration of the test drugs in combination slightly increased the bioavailability of both--nifedipine [N] to 18% and quinidine [Q] to 16%--and decreased the clearance of both drugs.,Pharmacokinetic interactions of nifedipine and quinidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7480098/),%,16,96484,DB01115,Nifedipine
,9156957,pKa,A pKa value of 8.7 means that amlodipine is predominantly present in the ionized form at a physiologic pH.,Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156957/),,8.7,96632,DB01115,Nifedipine
,6863580,half-time,"After intravenous dosing, the drug was eliminated with a half-time of 1.77 +/- 0.25 hour, and total clearance was calculated at 0.62 +/- 0.09 liter/kg/hr.",Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6863580/),h,1.77,96769,DB01115,Nifedipine
,6863580,total clearance,"After intravenous dosing, the drug was eliminated with a half-time of 1.77 +/- 0.25 hour, and total clearance was calculated at 0.62 +/- 0.09 liter/kg/hr.",Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6863580/),[l] / [h·kg],0.62,96770,DB01115,Nifedipine
,6863580,Bioavailability,Bioavailability was 0.45 +/- 0.08.,Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6863580/),,0.45,96771,DB01115,Nifedipine
,2711027,apparent oral clearance (CLo) ratio,The apparent oral clearance (CLo) ratio of (+)- to (-)-NV was 1.69.,"Stereoselective disposition of nilvadipine, a new dihydropyridine calcium antagonist, in the rat and dog. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2711027/),,1.69,99211,DB01115,Nifedipine
,6184565,half-life,"The half-life appears to be approximately 5 h, but may increase as dose size is increased.",Clinical pharmacokinetics of calcium channel antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184565/),h,5,100878,DB01115,Nifedipine
,2455148,maximum nifedipine plasma concentration,"The maximum nifedipine plasma concentration after the capsule was 257 ng/ml compared with 50 ng/ml for the tablet, and the time of maximum concentration was significantly earlier for the capsule.",Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455148/),[ng] / [ml],257,102745,DB01115,Nifedipine
,2455148,maximum nifedipine plasma concentration,"The maximum nifedipine plasma concentration after the capsule was 257 ng/ml compared with 50 ng/ml for the tablet, and the time of maximum concentration was significantly earlier for the capsule.",Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455148/),[ng] / [ml],50,102746,DB01115,Nifedipine
,17723537,flow rate,Its flow rate was 1 ml min(-1).,Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),[ml] / [min],1,102785,DB01115,Nifedipine
,17723537,elution time,"The elution time for nifedipine and carbamazepine was approximately 12 and 8 min, respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),min,12,102786,DB01115,Nifedipine
,17723537,elution time,"The elution time for nifedipine and carbamazepine was approximately 12 and 8 min, respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),min,8,102787,DB01115,Nifedipine
,17723537,Limits of detection,"Limits of detection and quantification in plasma were 0.5 and 1.5 ng ml(-1), respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),[ng] / [ml],0.5,102788,DB01115,Nifedipine
,17723537,Limits of detection,"Limits of detection and quantification in plasma were 0.5 and 1.5 ng ml(-1), respectively.",Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),[ng] / [ml],1.5,102789,DB01115,Nifedipine
greater,17723537,Recovery,Recovery was greater than 98%.,Sensitive and simple liquid chromatographic method with ultraviolet detection for the determination of nifedipine in canine plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723537/),%,98,102790,DB01115,Nifedipine
,2977393,Half lives,"Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively.",Amlodipine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977393/),h,31.2,104994,DB01115,Nifedipine
,2977393,Half lives,"Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively.",Amlodipine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977393/),h,33,104995,DB01115,Nifedipine
,2977393,Half lives,"Half lives were 31.2, 33 and 36.8 hours for 2.5, 5 and 10 mg respectively.",Amlodipine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2977393/),h,36.8,104996,DB01115,Nifedipine
,1532771,bioavailability,"Following oral administration, bioavailability is 60 to 65% and plasma concentrations rise gradually to peak 6 to 8h after administration.",Clinical pharmacokinetics of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),%,60 to 65,105309,DB01115,Nifedipine
,1532771,terminal elimination half-life,Amlodipine is extensively metabolised in the liver (but there is no significant presystemic or first-pass metabolism) and is slowly cleared with a terminal elimination half-life of 40 to 50h.,Clinical pharmacokinetics of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),h,40 to 50,105310,DB01115,Nifedipine
,1532771,Volume of distribution,Volume of distribution is large (21 L/kg) and there is a high degree of protein binding (98%).,Clinical pharmacokinetics of amlodipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),[l] / [kg],21,105311,DB01115,Nifedipine
,1532771,protein binding,Volume of distribution is large (21 L/kg) and there is a high degree of protein binding (98%).,Clinical pharmacokinetics of amlodipine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1532771/),%,98,105312,DB01115,Nifedipine
,3402524,elimination half-life,"After i.v. nisoldipine, the elimination half-life was 9.7 h in control subjects and 16.6 h in the cirrhotics.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),h,9.7,105352,DB01115,Nifedipine
,3402524,elimination half-life,"After i.v. nisoldipine, the elimination half-life was 9.7 h in control subjects and 16.6 h in the cirrhotics.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),h,16.6,105353,DB01115,Nifedipine
,3402524,volume of distribution,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[l] / [kg],4.1,105354,DB01115,Nifedipine
,3402524,volume of distribution,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[l] / [kg],6.4,105355,DB01115,Nifedipine
,3402524,total systemic clearance,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[ml] / [min],847,105356,DB01115,Nifedipine
,3402524,total systemic clearance,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[ml] / [min],494,105357,DB01115,Nifedipine
,3402524,systemic availability,"On oral nisoldipine, systemic availability was fourfold higher in patients with cirrhosis: 14.7% versus 3.7%.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),%,14.7,105358,DB01115,Nifedipine
,3402524,systemic availability,"On oral nisoldipine, systemic availability was fourfold higher in patients with cirrhosis: 14.7% versus 3.7%.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),%,3.7,105359,DB01115,Nifedipine
,2341826,oral plasma clearance,"The oral plasma clearance of nifedipine was 1189 +/- 876 ml min-1, and the mean plasma half-life (t1/2) was 5.99 +/- 3.05 h.",Nifedipine as an antihypertensive drug in patients with renal failure--pharmacokinetics and effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341826/),[ml] / [min],1189,105985,DB01115,Nifedipine
,2341826,plasma half-life (t1/2),"The oral plasma clearance of nifedipine was 1189 +/- 876 ml min-1, and the mean plasma half-life (t1/2) was 5.99 +/- 3.05 h.",Nifedipine as an antihypertensive drug in patients with renal failure--pharmacokinetics and effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341826/),h,5.99,105986,DB01115,Nifedipine
,2341826,clearance,"The mean Cr-EDTA clearance remained unchanged during the study (initial value 31.4 +/- 12.3 ml min-1; final value 32.7 +/- 14.4 ml min-1), and in three patients it increased.",Nifedipine as an antihypertensive drug in patients with renal failure--pharmacokinetics and effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341826/),[ml] / [min],31.4,105987,DB01115,Nifedipine
,2341826,clearance,"The mean Cr-EDTA clearance remained unchanged during the study (initial value 31.4 +/- 12.3 ml min-1; final value 32.7 +/- 14.4 ml min-1), and in three patients it increased.",Nifedipine as an antihypertensive drug in patients with renal failure--pharmacokinetics and effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341826/),[ml] / [min],32.7,105988,DB01115,Nifedipine
,28774813,Cmax,"Extension of the virtual bioequivalence study to Japanese elderly, who show high incidence of achlorhydria, indicated bio-inequivalence which Cmax and AUC ratios between nifedipine control-released reference and test formulations were 3.08 (90%CI, 2.81-3.38) and 1.57 (90%CI, 1.43-1.74), respectively.",Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28774813/),,3.08,106885,DB01115,Nifedipine
,28774813,AUC ratios,"Extension of the virtual bioequivalence study to Japanese elderly, who show high incidence of achlorhydria, indicated bio-inequivalence which Cmax and AUC ratios between nifedipine control-released reference and test formulations were 3.08 (90%CI, 2.81-3.38) and 1.57 (90%CI, 1.43-1.74), respectively.",Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28774813/),,1.57,106886,DB01115,Nifedipine
,9243357,Maximum concentration (Cmax),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[ng] / [ml],528,107465,DB01115,Nifedipine
,9243357,Maximum concentration (Cmax),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[ng] / [ml],"2,689",107466,DB01115,Nifedipine
,9243357,area under the concentration-time curve (AUC),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[h·ng] / [ml],"6,550",107467,DB01115,Nifedipine
,9243357,area under the concentration-time curve (AUC),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[h·ng] / [ml],"18,562",107468,DB01115,Nifedipine
,9243357,time to reach Cmax (tmax),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),h,1 to 8,107469,DB01115,Nifedipine
,9243357,Half-life (t1/2),"Half-life (t1/2) exhibited less important variations, ranging from 4.4 to 9.1 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),h,4.4 to 9.1,107470,DB01115,Nifedipine
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.51,108535,DB01115,Nifedipine
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.70,108536,DB01115,Nifedipine
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.81,108537,DB01115,Nifedipine
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],1.81,108538,DB01115,Nifedipine
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],2.83,108539,DB01115,Nifedipine
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],3.63,108540,DB01115,Nifedipine
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],1.5-2.0,109392,DB01115,Nifedipine
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],2.5,109393,DB01115,Nifedipine
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],3.1,109394,DB01115,Nifedipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],63.2,109408,DB01115,Nifedipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],46.4,109409,DB01115,Nifedipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],66.8,109410,DB01115,Nifedipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),,42.2,109411,DB01115,Nifedipine
,2468876,terminal half-life,"The terminal half-life is on average 8 h, and thus substantially longer than the terminal half-life of 2-3 h for nifedipine.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,8,109841,DB01115,Nifedipine
,2468876,terminal half-life,"The terminal half-life is on average 8 h, and thus substantially longer than the terminal half-life of 2-3 h for nifedipine.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,2-3,109842,DB01115,Nifedipine
,2468876,bioavailability,"Despite its almost complete absorption, bioavailability is on average 15-25% and shows great interindividual variability ranging from 7 to 40%.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),%,15-25,109843,DB01115,Nifedipine
,2468876,systemic plasma clearance,The systemic plasma clearance of the drug is on average 18 ml/min/kg and thus approaches the liver blood flow.,Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),[ml] / [kg·min],18,109844,DB01115,Nifedipine
,2468876,half-life,"In patients with liver cirrhosis, the half-life is prolonged to 19.6 h, the total plasma clearance is decreased by 50%, and the bioavailability is more than doubled to 54%.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,19.6,109845,DB01115,Nifedipine
,2468876,bioavailability,"In patients with liver cirrhosis, the half-life is prolonged to 19.6 h, the total plasma clearance is decreased by 50%, and the bioavailability is more than doubled to 54%.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),%,54,109846,DB01115,Nifedipine
,2468876,terminal elimination half-life,Systemic clearance is not changed but the terminal elimination half-life is slightly prolonged to 10.5 h.,Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,10.5,109847,DB01115,Nifedipine
,2468876,Bioavailability,"Bioavailability, which is 21.2%, is not grossly altered in renal failure.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),%,21.2,109848,DB01115,Nifedipine
,1499595,area under the plasma level time curve (AUC infinity),The area under the plasma level time curve (AUC infinity) of co-dergocrine increased from 0.59 +/- 0.41 ng.ml-1. (mean +/- SD) in the normals to 1.24 +/- 0.95 ng.,Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),[ng] / [ml],0.59,110870,DB01115,Nifedipine
,1499595,area under the plasma level time curve (AUC infinity),The area under the plasma level time curve (AUC infinity) of co-dergocrine increased from 0.59 +/- 0.41 ng.ml-1. (mean +/- SD) in the normals to 1.24 +/- 0.95 ng.,Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),ng,1.24,110871,DB01115,Nifedipine
,1499595,AUC infinity,"Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.",Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),[h·ng] / [ml],564.5,110872,DB01115,Nifedipine
,1499595,AUC infinity,"Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.",Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),ng,1547.5,110873,DB01115,Nifedipine
,1499595,AUC infinity,"Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.",Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1499595/),ng,929,110874,DB01115,Nifedipine
,3358894,half-life,The half-life in the elderly was significantly longer (8.8 +/- 0.9 h) compared with that in the young (5.8 +/- 1.1 h) (P less than 0.01).,The effect of ageing on the disposition of nifedipine and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358894/),h,8.8,111099,DB01115,Nifedipine
,3358894,half-life,The half-life in the elderly was significantly longer (8.8 +/- 0.9 h) compared with that in the young (5.8 +/- 1.1 h) (P less than 0.01).,The effect of ageing on the disposition of nifedipine and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358894/),h,5.8,111100,DB01115,Nifedipine
,16033250,t(max),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,8.5,113252,DB01115,Nifedipine
,16033250,C(max),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),[ng] / [ml],36.55,113253,DB01115,Nifedipine
,16033250,AUC,The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),[ng] / [h·ml],347.06,113254,DB01115,Nifedipine
,16033250,AUC,The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),[ng] / [h·ml],409.99,113255,DB01115,Nifedipine
,16033250,A(half-life),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,2.26,113256,DB01115,Nifedipine
,16033250,D(half-life),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,2.43,113257,DB01115,Nifedipine
,16033250,E(half-life),The mean values were as follows: t(max): 8.5 +/- 1.2 h; C(max): 36.55 +/- 6.76 ng/ml; AUC: 347.06 +/- 51.61 ng/h/ml; AUC 409.99 +/- 61.08 ng/h/ml; A(half-life): 2.26 +/- 0.36 h; D(half-life): 2.43 +/- 0.44 h; E(half-life): 4.62 +/- 0.79 h.,"Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16033250/),h,4.62,113258,DB01115,Nifedipine
,21970310,clearance factor C(trough)-0.180,The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),,1,113291,DB01115,Nifedipine
<,21970310,C(trough),The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),[ng] / [ml],1.7,113292,DB01115,Nifedipine
,7932048,mean dissolution time,"Among the seven formulations, the tablet having the mean dissolution time of 0.8-1.3 h gave prolonged plasma nifedipine levels without decrease of AUC after oral administration to dogs.",In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcelluloses in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932048/),h,0.8-1.3,115105,DB01115,Nifedipine
,1595912,concentration,The plasma nifedipine concentration (mean value +/- SD) at steady state for 21 patients receiving nifedipine was 119 +/- 42.5 ng/mL.,Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595912/),ng,119,117120,DB01115,Nifedipine
,1595912,at steady state,The plasma nifedipine concentration (mean value +/- SD) at steady state for 21 patients receiving nifedipine was 119 +/- 42.5 ng/mL.,Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595912/),ng,119,117121,DB01115,Nifedipine
,1595912,systemic clearance,"The pharmacokinetic variables for nifedipine were as follows (mean values +/- SD): systemic clearance, 0.525 +/- 0.228 L.h-1.kg-1; apparent volume of distribution, 0.738 +/- 0.446 L/kg; and elimination half-life, 1.02 +/- 0.51 h.",Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595912/),[l] / [h·kg],0.525,117122,DB01115,Nifedipine
,1595912,apparent volume of distribution,"The pharmacokinetic variables for nifedipine were as follows (mean values +/- SD): systemic clearance, 0.525 +/- 0.228 L.h-1.kg-1; apparent volume of distribution, 0.738 +/- 0.446 L/kg; and elimination half-life, 1.02 +/- 0.51 h.",Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595912/),[l] / [kg],0.738,117123,DB01115,Nifedipine
,1595912,elimination half-life,"The pharmacokinetic variables for nifedipine were as follows (mean values +/- SD): systemic clearance, 0.525 +/- 0.228 L.h-1.kg-1; apparent volume of distribution, 0.738 +/- 0.446 L/kg; and elimination half-life, 1.02 +/- 0.51 h.",Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595912/),h,1.02,117124,DB01115,Nifedipine
,6345374,half-life,"The peak plasma concentrations and areas under the plasma concentration time curve were dose-dependent; kinetics were linear between 20 and 60 mg, and the half-life of nifedipine tablets was close to 10 hours.",Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6345374/),h,10,117274,DB01115,Nifedipine
,1534713,oral bioavailability,It has high oral bioavailability (60-80%) and accumulates to a steady-state with once-daily administration over a period of 1-1 1/2 weeks.,Pharmacokinetics and pharmacodynamics of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1534713/),%,60-80,118229,DB01115,Nifedipine
,15563062,T1/2beta,"When m-Nif was intravenously administered, the plasma concentration-time curve was fit to a two-compartment model and T1/2beta was 117 min.",[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,117,120762,DB01115,Nifedipine
,15563062,T1/2 (Ke),T1/2 (Ke) and Cmax were 147 min and 20 microg x L(-1); at the low dose of 1.152 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,147,120763,DB01115,Nifedipine
,15563062,Cmax,T1/2 (Ke) and Cmax were 147 min and 20 microg x L(-1); at the low dose of 1.152 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),[μg] / [l],20,120764,DB01115,Nifedipine
,15563062,T1/2 (Ke),T1/2 (Ke) was 122 min and Cmax was 36 microg x L(-1) at the middle dose of 3.456 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,122,120765,DB01115,Nifedipine
,15563062,Cmax,T1/2 (Ke) was 122 min and Cmax was 36 microg x L(-1) at the middle dose of 3.456 mg x kg(-1).,[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),[μg] / [l],36,120766,DB01115,Nifedipine
,15563062,T1/2 (Ke),"T1/2 (Ke) was 144 min and Cmax was 69 microg x L(-1) at the high dose of 10.37 mg x kg(-1), respectively.",[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),min,144,120767,DB01115,Nifedipine
,15563062,Cmax,"T1/2 (Ke) was 144 min and Cmax was 69 microg x L(-1) at the high dose of 10.37 mg x kg(-1), respectively.",[Pharmacokinetics of m-nifedipine in Beagle dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563062/),[μg] / [l],69,120768,DB01115,Nifedipine
,1489189,absorption rate,Nifedipine significantly increased the absorption rate of cefixime (20.7 +/- 4.3 versus 16 +/- 3.5 mg/h in the absence of nifedipine).,Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489189/),[mg] / [h],20.7,122355,DB01115,Nifedipine
,1489189,absorption rate,Nifedipine significantly increased the absorption rate of cefixime (20.7 +/- 4.3 versus 16 +/- 3.5 mg/h in the absence of nifedipine).,Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489189/),[mg] / [h],16,122356,DB01115,Nifedipine
,1489189,absolute bioavailability,The absolute bioavailability of cefixime alone was 31% +/- 6% compared with 53% +/- 1% (P < 0.01) in the presence of nifedipine.,Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489189/),%,31,122357,DB01115,Nifedipine
,1489189,absolute bioavailability,The absolute bioavailability of cefixime alone was 31% +/- 6% compared with 53% +/- 1% (P < 0.01) in the presence of nifedipine.,Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489189/),%,53,122358,DB01115,Nifedipine
,1489189,peak concentrations,The observed peak concentrations in serum were significantly different (2.5 +/- 0.3 mg/liter without nifedipine and 3.7 +/- 1.1 mg/liter with nifedipine; P < 0.02).,Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489189/),[mg] / [l],2.5,122359,DB01115,Nifedipine
,1489189,peak concentrations,The observed peak concentrations in serum were significantly different (2.5 +/- 0.3 mg/liter without nifedipine and 3.7 +/- 1.1 mg/liter with nifedipine; P < 0.02).,Modification of cefixime bioavailability by nifedipine in humans: involvement of the dipeptide carrier system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1489189/),[mg] / [l],3.7,122360,DB01115,Nifedipine
,6743779,AUC0----infinity,"The areas under the serum concentration time curves were not significantly different (AUC0----infinity 319.8 +/- 28.0 (SEM) ng ml-1 h-1 for capsules, 260.8 +/- 15.3 ng ml-1 h-1 for tablets).",Bioavailability of nifedipine: a comparison between two preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743779/),[ng] / [h·ml],319.8,123647,DB01115,Nifedipine
,6743779,AUC0----infinity,"The areas under the serum concentration time curves were not significantly different (AUC0----infinity 319.8 +/- 28.0 (SEM) ng ml-1 h-1 for capsules, 260.8 +/- 15.3 ng ml-1 h-1 for tablets).",Bioavailability of nifedipine: a comparison between two preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743779/),[ng] / [h·ml],260.8,123648,DB01115,Nifedipine
,6743779,peak serum levels,"The peak serum levels and the time of their occurrence were 162.4 +/- 23.4 ng ml-1 at 30 min for capsules and 43.0 +/- 3.0 ng ml-1 at 1-2 h for tablets, indicating that the absorption of nifedipine from the capsule is faster than from the tablet form.",Bioavailability of nifedipine: a comparison between two preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743779/),[ng] / [ml],162.4,123649,DB01115,Nifedipine
,6743779,peak serum levels,"The peak serum levels and the time of their occurrence were 162.4 +/- 23.4 ng ml-1 at 30 min for capsules and 43.0 +/- 3.0 ng ml-1 at 1-2 h for tablets, indicating that the absorption of nifedipine from the capsule is faster than from the tablet form.",Bioavailability of nifedipine: a comparison between two preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743779/),[ng] / [ml],43.0,123650,DB01115,Nifedipine
,6630401,sensitivity,"Using a single-step solvent extraction or a bonded-phase column extraction and electron capture detection, an assay sensitivity of 10 to 25 ng/ml can be achieved using 0.25 ml of serum.",Rapid GC method for quantitation of nifedipine in serum using electron capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6630401/),[ng] / [ml],10 to 25,123787,DB01115,Nifedipine
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124537,DB01115,Nifedipine
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,24,124538,DB01115,Nifedipine
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,34,124539,DB01115,Nifedipine
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,27,124540,DB01115,Nifedipine
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124541,DB01115,Nifedipine
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,37,124542,DB01115,Nifedipine
,18394772,peak,"Following capsule administration there was a rapid rise in plasma concentration of drug achieving a peak of 97.5 microg/l (median) at 1h, then declined to 59.5 microg/l (median) at 5h.",Nifedipine gastrointestinal therapeutic system (GITS) as an alternative to slow-release for tocolysis--tolerance and pharmacokinetic profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18394772/),[μg] / [l],97.5,127526,DB01115,Nifedipine
,18394772,peak,"Following capsule administration there was a rapid rise in plasma concentration of drug achieving a peak of 97.5 microg/l (median) at 1h, then declined to 59.5 microg/l (median) at 5h.",Nifedipine gastrointestinal therapeutic system (GITS) as an alternative to slow-release for tocolysis--tolerance and pharmacokinetic profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18394772/),[μg] / [l],59.5,127527,DB01115,Nifedipine
,1937348,area under the plasma concentration-time curve (AUC,"Due to the small number of subjects, comparison of the NF pharmacokinetics at dose 1 and 26 failed to show a bimodality in the frequency distribution of its area under the plasma concentration-time curve (AUC 274.5 to 317.1 ng ml-1 h, NS).",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),[h·ng] / [ml],274.5 to 317.1,128876,DB01115,Nifedipine
,1937348,t1/2,"Hepatic microsomal autoinduction (t1/2 2.87 to 3.06 h, NS) was not found.",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),h,2.87 to 3.06,128877,DB01115,Nifedipine
,1937348,urinary excretion,"Unlike what has been suggested by in vitro studies, NF treatment did not modify significantly the urinary excretion of 6 beta-hydroxycortisol (318 to 265 micrograms/d, NS).",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),[μg] / [d],318 to 265,128878,DB01115,Nifedipine
,6862586,bioavailability,"Because of presystemic metabolism, the bioavailability is about 56% to 77%.",Pharmacokinetics and metabolism of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),%,56,129426,DB01115,Nifedipine
,6862586,bioavailability,"Because of presystemic metabolism, the bioavailability is about 56% to 77%.",Pharmacokinetics and metabolism of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),%,77,129427,DB01115,Nifedipine
,6862586,plasma concentration,"After oral administration of 10 mg, the mean plasma concentration of nifedipine reaches maximum values of 160 +/- 49 micrograms/liter after 30 to 60 minutes.",Pharmacokinetics and metabolism of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),[μg] / [l],160,129428,DB01115,Nifedipine
,6862586,maximum,"After oral administration of 10 mg, the mean plasma concentration of nifedipine reaches maximum values of 160 +/- 49 micrograms/liter after 30 to 60 minutes.",Pharmacokinetics and metabolism of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),[μg] / [l],160,129429,DB01115,Nifedipine
,6862586,half-life,"After intravenous administration (0.015 mg/kg) biphasic elimination occurs, the half-life of the alpha-phase being about 13 minutes and of the beta-phase 1.26 +/- 0.55 hours in healthy volunteers.",Pharmacokinetics and metabolism of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),min,13,129430,DB01115,Nifedipine
,6862586,half-life,"After intravenous administration (0.015 mg/kg) biphasic elimination occurs, the half-life of the alpha-phase being about 13 minutes and of the beta-phase 1.26 +/- 0.55 hours in healthy volunteers.",Pharmacokinetics and metabolism of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),h,1.26,129431,DB01115,Nifedipine
,6862586,half-life,"After oral administration of higher doses (40 mg) and after continuous infusion over 24 hours, a third phase with a half-life of about 8 hours can be seen.",Pharmacokinetics and metabolism of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),h,8,129432,DB01115,Nifedipine
,6862586,apparent volume of distribution of the central compartment (Vce),"The apparent volume of distribution of the central compartment (Vce) is 0.294 +/- 0.1 l/kg, and the total body clearance amounts to 0.45 +/- 0.1 liter/hr . kg.",Pharmacokinetics and metabolism of nifedipine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),[l] / [kg],0.294,129433,DB01115,Nifedipine
,6862586,total body clearance,"The apparent volume of distribution of the central compartment (Vce) is 0.294 +/- 0.1 l/kg, and the total body clearance amounts to 0.45 +/- 0.1 liter/hr . kg.",Pharmacokinetics and metabolism of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6862586/),[l] / [h·kg],0.45,129434,DB01115,Nifedipine
,14872555,Cmax,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),[ng] / [ml],143.12,130187,DB01115,Nifedipine
,14872555,AUC,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),[h·ng] / [ml],293.77,130188,DB01115,Nifedipine
,14872555,T1/2,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),h,3.08,130189,DB01115,Nifedipine
,14872555,Tmax,"The mean Cmax was 143.12+/-53.48 ng/ml, the mean AUC was 293.77+/-115.62 ng.h/ml, the mean T1/2 was 3.08+/-1.61 h, and the median value of Tmax was 0.61 h.",Pharmacokinetics of nifedipine in Taiwanese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),h,0.61,130190,DB01115,Nifedipine
,14872555,AUC distribution,"According to the antimode of AUC distribution of 22.5 ng.h/ml/mg proposed by Kleinbloesem, 69.7% of Taiwanese can be categorized as slow metabolizers.",Pharmacokinetics of nifedipine in Taiwanese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872555/),[h·ng] / [mg·ml],22.5,130191,DB01115,Nifedipine
,1840130,retention times,"Under these conditions, the retention times of amlodipine and the internal standard desipramine were 10.6 and 12.9 min, respectively.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),min,10.6,130413,DB01115,Nifedipine
,1840130,retention times,"Under these conditions, the retention times of amlodipine and the internal standard desipramine were 10.6 and 12.9 min, respectively.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),min,12.9,130414,DB01115,Nifedipine
,1840130,sensitivity,"Using 1 ml of plasma, sensitivity of the assay was 2.5 ng ml-1 at which the RSD was 11%.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[ng] / [ml],2.5,130415,DB01115,Nifedipine
,1840130,half-life (t1/2),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),h,6.5,130416,DB01115,Nifedipine
,1840130,systemic clearance (CL),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[l] / [h·kg],4.8,130417,DB01115,Nifedipine
,1840130,apparent volume of distribution at steady state (Vdss),"The mean half-life (t1/2) of amlodipine was 6.5 h, the systemic clearance (CL) was 4.8 l h-1 kg-1 and the apparent volume of distribution at steady state (Vdss) was 30.2 l kg-1.",Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1840130/),[l] / [kg],30.2,130418,DB01115,Nifedipine
,9031742,encapsulation ratio,2. The average diameters of the nanoparticles ranged from 0.12 to 0.21 micron; the encapsulation ratio was 82% to 88%.,The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9031742/),%,82,131076,DB01115,Nifedipine
,9031742,encapsulation ratio,2. The average diameters of the nanoparticles ranged from 0.12 to 0.21 micron; the encapsulation ratio was 82% to 88%.,The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9031742/),%,88,131077,DB01115,Nifedipine
,3595068,Cmax,"The mean Cmax values for fasting, low-fat, and high-fat meals were 78.9, 42.2, and 58.7 ng/ml, respectively.",Effect of food on nifedipine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595068/),[ng] / [ml],78.9,132264,DB01115,Nifedipine
,3595068,Cmax,"The mean Cmax values for fasting, low-fat, and high-fat meals were 78.9, 42.2, and 58.7 ng/ml, respectively.",Effect of food on nifedipine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595068/),[ng] / [ml],42.2,132265,DB01115,Nifedipine
,3595068,Cmax,"The mean Cmax values for fasting, low-fat, and high-fat meals were 78.9, 42.2, and 58.7 ng/ml, respectively.",Effect of food on nifedipine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595068/),[ng] / [ml],58.7,132266,DB01115,Nifedipine
,3595068,tmax,"The mean tmax values for these three conditions were 0.97, 1.89, and 1.07 hours, respectively.",Effect of food on nifedipine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595068/),h,0.97,132267,DB01115,Nifedipine
,3595068,tmax,"The mean tmax values for these three conditions were 0.97, 1.89, and 1.07 hours, respectively.",Effect of food on nifedipine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595068/),h,1.89,132268,DB01115,Nifedipine
,3595068,tmax,"The mean tmax values for these three conditions were 0.97, 1.89, and 1.07 hours, respectively.",Effect of food on nifedipine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3595068/),h,1.07,132269,DB01115,Nifedipine
,18673251,absolute bioavailability,The absolute bioavailability for both formulations was ca. 60 %.,"Effect of para-sulfonato-calix[n]arenes on the solubility, chemical stability, and bioavailability of a water insoluble drug nifedipine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18673251/),%,60,132363,DB01115,Nifedipine
,2467131,elimination half-life,"The elimination half-life was of the order of 50 h, similar to previously observed values, and did not vary with differences in renal function.",Pharmacokinetics of amlodipine in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467131/),h,50,133739,DB01115,Nifedipine
,8363681,time to control,The mean time to control was 67.5 minutes for labetalol and 60.0 minutes for nifedipine (P > .2).,Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363681/),min,67.5,134042,DB01115,Nifedipine
,8363681,time to control,The mean time to control was 67.5 minutes for labetalol and 60.0 minutes for nifedipine (P > .2).,Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363681/),min,60.0,134043,DB01115,Nifedipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB01115,Nifedipine
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,39.0,134661,DB01115,Nifedipine
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,18.3,134662,DB01115,Nifedipine
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,12.3,134663,DB01115,Nifedipine
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,68.0,134664,DB01115,Nifedipine
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,52.6,134665,DB01115,Nifedipine
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,13.5,134666,DB01115,Nifedipine
,2967593,oral bioavailability,The drug was well absorbed by the oral route while the mean oral bioavailability for unchanged drug was 62.5%.,Metabolism and kinetics of amlodipine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),%,62.5,135374,DB01115,Nifedipine
,2967593,total recovered radioactivity,Mean total recovered radioactivity in urine and faeces amounted to 84% for both the oral and intravenous routes.,Metabolism and kinetics of amlodipine in man. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),%,84,135375,DB01115,Nifedipine
,2967593,half-life,"4. For the two volunteers, amlodipine concentrations in plasma declined with a mean half-life of 33 h, while slower elimination of total drug-related material from plasma was observed, consistent with prolonged excretion (up to 12 days) of metabolites in urine and faeces.",Metabolism and kinetics of amlodipine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),h,33,135376,DB01115,Nifedipine
up to,2967593,excretion,"4. For the two volunteers, amlodipine concentrations in plasma declined with a mean half-life of 33 h, while slower elimination of total drug-related material from plasma was observed, consistent with prolonged excretion (up to 12 days) of metabolites in urine and faeces.",Metabolism and kinetics of amlodipine in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967593/),d,12,135377,DB01115,Nifedipine
,8156973,half-life,MHD is eliminated with a half-life of about 8-10 h.,Clinical pharmacology and pharmacokinetics of oxcarbazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156973/),h,8-10,135672,DB01115,Nifedipine
,2603904,peak concentration,The peak concentration of nifedipine during sublingual therapy ranged from 23.4 to 197.9 ng/ml and reflected substantial interpatient variability.,Nifedipine pharmacokinetics during preterm labor tocolysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2603904/),[ng] / [ml],23.4 to 197.9,136572,DB01115,Nifedipine
,2603904,measurable trough,The mean (+/- SD) measurable trough value in patients who received 20 mg of nifedipine orally every 6 hours was 7.2 +/- 5.5 ng/ml.,Nifedipine pharmacokinetics during preterm labor tocolysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2603904/),[ng] / [ml],7.2,136573,DB01115,Nifedipine
,2603904,half-life,The maternal mean half-life of nifedipine was 81 minutes (range 49 to 137 minutes).,Nifedipine pharmacokinetics during preterm labor tocolysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2603904/),min,81,136574,DB01115,Nifedipine
,23447047,Tmax,"The main pharmacokinetic parameters of nifedipine, as Tmax, t1/2α, t1/2β, t1/2z, Cmax, AUC0~36, AUC0~∞ were 2.80±0.50 h, 6.78±2.52 h, 6.82±2.53 h, 6.69±2.22 h, 76.69±19.51 (ng/mL), 546.49±162.28 (ng · h/mL) and 564.05±176.74 (ng · h/mL), respectively.","A more rapid, sensitive, and specific HPLC-MS/MS method for nifedipine analysis in human plasma and application to a pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447047/),h,2.80,138263,DB01115,Nifedipine
,23447047,AUC0~∞,"The main pharmacokinetic parameters of nifedipine, as Tmax, t1/2α, t1/2β, t1/2z, Cmax, AUC0~36, AUC0~∞ were 2.80±0.50 h, 6.78±2.52 h, 6.82±2.53 h, 6.69±2.22 h, 76.69±19.51 (ng/mL), 546.49±162.28 (ng · h/mL) and 564.05±176.74 (ng · h/mL), respectively.","A more rapid, sensitive, and specific HPLC-MS/MS method for nifedipine analysis in human plasma and application to a pharmacokinetic study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447047/),[h·ng] / [ml],564.05,138264,DB01115,Nifedipine
,2530866,absolute bioavailability,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,64,140280,DB01115,Nifedipine
,2530866,elimination half-life,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140281,DB01115,Nifedipine
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 10,140282,DB01115,Nifedipine
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,10,140283,DB01115,Nifedipine
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,30,140284,DB01115,Nifedipine
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 6,140285,DB01115,Nifedipine
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,48,140286,DB01115,Nifedipine
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,35,140287,DB01115,Nifedipine
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,60,140288,DB01115,Nifedipine
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140289,DB01115,Nifedipine
,2429095,Maximum plasma concentrations,Maximum plasma concentrations of nifedipine (37.1 +/- 16.7 ng/ml) and atenolol (276.3 +/- 107.2 ng/ml) and terminal half-life of atenolol (9.9 +/- 2.6 h) were not altered by combined administration of the drugs.,Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429095/),[ng] / [ml],37.1,141143,DB01115,Nifedipine
,2429095,Maximum plasma concentrations,Maximum plasma concentrations of nifedipine (37.1 +/- 16.7 ng/ml) and atenolol (276.3 +/- 107.2 ng/ml) and terminal half-life of atenolol (9.9 +/- 2.6 h) were not altered by combined administration of the drugs.,Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429095/),[ng] / [ml],276.3,141144,DB01115,Nifedipine
,2429095,terminal half-life,Maximum plasma concentrations of nifedipine (37.1 +/- 16.7 ng/ml) and atenolol (276.3 +/- 107.2 ng/ml) and terminal half-life of atenolol (9.9 +/- 2.6 h) were not altered by combined administration of the drugs.,Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429095/),h,9.9,141145,DB01115,Nifedipine
,3370080,Maximal concentrations Cmax,"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[ng] / [ml],46.4 and 251.0,141263,DB01115,Nifedipine
,3370080,Maximal concentrations Cmax,"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[ng] / [ml],100.7,141264,DB01115,Nifedipine
,3370080,Maximal concentrations Cmax,"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[ng] / [ml],112.6,141265,DB01115,Nifedipine
,3370080,Maximal concentrations Cmax,"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[h·ng] / [ml],35.5 and 279.7,141266,DB01115,Nifedipine
,3370080,Maximal concentrations Cmax,"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[h·ng] / [ml],115.8,141267,DB01115,Nifedipine
,3370080,Maximal concentrations Cmax,"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),,125.2,141268,DB01115,Nifedipine
,3370080,areas under the curves (AUC0-infinity),"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[h·ng] / [ml],173.6,141269,DB01115,Nifedipine
,3370080,areas under the curves (AUC0-infinity),"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[h·ng] / [ml],188.6,141270,DB01115,Nifedipine
,3370080,areas under the curves (AUC0-infinity),"Maximal concentrations Cmax varied between 46.4 and 251.0 ng/ml (median 100.7, mean 112.6) after P and between 35.5 and 279.7 ng.h/ml (median 115.8, mean 125.2) after R. Mean areas under the curves (AUC0-infinity) were 173.6 (median 151.4 P) and 188.6 ng.h/ml (median 163.1, R).",[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),[h·ng] / [ml],163.1,141271,DB01115,Nifedipine
,3370080,bioavailability,Since the bioavailability of P is 97% the two preparations are bioequivalent.,[A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370080/),%,97,141272,DB01115,Nifedipine
,8369004,concentrations,"On Day 4 mean pre-dose nifedipine concentrations were 20.5, 24.9, 31.8 ng/ml and Cmax values were 42.3, 51.7 and 93.9 ng/ml for the 60, 90 and 120 mg dose, respectively (n = 15).",Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369004/),ng,20,142397,DB01115,Nifedipine
,8369004,concentrations,"On Day 4 mean pre-dose nifedipine concentrations were 20.5, 24.9, 31.8 ng/ml and Cmax values were 42.3, 51.7 and 93.9 ng/ml for the 60, 90 and 120 mg dose, respectively (n = 15).",Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369004/),ng,24.9,142398,DB01115,Nifedipine
,8369004,concentrations,"On Day 4 mean pre-dose nifedipine concentrations were 20.5, 24.9, 31.8 ng/ml and Cmax values were 42.3, 51.7 and 93.9 ng/ml for the 60, 90 and 120 mg dose, respectively (n = 15).",Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369004/),ng,31.8,142399,DB01115,Nifedipine
,8369004,Cmax,"On Day 4 mean pre-dose nifedipine concentrations were 20.5, 24.9, 31.8 ng/ml and Cmax values were 42.3, 51.7 and 93.9 ng/ml for the 60, 90 and 120 mg dose, respectively (n = 15).",Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369004/),[ng] / [ml],42.3,142400,DB01115,Nifedipine
,8369004,Cmax,"On Day 4 mean pre-dose nifedipine concentrations were 20.5, 24.9, 31.8 ng/ml and Cmax values were 42.3, 51.7 and 93.9 ng/ml for the 60, 90 and 120 mg dose, respectively (n = 15).",Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369004/),[ng] / [ml],51.7,142401,DB01115,Nifedipine
,8369004,Cmax,"On Day 4 mean pre-dose nifedipine concentrations were 20.5, 24.9, 31.8 ng/ml and Cmax values were 42.3, 51.7 and 93.9 ng/ml for the 60, 90 and 120 mg dose, respectively (n = 15).",Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8369004/),[ng] / [ml],93.9,142402,DB01115,Nifedipine
,16920316,analytical recovery,The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1.,Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920316/),%,94,142680,DB01115,Nifedipine
,16920316,analytical recovery,The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1.,Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920316/),%,89,142681,DB01115,Nifedipine
,4026905,biological half-life,"In this experiment, the absorption, excretion, distribution and metabolism of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)-1, 4-dihydropyridine (PP-1466) were investigated following oral or intravenous administration, single dose or repeated dose administration using male SLC-Wistar rats and the results of this investigation were summarized as follows: After oral administration of 14C-PP-1466 to rats, the blood level reached the maximum at 1 h and decreased with the biological half-life of about 5 h.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),h,5,142703,DB01115,Nifedipine
,4026905,excretion,"After oral and intravenous administrations, the excretion in feces and urine during 48 h was 63.0 and 32.4, 58.6 and 41.6%, respectively.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),%,63.0,142704,DB01115,Nifedipine
,4026905,excretion,"After oral and intravenous administrations, the excretion in feces and urine during 48 h was 63.0 and 32.4, 58.6 and 41.6%, respectively.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),%,32.4,142705,DB01115,Nifedipine
,4026905,excretion,"After oral and intravenous administrations, the excretion in feces and urine during 48 h was 63.0 and 32.4, 58.6 and 41.6%, respectively.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),%,58.6,142706,DB01115,Nifedipine
,4026905,excretion,"After oral and intravenous administrations, the excretion in feces and urine during 48 h was 63.0 and 32.4, 58.6 and 41.6%, respectively.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),%,41.6,142707,DB01115,Nifedipine
,4026905,Biliary excretion,"Biliary excretion amounted to 57.6 and 46.2% during 48 h, respectively.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),%,57.6,142708,DB01115,Nifedipine
,4026905,Biliary excretion,"Biliary excretion amounted to 57.6 and 46.2% during 48 h, respectively.","Absorption, distribution, metabolism and excretion of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)- 1,4-dihydropyridine (PP-1466) in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026905/),%,46.2,142709,DB01115,Nifedipine
,7866520,extraction recovery,"The validation of the method shows that the extraction recovery is ca. 85%, the limit of detection is 2 ng/ml and the standard deviations of the intra-day precision test range from 5.8 to 7.4% with respect to the concentration.",Determination of nifedipine in human serum by gas chromatography-mass spectrometry: validation of the method and its use in bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7866520/),%,85,143680,DB01115,Nifedipine
,20137768,AUC(0-tlast),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],466.7,143954,DB01115,Nifedipine
,20137768,C(max),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],21.9,143955,DB01115,Nifedipine
,20137768,AUC(0-tlast),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],507.8,143956,DB01115,Nifedipine
,20137768,C(max)),"Under fasting conditions total and maximum exposure, represented by geometric mean AUC(0-tlast)- and C(max)-values, respectively were 466.7 h*ng/ml (AUC(0-tlast)) and 21.9 ng/ml (C(max)) for Test and 507.8 h*ng/ml (AUC(0-tlast)) and 22.0 ng/ml (C(max)) for Reference tablets.",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],22.0,143957,DB01115,Nifedipine
,20137768,AUC(0-tlast),"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],481.8,143958,DB01115,Nifedipine
,20137768,C(max),"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],25.3,143959,DB01115,Nifedipine
,20137768,AUC(0-tlast,"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[h·ng] / [ml],595.9,143960,DB01115,Nifedipine
,20137768,C(max),"Both, total and maximum exposure, represented by geometric mean values for AUC(0-tlast) and C(max), were considerably lower (differences also statistically significant) after administration of Test with 481.8 h*ng/ml for AUC(0-tlast) and 25.3 ng/ml for C(max) in comparison to Reference tablets with 595.9 h*ng/ml for AUC(0-tlast) and 31.9 ng/ml for C(max).",Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137768/),[ng] / [ml],31.9,143961,DB01115,Nifedipine
,14738715,t1/2 beta,Dibudipine showed a bi-exponential decline after IV injection in the rats with a t1/2 beta of 2.5 +/- 0.5(mean +/- SE) hr.,Application of a new high performance liquid chromatography method to the pharmacokinetics of dibudipine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14738715/),h,2.5,144177,DB01115,Nifedipine
,25984962,AUC(0-12),"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),[ngh] / [ml],250.2,146168,DB01115,Nifedipine
,25984962,ClT/F,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),[l] / [h],89.2,146169,DB01115,Nifedipine
,25984962,Vd/F,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),l,600.0,146170,DB01115,Nifedipine
,25984962,t1/2,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),h,5.1,146171,DB01115,Nifedipine
,25984962,amniotic fluid/plasma concentration ratio,The mean amniotic fluid/plasma concentration ratio was 0.05.,Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),,0.05,146172,DB01115,Nifedipine
,8408733,area under the curve (AUC0-8),Nifedipine area under the curve (AUC0-8) increased 36.6% from 333 to 455 micrograms.hr/L (P < .05) after quinidine administration.,Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408733/),[h·μg] / [l],333,146746,DB01115,Nifedipine
,8408733,area under the curve (AUC0-8),Nifedipine area under the curve (AUC0-8) increased 36.6% from 333 to 455 micrograms.hr/L (P < .05) after quinidine administration.,Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408733/),[h·μg] / [l],455,146747,DB01115,Nifedipine
,2795963,area under the curve (AUC),"The area under the curve (AUC) of captopril in the elderly group (335.4 +/- 98.6 hr.2ng/ml) was significantly greater than in the young group (186.7 +/- 79.9) (p less than 0.005), while no significant differences in Cmax, Tmax and T1/2 were observed.",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),2·h,335.4,149720,DB01115,Nifedipine
,2795963,area under the curve (AUC),"The area under the curve (AUC) of captopril in the elderly group (335.4 +/- 98.6 hr.2ng/ml) was significantly greater than in the young group (186.7 +/- 79.9) (p less than 0.005), while no significant differences in Cmax, Tmax and T1/2 were observed.",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),[ng] / [ml],186.7,149721,DB01115,Nifedipine
,2795963,Cmax,"Cmax and AUC of nifedipine in the elderly tended to be higher than in the young group (303.5 v.s. 210.0 ng/ml and 1258.9 v.s. 725.1 hr.ng/ml, p less than 0.1, respectively).",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),[ng] / [ml],303.5,149722,DB01115,Nifedipine
,2795963,AUC,"Cmax and AUC of nifedipine in the elderly tended to be higher than in the young group (303.5 v.s. 210.0 ng/ml and 1258.9 v.s. 725.1 hr.ng/ml, p less than 0.1, respectively).",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),[h·ng] / [ml],1258.9,149723,DB01115,Nifedipine
,1884725,total,Six h after dosing the time of onset of chest pain and total exercise time were longer and total work was significantly higher during both nifedipine-ER (plasma concentration 260 nmol/l) and placebo treatment than after nifedipine capsules (plasma concentration 78 nmol/l).,Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884725/),,260,150293,DB01115,Nifedipine
,4096741,peak concentrations,"2 h after dosing, peak concentrations of 13 to 74 ng/ml were reached, the minimal therapeutic plasma level of 10-15 ng/ml was - in general - upheld for 10 respectively 8 h.",[Bioavailability of new nifedipine preparations in man. 1. Pharmacokinetics of nifedipine in the form of sustained-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096741/),[ng] / [ml],13 to 74,150524,DB01115,Nifedipine
,4096741,minimal therapeutic plasma level,"2 h after dosing, peak concentrations of 13 to 74 ng/ml were reached, the minimal therapeutic plasma level of 10-15 ng/ml was - in general - upheld for 10 respectively 8 h.",[Bioavailability of new nifedipine preparations in man. 1. Pharmacokinetics of nifedipine in the form of sustained-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096741/),[ng] / [ml],10-15,150525,DB01115,Nifedipine
,4096741,Terminal elimination half-lives,"Terminal elimination half-lives were calculated to be 5 and 8 h, respectively.",[Bioavailability of new nifedipine preparations in man. 1. Pharmacokinetics of nifedipine in the form of sustained-release tablets]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096741/),h,5,150526,DB01115,Nifedipine
,4096741,Terminal elimination half-lives,"Terminal elimination half-lives were calculated to be 5 and 8 h, respectively.",[Bioavailability of new nifedipine preparations in man. 1. Pharmacokinetics of nifedipine in the form of sustained-release tablets]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096741/),h,8,150527,DB01115,Nifedipine
,6315329,plasma level peaks,"After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml.",[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6315329/),[ng] / [ml],87.7,151428,DB01115,Nifedipine
,6315329,plasma level peaks,"After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml.",[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6315329/),[ng] / [ml],46.1,151429,DB01115,Nifedipine
,26406153,particle size,The particle size of optimum formulation was 22.8 ± 4.0 nm.,Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26406153/),,22.8,151552,DB01115,Nifedipine
,22040887,duration of,"In vivo absorption profiles calculated by deconvolution method suggested that the duration of drug absorption from DCMT-S was prolonged from 6 h in fasted condition to 8 h in fed condition, suggesting longer gastro-intestinal (GI) transit time in fed condition allowed longer drug release duration from DCMT-S.",Factors affecting the absorption of nilvadipine from disintegration-controlled matrix tablet in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22040887/),,6,153675,DB01115,Nifedipine
,22040887,duration of,"In vivo absorption profiles calculated by deconvolution method suggested that the duration of drug absorption from DCMT-S was prolonged from 6 h in fasted condition to 8 h in fed condition, suggesting longer gastro-intestinal (GI) transit time in fed condition allowed longer drug release duration from DCMT-S.",Factors affecting the absorption of nilvadipine from disintegration-controlled matrix tablet in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22040887/),,8,153676,DB01115,Nifedipine
,11748687,overall extraction recoveries,"The overall extraction recoveries of NIT and DNIT were determined to be about 75% and 78% on average, respectively.",Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),%,75,154257,DB01115,Nifedipine
,11748687,overall extraction recoveries,"The overall extraction recoveries of NIT and DNIT were determined to be about 75% and 78% on average, respectively.",Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),%,78,154258,DB01115,Nifedipine
,11748687,ch,The chromatographic run time was approximately 3 min.,Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),min,3,154259,DB01115,Nifedipine
,11748687,run time,The chromatographic run time was approximately 3 min.,Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),min,3,154260,DB01115,Nifedipine
,3707813,volume of distribution (V),"Mean volume of distribution (V) rose from 0.33 +/- 0.07 to 0.39 +/- 0.06 1 kg-1 corrected body weight (CBW) in the presence of nifedipine (t = 2.23, P = 0.052).",The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707813/),[1] / [kg],0.33,154843,DB01115,Nifedipine
,3707813,volume of distribution (V),"Mean volume of distribution (V) rose from 0.33 +/- 0.07 to 0.39 +/- 0.06 1 kg-1 corrected body weight (CBW) in the presence of nifedipine (t = 2.23, P = 0.052).",The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707813/),[1] / [kg],0.39,154844,DB01115,Nifedipine
,10885439,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of nifedipine during the UVA irradiation session (median 206 ng x ml(-1) x h(-1)) was significantly higher than during the non-irradiation control session (median 174.5 ng x ml(-1) x h(-1)) (P=0.03; 95% C.I. for difference in medians 9.9 to 55.9 ng x ml(-1) x h(-1)).,The effect of whole-body sunbed ultraviolet A exposure on the pharmacokinetics of the photolabile drug nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885439/),[ng] / [h·ml],206,155091,DB01115,Nifedipine
,10885439,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of nifedipine during the UVA irradiation session (median 206 ng x ml(-1) x h(-1)) was significantly higher than during the non-irradiation control session (median 174.5 ng x ml(-1) x h(-1)) (P=0.03; 95% C.I. for difference in medians 9.9 to 55.9 ng x ml(-1) x h(-1)).,The effect of whole-body sunbed ultraviolet A exposure on the pharmacokinetics of the photolabile drug nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885439/),[ng] / [h·ml],174.5,155092,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,28.0,156443,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,5.1,156444,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,9.9,156445,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,2.8,156446,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22. 9,156447,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,14.7,156448,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22.3,156449,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,11.1,156450,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,39.6,156451,DB01115,Nifedipine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,26,156452,DB01115,Nifedipine
,3354229,terminal half-lives,"2. After i.v. dosing (0.1 mg/kg), the plasma concentrations of nilvadipine declined two- or three-exponential with terminal half-lives of 0.73 h in mice, 1.2 h in male and female rats, 3.7 h in rabbits and 5.0 h in dogs.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),h,0.73,159676,DB01115,Nifedipine
,3354229,terminal half-lives,"2. After i.v. dosing (0.1 mg/kg), the plasma concentrations of nilvadipine declined two- or three-exponential with terminal half-lives of 0.73 h in mice, 1.2 h in male and female rats, 3.7 h in rabbits and 5.0 h in dogs.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),h,1.2,159677,DB01115,Nifedipine
,3354229,terminal half-lives,"2. After i.v. dosing (0.1 mg/kg), the plasma concentrations of nilvadipine declined two- or three-exponential with terminal half-lives of 0.73 h in mice, 1.2 h in male and female rats, 3.7 h in rabbits and 5.0 h in dogs.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),h,3.7,159678,DB01115,Nifedipine
,3354229,terminal half-lives,"2. After i.v. dosing (0.1 mg/kg), the plasma concentrations of nilvadipine declined two- or three-exponential with terminal half-lives of 0.73 h in mice, 1.2 h in male and female rats, 3.7 h in rabbits and 5.0 h in dogs.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),h,5.0,159679,DB01115,Nifedipine
greater,3354229,volume of distribution at steady-state,The volume of distribution at steady-state was high (greater than 4 L/kg) in all species.,"Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),[l] / [kg],4,159680,DB01115,Nifedipine
,3354229,Bioavailability,"Bioavailability was low in male rats (3-4%) and rabbits (2%), but in other species was 29-44%.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),%,3-4,159681,DB01115,Nifedipine
,3354229,Bioavailability,"Bioavailability was low in male rats (3-4%) and rabbits (2%), but in other species was 29-44%.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),%,2,159682,DB01115,Nifedipine
,3354229,Bioavailability,"Bioavailability was low in male rats (3-4%) and rabbits (2%), but in other species was 29-44%.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),%,29-44,159683,DB01115,Nifedipine
,3354229,free fraction,"4. The free fraction of nilvadipine in plasma was 1.94% in mice, 1.89% in rabbits and 0.85% in dogs, with no dependence on plasma concentration over a range of 10-100 ng/ml.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),%,1.94,159684,DB01115,Nifedipine
,3354229,free fraction,"4. The free fraction of nilvadipine in plasma was 1.94% in mice, 1.89% in rabbits and 0.85% in dogs, with no dependence on plasma concentration over a range of 10-100 ng/ml.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),%,1.89,159685,DB01115,Nifedipine
,3354229,free fraction,"4. The free fraction of nilvadipine in plasma was 1.94% in mice, 1.89% in rabbits and 0.85% in dogs, with no dependence on plasma concentration over a range of 10-100 ng/ml.","Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3354229/),%,0.85,159686,DB01115,Nifedipine
,19301938,maximum serum concentration (C(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],245.1,160184,DB01115,Nifedipine
,19301938,maximum serum concentration (C(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],73.6,160185,DB01115,Nifedipine
,19301938,time to reach C(max) (t(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),min,69.2,160186,DB01115,Nifedipine
,19301938,time to reach C(max) (t(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),min,40,160187,DB01115,Nifedipine
,19301938,area under the serum concentration-time curve from 0 to 6 hours (AUC(6)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[h·ng] / [ml],756.5,160188,DB01115,Nifedipine
,19301938,area under the serum concentration-time curve from 0 to 6 hours (AUC(6)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[h·ng] / [ml],238.2,160189,DB01115,Nifedipine
above,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1000,160190,DB01115,Nifedipine
,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1037.8,160191,DB01115,Nifedipine
,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1044.75,160192,DB01115,Nifedipine
,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1364.1,160193,DB01115,Nifedipine
,2772014,absolute bioavailability,The absolute bioavailability of 1 was 53% because of presystemic metabolism.,Bioavailability of nifedipine from different oral dosage forms in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2772014/),%,53,160724,DB01115,Nifedipine
,2772014,bioavailability,"The bioavailability of Adalat (Bayer) tablets, Nifedipina (Terapia) and Corinfar (VEB Arzneimittelwerk Dresden) sugar-coated tablets was 93%, 92% and 86% (respectively) as compared with Adalat capsules.",Bioavailability of nifedipine from different oral dosage forms in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2772014/),%,93,160725,DB01115,Nifedipine
,2772014,bioavailability,"The bioavailability of Adalat (Bayer) tablets, Nifedipina (Terapia) and Corinfar (VEB Arzneimittelwerk Dresden) sugar-coated tablets was 93%, 92% and 86% (respectively) as compared with Adalat capsules.",Bioavailability of nifedipine from different oral dosage forms in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2772014/),%,92,160726,DB01115,Nifedipine
,2772014,bioavailability,"The bioavailability of Adalat (Bayer) tablets, Nifedipina (Terapia) and Corinfar (VEB Arzneimittelwerk Dresden) sugar-coated tablets was 93%, 92% and 86% (respectively) as compared with Adalat capsules.",Bioavailability of nifedipine from different oral dosage forms in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2772014/),%,86,160727,DB01115,Nifedipine
,8032493,determination limits,"The determination limits were 2 and 10 ng/ml, respectively, and the detection limits were 1 and 5 ng/ml, respectively.",Evaluation of chromatographic methods for the determination of nifedipine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032493/),[ng] / [ml],2,161429,DB01115,Nifedipine
,8032493,determination limits,"The determination limits were 2 and 10 ng/ml, respectively, and the detection limits were 1 and 5 ng/ml, respectively.",Evaluation of chromatographic methods for the determination of nifedipine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032493/),[ng] / [ml],10,161430,DB01115,Nifedipine
,8032493,detection limits,"The determination limits were 2 and 10 ng/ml, respectively, and the detection limits were 1 and 5 ng/ml, respectively.",Evaluation of chromatographic methods for the determination of nifedipine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032493/),[ng] / [ml],1,161431,DB01115,Nifedipine
,8032493,detection limits,"The determination limits were 2 and 10 ng/ml, respectively, and the detection limits were 1 and 5 ng/ml, respectively.",Evaluation of chromatographic methods for the determination of nifedipine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032493/),[ng] / [ml],5,161432,DB01115,Nifedipine
,8032493,Recoveries,"Recoveries based on three different concentrations were 88.7-95.8% and 93.7-104.2%, respectively.",Evaluation of chromatographic methods for the determination of nifedipine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032493/),%,88.7-95.8,161433,DB01115,Nifedipine
,8032493,Recoveries,"Recoveries based on three different concentrations were 88.7-95.8% and 93.7-104.2%, respectively.",Evaluation of chromatographic methods for the determination of nifedipine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8032493/),%,93.7-104.2,161434,DB01115,Nifedipine
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162611,DB01115,Nifedipine
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162612,DB01115,Nifedipine
,8068867,CLH,An increase to 72 +/- 25 mL min-1 in the CLH of cortisol to 6 beta-hydroxycortisol was calculated following rifampicin treatment.,Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],72,162613,DB01115,Nifedipine
,6339196,bioavailability,"However, the bioavailability of verapamil has been studied extensively; about 22% of an orally administered dose of verapamil is systemically available.",Calcium antagonists. Pharmacokinetic properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),%,22,163725,DB01115,Nifedipine
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,8,163726,DB01115,Nifedipine
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,5,163727,DB01115,Nifedipine
,2049247,area under the plasma concentration-time curve (AUC),2. The area under the plasma concentration-time curve (AUC) of nifedipine was three fold higher in South Asians (989 +/- 166 ng ml-1 h) than in Caucasians (323 +/- 116 ng ml-1 h).,Ethnic differences in the pharmacokinetics of oral nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049247/),[h·ng] / [ml],989,164543,DB01115,Nifedipine
,2049247,area under the plasma concentration-time curve (AUC),2. The area under the plasma concentration-time curve (AUC) of nifedipine was three fold higher in South Asians (989 +/- 166 ng ml-1 h) than in Caucasians (323 +/- 116 ng ml-1 h).,Ethnic differences in the pharmacokinetics of oral nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049247/),[h·ng] / [ml],323,164544,DB01115,Nifedipine
greater,20704460,recovery,"The limit of quantitation for NF was 5 ng/mL in serum, and the recovery was greater than 90%.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),%,90,164908,DB01115,Nifedipine
,20704460,Cmax,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[μg] / [l],320.2,164909,DB01115,Nifedipine
,20704460,Tmax,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,3.2,164910,DB01115,Nifedipine
,20704460,t1/2,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,6.60,164911,DB01115,Nifedipine
,20704460,AUC0-24,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[h·mg] / [l],2.03,164912,DB01115,Nifedipine
,20704460,AUC0-∞,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[h·mg] / [l],2.50,164913,DB01115,Nifedipine
,20704460,MRT0-24,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,8.57,164914,DB01115,Nifedipine
,20704460,MRT0-∞,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,15.2,164915,DB01115,Nifedipine
,1910493,elimination half-life,The elimination half-life of intravenous indocyanine green was only 1 hour after oral nifedipine (20 mg) significantly decreased.,[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910493/),h,1,165139,DB01115,Nifedipine
,15265551,times of first nifedipine appearance (TFA),"The times of first nifedipine appearance (TFA) in plasma were 0.7 +/- 0.3 h for SR, 2.5 +/- 1.2 h for CC-1, and 5.3 +/- 1.0 h for CC-2.",Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265551/),h,0.7,165449,DB01115,Nifedipine
,15265551,times of first nifedipine appearance (TFA),"The times of first nifedipine appearance (TFA) in plasma were 0.7 +/- 0.3 h for SR, 2.5 +/- 1.2 h for CC-1, and 5.3 +/- 1.0 h for CC-2.",Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265551/),h,2.5,165450,DB01115,Nifedipine
,15265551,times of first nifedipine appearance (TFA),"The times of first nifedipine appearance (TFA) in plasma were 0.7 +/- 0.3 h for SR, 2.5 +/- 1.2 h for CC-1, and 5.3 +/- 1.0 h for CC-2.",Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15265551/),h,5.3,165451,DB01115,Nifedipine
,2777428,tmax,"From the liquid-filled capsules, nifedipine was absorbed rapidly (tmax at 30-40 min).",Pharmacokinetics and acute side-effects of nifedipine given as slow-release tablets or liquid-filled capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777428/),min,30-40,166058,DB01115,Nifedipine
,2486739,maximum concentration,"With the 10 mg capsule nifedipine was rapidly absorbed, reaching a maximum concentration of 120 +/- 39 ng/ml in 0.52 +/- 0.07 h, and also rapidly eliminated with an apparent halflife of 5.51 +/- 0.64 h.",[Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486739/),[ng] / [ml],120,167549,DB01115,Nifedipine
,2486739,apparent halflife,"With the 10 mg capsule nifedipine was rapidly absorbed, reaching a maximum concentration of 120 +/- 39 ng/ml in 0.52 +/- 0.07 h, and also rapidly eliminated with an apparent halflife of 5.51 +/- 0.64 h.",[Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486739/),h,5.51,167550,DB01115,Nifedipine
,2486739,maximum concentration,"With the 20 mg slow release tablet nifedipine absorption was slower, reaching a maximum concentration of 39 +/- 7 ng/ml in 1.82 +/- 0.43 h, and the apparent half-life (16.89 +/- 3.14 h) was longer than with the capsule.",[Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486739/),[ng] / [ml],39,167551,DB01115,Nifedipine
,2486739,apparent half-life,"With the 20 mg slow release tablet nifedipine absorption was slower, reaching a maximum concentration of 39 +/- 7 ng/ml in 1.82 +/- 0.43 h, and the apparent half-life (16.89 +/- 3.14 h) was longer than with the capsule.",[Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2486739/),h,16.89,167552,DB01115,Nifedipine
,8593428,detection limit,The detection limit was 1 ng/ml.,Determination of barnidipine in human serum and dog plasma by HPLC with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593428/),[ng] / [ml],1,167615,DB01115,Nifedipine
,8593428,HCl,HCl was 6.9% and the recovery was 104%.,Determination of barnidipine in human serum and dog plasma by HPLC with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593428/),%,6.9,167616,DB01115,Nifedipine
,8593428,recovery,HCl was 6.9% and the recovery was 104%.,Determination of barnidipine in human serum and dog plasma by HPLC with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593428/),%,104,167617,DB01115,Nifedipine
,3243913,area under the plasma concentration-time curve (AUC0----infinity),"While there were no significant differences in the mean area under the plasma concentration-time curve (AUC0----infinity) between dosing regimens 2 (38.7 ng.hr/mL) and 3 (42.1 ng.hr/mL) (P greater than 0.05), the mean AUC0----infinity after regimen 1 (76.3 ng.hr/mL) was significantly greater than after dosing regimens 2 or 3 (P less than 0.05).",Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243913/),[h·ng] / [ml],38.7,168701,DB01115,Nifedipine
,3243913,area under the plasma concentration-time curve (AUC0----infinity),"While there were no significant differences in the mean area under the plasma concentration-time curve (AUC0----infinity) between dosing regimens 2 (38.7 ng.hr/mL) and 3 (42.1 ng.hr/mL) (P greater than 0.05), the mean AUC0----infinity after regimen 1 (76.3 ng.hr/mL) was significantly greater than after dosing regimens 2 or 3 (P less than 0.05).",Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243913/),[h·ng] / [ml],42.1,168702,DB01115,Nifedipine
,3243913,AUC0----infinity,"While there were no significant differences in the mean area under the plasma concentration-time curve (AUC0----infinity) between dosing regimens 2 (38.7 ng.hr/mL) and 3 (42.1 ng.hr/mL) (P greater than 0.05), the mean AUC0----infinity after regimen 1 (76.3 ng.hr/mL) was significantly greater than after dosing regimens 2 or 3 (P less than 0.05).",Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243913/),[h·ng] / [ml],76.3,168703,DB01115,Nifedipine
,3243913,maximal plasma concentrations (Cmax),"The mean maximal plasma concentrations (Cmax) were 31.6, 1.3 and 6.3 ng/mL after dosing regimens 1, 2 and 3, respectively.",Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243913/),[ng] / [ml],31.6,168704,DB01115,Nifedipine
,3243913,maximal plasma concentrations (Cmax),"The mean maximal plasma concentrations (Cmax) were 31.6, 1.3 and 6.3 ng/mL after dosing regimens 1, 2 and 3, respectively.",Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243913/),[ng] / [ml],1.3,168705,DB01115,Nifedipine
,3243913,maximal plasma concentrations (Cmax),"The mean maximal plasma concentrations (Cmax) were 31.6, 1.3 and 6.3 ng/mL after dosing regimens 1, 2 and 3, respectively.",Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3243913/),[ng] / [ml],6.3,168706,DB01115,Nifedipine
,9570001,relative bioavailability,"GJC significantly increased nifedipine bioavailability (relative bioavailability 2.02, compared with (tap) water), indicating that GJC may affect both extrahepatic and hepatic first-pass metabolism, although a reduction in systemic nifedipine clearance cannot be ruled out.",Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9570001/),,2.02,171589,DB01115,Nifedipine
,7210701,rate of metabolism,"2. The rate of metabolism of the drug in rat liver was 1.76 mumol/g tissue per 20 min, while the values in the intestine, kidney, lung and blood were less than 0.1 mumol/g tissue per 20 min, suggesting that the first-pass effect observed in vivo was due mainly to metabolism of the drug in the liver.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],1.76,171655,DB01115,Nifedipine
less,7210701,rate of metabolism,"2. The rate of metabolism of the drug in rat liver was 1.76 mumol/g tissue per 20 min, while the values in the intestine, kidney, lung and blood were less than 0.1 mumol/g tissue per 20 min, suggesting that the first-pass effect observed in vivo was due mainly to metabolism of the drug in the liver.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],0.1,171656,DB01115,Nifedipine
,7210701,rates of liver metabolism,"3. The rates of liver metabolism were 1.76, 0.45 and 0.55 mumol/g tissue per 20 min in rats, dogs and monkeys, respectively.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],1.76,171657,DB01115,Nifedipine
,7210701,rates of liver metabolism,"3. The rates of liver metabolism were 1.76, 0.45 and 0.55 mumol/g tissue per 20 min in rats, dogs and monkeys, respectively.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],0.45,171658,DB01115,Nifedipine
,7210701,rates of liver metabolism,"3. The rates of liver metabolism were 1.76, 0.45 and 0.55 mumol/g tissue per 20 min in rats, dogs and monkeys, respectively.","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[μM] / [20·g·min·tissue],0.55,171659,DB01115,Nifedipine
,7210701,plasma clearance,"This species difference correlates well with the differences in plasma clearance values, which were 197, 37 and 27 ml/min per kg in rats, dogs and monkeys, respectively, after i.v. administration of nicardipine hydrochloride (0.4 mg/kg).","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[ml] / [kg·min],197,171660,DB01115,Nifedipine
,7210701,plasma clearance,"This species difference correlates well with the differences in plasma clearance values, which were 197, 37 and 27 ml/min per kg in rats, dogs and monkeys, respectively, after i.v. administration of nicardipine hydrochloride (0.4 mg/kg).","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[ml] / [kg·min],37,171661,DB01115,Nifedipine
,7210701,plasma clearance,"This species difference correlates well with the differences in plasma clearance values, which were 197, 37 and 27 ml/min per kg in rats, dogs and monkeys, respectively, after i.v. administration of nicardipine hydrochloride (0.4 mg/kg).","Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7210701/),[ml] / [kg·min],27,171662,DB01115,Nifedipine
,2808746,maximum concentration,Levels rose after drug administration reaching a maximum concentration of 48.7 +/- 7.3 ng/ml in 2.1 +/- 0.7 h (mean +/- SEM).,Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808746/),[ng] / [ml],48.7,172037,DB01115,Nifedipine
,2808746,terminal half-life,Concentrations then decayed with a terminal half-life of 16.9 +/- 3.1 hours.,Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808746/),h,16.9,172038,DB01115,Nifedipine
,2808746,AUC,AUC was 526 +/- 62 ng h/ml.,Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808746/),[h·ng] / [ml],526,172039,DB01115,Nifedipine
higher,2808746,AUC/Dose,Fast and slow metabolizers were distinguished as those subjects with AUC/Dose values either lower or higher than 22.5 ng h/ml mg.,Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808746/),[h·ng] / [mg·ml],22.5,172040,DB01115,Nifedipine
,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],2,173364,DB01115,Nifedipine
less,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],1,173365,DB01115,Nifedipine
,3720939,half-life period,The mean half-life period of nifedipine in the serum was 4.51 hrs.,[Pharmacokinetics of nifedipine and its metabolite after a single oral dose of the drug in patients with stenocardia of effort]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720939/),h,4.51,175048,DB01115,Nifedipine
,3720939,Binding,Binding to the blood serum proteins was 97.4% for nifedipine and 90.5% for its metabolite.,[Pharmacokinetics of nifedipine and its metabolite after a single oral dose of the drug in patients with stenocardia of effort]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720939/),%,97.4,175049,DB01115,Nifedipine
,3720939,Binding,Binding to the blood serum proteins was 97.4% for nifedipine and 90.5% for its metabolite.,[Pharmacokinetics of nifedipine and its metabolite after a single oral dose of the drug in patients with stenocardia of effort]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720939/),%,90.5,175050,DB01115,Nifedipine
,1608848,Peak serum concentrations,Peak serum concentrations of 38.6 +/- 18 ng/ml occurred at approximately 40 minutes after ingestion of nifedipine 10 mg.,Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608848/),[ng] / [ml],38.6,176482,DB01115,Nifedipine
,1608848,terminal elimination half-life,The terminal elimination half-life (mean 1.3 +/- 0.5 hrs) was shorter than that reported for normotensive volunteers and nonpregnant hypertensives after oral dosing.,Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608848/),h,1.3,176483,DB01115,Nifedipine
,1608848,apparent elimination clearance,Mean +/- SD apparent elimination clearance of 2.0 +/- 0.8 L/hr/kg was more rapid than that in healthy volunteers (mean 0.49 +/- 0.09 L/hr/kg).,Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608848/),[l] / [h·kg],2.0,176484,DB01115,Nifedipine
,1608848,apparent elimination clearance,Mean +/- SD apparent elimination clearance of 2.0 +/- 0.8 L/hr/kg was more rapid than that in healthy volunteers (mean 0.49 +/- 0.09 L/hr/kg).,Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608848/),[l] / [h·kg],0.49,176485,DB01115,Nifedipine
,2800577,AUC,"The mean AUC for fasting and meal conditions were 315.0 and 411.4 ng.h/mL, and the mean Cmax were 42.6 and 86.6 micrograms/mL, respectively.",Effect of food on nifedipine sustained-release preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800577/),[h·ng] / [ml],315.0,176751,DB01115,Nifedipine
,2800577,AUC,"The mean AUC for fasting and meal conditions were 315.0 and 411.4 ng.h/mL, and the mean Cmax were 42.6 and 86.6 micrograms/mL, respectively.",Effect of food on nifedipine sustained-release preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800577/),[h·ng] / [ml],411.4,176752,DB01115,Nifedipine
,2800577,Cmax,"The mean AUC for fasting and meal conditions were 315.0 and 411.4 ng.h/mL, and the mean Cmax were 42.6 and 86.6 micrograms/mL, respectively.",Effect of food on nifedipine sustained-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800577/),[μg] / [ml],42.6,176753,DB01115,Nifedipine
,2800577,Cmax,"The mean AUC for fasting and meal conditions were 315.0 and 411.4 ng.h/mL, and the mean Cmax were 42.6 and 86.6 micrograms/mL, respectively.",Effect of food on nifedipine sustained-release preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800577/),[μg] / [ml],86.6,176754,DB01115,Nifedipine
,9643616,steady state (t,"At presumed ICG steady state (t=45 min), subjects were dosed with oral nifedipine (20 mg), captopril (50 mg) or placebo.",The influence of nifedipine and captopril on liver blood flow in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643616/),min,45,176948,DB01115,Nifedipine
,9643616,Portal venous flow,"Portal venous flow was 15% (+ 5, + 86 ml min(-1)) higher compared to placebo after nifedipine but not after captopril (-3%; -49, +33 ml min(-1)).",The influence of nifedipine and captopril on liver blood flow in healthy subjects. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643616/),[ml] / [min],5,176949,DB01115,Nifedipine
,9643616,Portal venous flow,"Portal venous flow was 15% (+ 5, + 86 ml min(-1)) higher compared to placebo after nifedipine but not after captopril (-3%; -49, +33 ml min(-1)).",The influence of nifedipine and captopril on liver blood flow in healthy subjects. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643616/),[ml] / [min],86,176950,DB01115,Nifedipine
,24440839,diameters,"The mean diameters of drug free nano-fiber and nano-fiber including NP or UN were 751.5 ± 67.2, 703.3 ± 71.2 and 2477.8 ± 206.1 nm, respectively.",Preparation and pharmaceutical evaluation of nano-fiber matrix supported drug delivery system using the solvent-based electrospinning method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440839/),nm,751.5,178186,DB01115,Nifedipine
,24440839,diameters,"The mean diameters of drug free nano-fiber and nano-fiber including NP or UN were 751.5 ± 67.2, 703.3 ± 71.2 and 2477.8 ± 206.1 nm, respectively.",Preparation and pharmaceutical evaluation of nano-fiber matrix supported drug delivery system using the solvent-based electrospinning method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440839/),nm,703.3,178187,DB01115,Nifedipine
,24440839,diameters,"The mean diameters of drug free nano-fiber and nano-fiber including NP or UN were 751.5 ± 67.2, 703.3 ± 71.2 and 2477.8 ± 206.1 nm, respectively.",Preparation and pharmaceutical evaluation of nano-fiber matrix supported drug delivery system using the solvent-based electrospinning method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24440839/),nm,2477.8,178188,DB01115,Nifedipine
,12367682,Limit of detection,Limit of detection and limit of quantification were 1.21 x 10(-9) M (0.42 ng ml(-1)) and 2.89 x 10(-9) M (1.00 ng ml(-1)) respectively.,Determination of nifedipine in human plasma by square wave adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367682/),M,1.21 x 10(-9),178806,DB01115,Nifedipine
,12367682,limit of quantification,Limit of detection and limit of quantification were 1.21 x 10(-9) M (0.42 ng ml(-1)) and 2.89 x 10(-9) M (1.00 ng ml(-1)) respectively.,Determination of nifedipine in human plasma by square wave adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367682/),[ng] / [ml],0.42,178807,DB01115,Nifedipine
,12367682,limit of quantification,Limit of detection and limit of quantification were 1.21 x 10(-9) M (0.42 ng ml(-1)) and 2.89 x 10(-9) M (1.00 ng ml(-1)) respectively.,Determination of nifedipine in human plasma by square wave adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367682/),M,2.89 x 10(-9),178808,DB01115,Nifedipine
,12367682,limit of quantification,Limit of detection and limit of quantification were 1.21 x 10(-9) M (0.42 ng ml(-1)) and 2.89 x 10(-9) M (1.00 ng ml(-1)) respectively.,Determination of nifedipine in human plasma by square wave adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367682/),[ng] / [ml],1.00,178809,DB01115,Nifedipine
,12367682,percentage recoveries,The percentage recoveries varied from 96.26 to 99.49%.,Determination of nifedipine in human plasma by square wave adsorptive stripping voltammetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367682/),%,96.26 to 99.49,178810,DB01115,Nifedipine
,3716455,total recovered radioactivity,Mean total recovered radioactivity amounted to 94.8%.,The metabolism of nicardipine hydrochloride in healthy male volunteers. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3716455/),%,94.8,179893,DB01115,Nifedipine
,2612540,AUC,"However, partial propranolol AUC values between 0-0.33, 0-0.5, 0-1.0 and 0-1.5 h were significantly larger after single and multiple doses of nifedipine indicating higher propranolol concentrations during the absorption phase.",Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612540/),h,0-0.33,179947,DB01115,Nifedipine
,2612540,AUC,"However, partial propranolol AUC values between 0-0.33, 0-0.5, 0-1.0 and 0-1.5 h were significantly larger after single and multiple doses of nifedipine indicating higher propranolol concentrations during the absorption phase.",Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612540/),h,0-0.5,179948,DB01115,Nifedipine
,2612540,AUC,"However, partial propranolol AUC values between 0-0.33, 0-0.5, 0-1.0 and 0-1.5 h were significantly larger after single and multiple doses of nifedipine indicating higher propranolol concentrations during the absorption phase.",Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612540/),h,0,179949,DB01115,Nifedipine
,3680562,detection limit,"Nilvadipine plasma concentrations up to 32 hours after drug treatment were determined by capillary column gas chromatography-negative-ion chemical ionization mass spectrometry (detection limit, 0.01 ng/mL).",Pharmacokinetics of nilvadipine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680562/),[ng] / [ml],0.01,180568,DB01115,Nifedipine
,3680562,detection limit,"Nilvadipine urinary concentrations were determined by capillary column gas chromatography with electron capture detector (detection limit, 0.5 ng/mL).",Pharmacokinetics of nilvadipine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680562/),[ng] / [ml],0.5,180569,DB01115,Nifedipine
,3680562,maximum plasma concentrations,"The mean +/- standard deviation maximum plasma concentrations of 1.48 +/- 0.47, 3.48 +/- 0.53, and 6.69 +/- 1.54 ng/mL were attained from 1.08 to 1.50 hours after doses of 2, 4, and 6 mg, respectively.",Pharmacokinetics of nilvadipine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680562/),[ng] / [ml],1.48,180570,DB01115,Nifedipine
,3680562,maximum plasma concentrations,"The mean +/- standard deviation maximum plasma concentrations of 1.48 +/- 0.47, 3.48 +/- 0.53, and 6.69 +/- 1.54 ng/mL were attained from 1.08 to 1.50 hours after doses of 2, 4, and 6 mg, respectively.",Pharmacokinetics of nilvadipine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680562/),[ng] / [ml],3.48,180571,DB01115,Nifedipine
,3680562,maximum plasma concentrations,"The mean +/- standard deviation maximum plasma concentrations of 1.48 +/- 0.47, 3.48 +/- 0.53, and 6.69 +/- 1.54 ng/mL were attained from 1.08 to 1.50 hours after doses of 2, 4, and 6 mg, respectively.",Pharmacokinetics of nilvadipine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680562/),[ng] / [ml],6.69,180572,DB01115,Nifedipine
,3680562,elimination half-life,The elimination half-life was dose-independent and averaged 11.0 +/- 2.3 hours.,Pharmacokinetics of nilvadipine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680562/),h,11.0,180573,DB01115,Nifedipine
,3196402,half-lives,The radioactivity was eliminated from plasma with half-lives between 42 h and 54 h within an observation period up to 3 days.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),h,42,181948,DB01115,Nifedipine
,3196402,half-lives,The radioactivity was eliminated from plasma with half-lives between 42 h and 54 h within an observation period up to 3 days.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),h,54,181949,DB01115,Nifedipine
,3196402,bioavailability,The bioavailability was estimated at 3.4% in rats and 11.7% in dogs.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),%,3.4,181950,DB01115,Nifedipine
,3196402,bioavailability,The bioavailability was estimated at 3.4% in rats and 11.7% in dogs.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),%,11.7,181951,DB01115,Nifedipine
,3196402,free fractions,[14C]nisoldipine was highly bound to plasma proteins with free fractions of 0.9-2.9%.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),%,0.9-2.9,181952,DB01115,Nifedipine
,1598834,flow rate,To increase life of the YWG-C18 column a mixture of methanol and 5 mmol.L-1 phosphate buffer (70:30 vol/vol) was selected as mobile phase with a flow rate of 0.8 ml.min-1.,[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ml] / [min],0.8,183331,DB01115,Nifedipine
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),%,95-102,183332,DB01115,Nifedipine
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ng] / [ml],10-1000,183333,DB01115,Nifedipine
,1598834,Vc,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg],6.3,183334,DB01115,Nifedipine
,1598834,Cl,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg·min],0.021,183335,DB01115,Nifedipine
,1598834,T1/2 alpha,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,30,183336,DB01115,Nifedipine
,1598834,T1/2 beta,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,230,183337,DB01115,Nifedipine
,1598834,AUC,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[min·μg] / [ml],102,183338,DB01115,Nifedipine
,25549928,Inhibitory concentration (IC50),Inhibitory concentration (IC50) was 12.1 μM.,"Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25549928/),μM,12.1,183915,DB01115,Nifedipine
,25549928,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of nifedipine in the presence of pioglitazone (1.0 mg/kg) was significantly higher (25.3 %) than that of the control.","Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25549928/),%,25.3,183916,DB01115,Nifedipine
,24151144,particle size,"The mean particle size of PhytoSolve and PBF were 138.5 ± 9.0 and 74.4 ± 2.5 nm, respectively.",Improved oral bioavalability of mebudipine upon administration in PhytoSolve and Phosal-based formulation (PBF). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151144/),nm,138.5,184065,DB01115,Nifedipine
,24151144,particle size,"The mean particle size of PhytoSolve and PBF were 138.5 ± 9.0 and 74.4 ± 2.5 nm, respectively.",Improved oral bioavalability of mebudipine upon administration in PhytoSolve and Phosal-based formulation (PBF). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151144/),nm,74.4,184066,DB01115,Nifedipine
,21601538,flow rate,"The mobile phase was composed of acetonitrile-10 mmol/L ammonium acetate (75:25, v/v) with a flow rate of 0.20 mL/min.",Determination of nifedipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601538/),[ml] / [min],0.20,185587,DB01115,Nifedipine
,21601538,run time,A high throughput was achieved with a run time of 1.4 min per sample.,Determination of nifedipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601538/),[min] / [sample],1.4,185588,DB01115,Nifedipine
,3987781,Cmax,"In Phase B, the Cmax was lower than that in phase A (43 +/- 6 vs 136 +/- 23 ng/ml, p less than 0.001), and both Cmax and maximum haemodynamic changes were delayed to the fourth hour after administration.",Effect of food ingestion on nifedipine absorption and haemodynamic response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987781/),[ng] / [ml],43,187695,DB01115,Nifedipine
,3987781,Cmax,"In Phase B, the Cmax was lower than that in phase A (43 +/- 6 vs 136 +/- 23 ng/ml, p less than 0.001), and both Cmax and maximum haemodynamic changes were delayed to the fourth hour after administration.",Effect of food ingestion on nifedipine absorption and haemodynamic response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987781/),[ng] / [ml],136,187696,DB01115,Nifedipine
,2261244,half-life,"Log concentration time curves were linear from 10-72 h for nifedipine, with a half-life of 7.5 h; and for M-I with a half-life of 8.2 h.",Pharmacokinetics and toxic effects of nifedipine in massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2261244/),h,7.5,188560,DB01115,Nifedipine
,2261244,half-life,"Log concentration time curves were linear from 10-72 h for nifedipine, with a half-life of 7.5 h; and for M-I with a half-life of 8.2 h.",Pharmacokinetics and toxic effects of nifedipine in massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2261244/),h,8.2,188561,DB01115,Nifedipine
,3542336,bioavailabilities,"Therefore, their bioavailabilities (diltiazem 40 to 50%; nifedipine 40 to 50%; verapamil 10 to 30%) are low despite almost complete absorption following oral administration.","Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542336/),%,40 to 50,190352,DB01115,Nifedipine
,3542336,bioavailabilities,"Therefore, their bioavailabilities (diltiazem 40 to 50%; nifedipine 40 to 50%; verapamil 10 to 30%) are low despite almost complete absorption following oral administration.","Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542336/),%,10 to 30,190353,DB01115,Nifedipine
,10945319,systemic clearance,"A lower systemic clearance (265+/-54 versus 310+/-56 mL/min; P = .04), but not oral clearance, was observed in African Americans.",CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945319/),[ml] / [min],265,191051,DB01115,Nifedipine
,10945319,systemic clearance,"A lower systemic clearance (265+/-54 versus 310+/-56 mL/min; P = .04), but not oral clearance, was observed in African Americans.",CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945319/),[ml] / [min],310,191052,DB01115,Nifedipine
,10945319,systemic clearance,"Hepatic CYP3A activity and the systemic clearance of midazolam were about 30% lower in G/G homozygotes than in A/A homozygotes (252+/-53 versus 310+/-54 mL/min; P = .02), and a gene-dose effect was present (P = .01).",CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945319/),[ml] / [min],310,191053,DB01115,Nifedipine
,3219156,pulse rate,"Subsequently, in a placebo-controlled comparison in healthy volunteers the pulse rate in supine position increased statistically significantly on day 1 from 61.0 b/min (placebo) after application of 2 x 8 mg of KW-3049 to 67.4 b/min.","Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219156/),[b] / [min],61.0,192099,DB01115,Nifedipine
,3219156,pulse rate,"Subsequently, in a placebo-controlled comparison in healthy volunteers the pulse rate in supine position increased statistically significantly on day 1 from 61.0 b/min (placebo) after application of 2 x 8 mg of KW-3049 to 67.4 b/min.","Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219156/),[b] / [min],67.4,192100,DB01115,Nifedipine
,3219156,pulse rate,After application of 2 x 10 mg of nifedipine the supine pulse rate increased to 63.3 b/min.,"Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219156/),[b] / [min],63.3,192101,DB01115,Nifedipine
,1680651,rapid phase t1/2,The two-compartment maternal pharmacokinetics demonstrated a rapid phase t1/2 of 11 min and a slower phase t 1/2 of 137 min.,Pharmacokinetics and pharmacodynamics of nifedipine in pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680651/),min,11,192172,DB01115,Nifedipine
,1680651,slower phase t 1/2,The two-compartment maternal pharmacokinetics demonstrated a rapid phase t1/2 of 11 min and a slower phase t 1/2 of 137 min.,Pharmacokinetics and pharmacodynamics of nifedipine in pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680651/),min,137,192173,DB01115,Nifedipine
,1680651,t 1/2,The drug reached the fetus via a first-order process with a t 1/2 of 22 min.,Pharmacokinetics and pharmacodynamics of nifedipine in pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680651/),min,22,192174,DB01115,Nifedipine
,12047482,bioavailability,"Under fed conditions the differences in bioavailability between the two products as characterized by the pharmacokinetic parameters AUC(0,tn) and Cmax were greater than after fasting conditions with point estimates of 69.6% and 81.0%, respectively.",The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047482/),%,69.6,192232,DB01115,Nifedipine
,12047482,bioavailability,"Under fed conditions the differences in bioavailability between the two products as characterized by the pharmacokinetic parameters AUC(0,tn) and Cmax were greater than after fasting conditions with point estimates of 69.6% and 81.0%, respectively.",The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047482/),%,81.0,192233,DB01115,Nifedipine
more,12047482,lag-times,"However, most striking was a pronounced delay in nifedipine absorption observed under fed conditions after administration of Slofedipine XL which resulted in lag-times of more than 15 h in 15 out of 24 subjects.",The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047482/),h,15,192234,DB01115,Nifedipine
,12047482,relative bioavailability,Owing to this lag-time under fed conditions the relative bioavailability of nifedipine from Slofedipine XL compared with Adalat OROS was only 28% over the intended dosing interval of 24 h.,The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12047482/),%,28,192235,DB01115,Nifedipine
,2620681,Maximal coronary dilation,Maximal coronary dilation amounted to 20 +/- 9% (4th min) in group I and to 18 +/- 9% (15th min) in group II.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),%,20,192636,DB01115,Nifedipine
,2620681,Maximal coronary dilation,Maximal coronary dilation amounted to 20 +/- 9% (4th min) in group I and to 18 +/- 9% (15th min) in group II.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),%,18,192637,DB01115,Nifedipine
,2620681,maximal plasma concentrations,In order to compare the pharmacokinetic properties of these compounds the dilation of the 'normal' coronary segments was correlated with the respective drug plasma levels; maximal plasma concentrations averaged 62 +/- 21 ng ml-1 (7th min) in group I and 17 +/- 7 ng ml-1 (4th min) in group II respectively.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),[ng] / [ml],62,192638,DB01115,Nifedipine
,2620681,maximal plasma concentrations,In order to compare the pharmacokinetic properties of these compounds the dilation of the 'normal' coronary segments was correlated with the respective drug plasma levels; maximal plasma concentrations averaged 62 +/- 21 ng ml-1 (7th min) in group I and 17 +/- 7 ng ml-1 (4th min) in group II respectively.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),[ng] / [ml],17,192639,DB01115,Nifedipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB01115,Nifedipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB01115,Nifedipine
,11737990,flow rate,"Mobile phase consisted of methanol (70%), water (25%) and acetonitril (5%) and its flow rate was 1 ml/min.",High performance liquid chromatography of mebudipine: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737990/),[ml] / [min],1,194350,DB01115,Nifedipine
>,11737990,extraction efficiency,The extraction efficiency was >90% and the minimum quantifiable concentration was 10 ng/ml (CV<10%).,High performance liquid chromatography of mebudipine: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737990/),%,90,194351,DB01115,Nifedipine
,11737990,minimum quantifiable concentration,The extraction efficiency was >90% and the minimum quantifiable concentration was 10 ng/ml (CV<10%).,High performance liquid chromatography of mebudipine: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737990/),[ng] / [ml],10,194352,DB01115,Nifedipine
,2847983,effective renal plasma flow,"Nifedipine did not cause any change in subjects with no family history of hypertension, but in those with one hypertensive parent there was a marked increase in effective renal plasma flow (from 644 +/- 39 to 847 +/- 42 [SEM] ml/min x 1.73 m2; p less than 0.001) and a decrease in filtration fraction (from 17.6 +/- 1.0 to 12.6 +/- 0.4%; p less than 0.001), while the glomerular filtration rate was unchanged, thus suggesting a prevailing efferent vasodilation.",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [1.73·m2·min],644,194443,DB01115,Nifedipine
,2847983,effective renal plasma flow,"Nifedipine did not cause any change in subjects with no family history of hypertension, but in those with one hypertensive parent there was a marked increase in effective renal plasma flow (from 644 +/- 39 to 847 +/- 42 [SEM] ml/min x 1.73 m2; p less than 0.001) and a decrease in filtration fraction (from 17.6 +/- 1.0 to 12.6 +/- 0.4%; p less than 0.001), while the glomerular filtration rate was unchanged, thus suggesting a prevailing efferent vasodilation.",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [1.73·m2·min],847,194444,DB01115,Nifedipine
,2847983,clearance,"Lithium clearance also rose (from 29.0 +/- 2.0 to 32.8 +/- 1.9 ml/min, p less than 0.001), and the derived value of fractional proximal reabsorption diminished (from 75.8 +/- 1.0 to 71.3 +/- 1.2%, p less than 0.001).",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [min],29.0,194445,DB01115,Nifedipine
,2847983,clearance,"Lithium clearance also rose (from 29.0 +/- 2.0 to 32.8 +/- 1.9 ml/min, p less than 0.001), and the derived value of fractional proximal reabsorption diminished (from 75.8 +/- 1.0 to 71.3 +/- 1.2%, p less than 0.001).",Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847983/),[ml] / [min],32.8,194446,DB01115,Nifedipine
,26385444,IC50,26 exhibited IC50 on MLCK assay of 2.1±1.7 μM with selectivity of L-type calcium channels and comparative to Nifedipine.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),μM,2.1,194550,DB01115,Nifedipine
,26385444,partition coefficient,It offered satisfactory physicochemical properties with partition coefficient of (ClogP) 4.64.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),,4.64,194551,DB01115,Nifedipine
,26385444,Cmax,Its pharmacokinetic profile is also good with Cmax at 0.40 μg/ml by oral route with Tmax reaching in 0.5 h which means in 30 min.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),[μg] / [ml],0.40,194552,DB01115,Nifedipine
,26385444,Tmax,Its pharmacokinetic profile is also good with Cmax at 0.40 μg/ml by oral route with Tmax reaching in 0.5 h which means in 30 min.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),h,0.5,194553,DB01115,Nifedipine
,26385444,t1/2,26 also exhibits superior t1/2 of 5.4 h and oral bioavailability of (F) 56.75% with an AUC0-∞ of 0.84 μg h/ml.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),h,5.4,194554,DB01115,Nifedipine
,26385444,oral bioavailability,26 also exhibits superior t1/2 of 5.4 h and oral bioavailability of (F) 56.75% with an AUC0-∞ of 0.84 μg h/ml.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),%,56.75,194555,DB01115,Nifedipine
,26385444,AUC0-∞,26 also exhibits superior t1/2 of 5.4 h and oral bioavailability of (F) 56.75% with an AUC0-∞ of 0.84 μg h/ml.,"Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26385444/),[h·μg] / [ml],0.84,194556,DB01115,Nifedipine
,14609284,stability constant,The phase solubility studies indicated the formation of a N-betaCD inclusion complex with a stability constant of 121.9 M(-1).,Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609284/),1/[M],121.9,194561,DB01115,Nifedipine
,6587753,biologic availability,"The mean biologic availability (22.8%) was in the same range as reported for normal persons, but individual variations would seem to be greater.",Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587753/),%,22.8,196157,DB01115,Nifedipine
,6587753,biologic availability,The biologic availability in the elderly was higher than in younger persons with a mean value of 37.69% and a wide range from 9.16 to 82.76%.,Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587753/),%,37.69,196158,DB01115,Nifedipine
,28042936,peak plasma concentration (Cmax ),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[ng] / [ml],26.41,197912,DB01115,Nifedipine
,28042936,time to reach Cmax (tmax ),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,1.79,197913,DB01115,Nifedipine
,28042936,area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[h·ng] / [ml],235.99,197914,DB01115,Nifedipine
,28042936,half-life (t½),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,4.34,197915,DB01115,Nifedipine
,28042936,volume of distribution divided by bioavailability (Vd/F),"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),l,560.96,197916,DB01115,Nifedipine
,28042936,ClT /F,"The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[l] / [h],84.77,197917,DB01115,Nifedipine
,28042936,Cmax,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[ng] / [ml],23.52,197918,DB01115,Nifedipine
,28042936,tmax,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,1.48,197919,DB01115,Nifedipine
,28042936,AUC0-12,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[h·ng] / [ml],202.23,197920,DB01115,Nifedipine
,28042936,t½,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),h,5.00,197921,DB01115,Nifedipine
,28042936,Vd/F,"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),l,609.40,197922,DB01115,Nifedipine
,28042936,apparent total clearance (ClT /F),"The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 .",Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28042936/),[l] / [h],98.94,197923,DB01115,Nifedipine
,3371839,Cmax,"An elevation of the mean Cmax was found, from 73.9 +/- 14.1 when nifedipine was taken alone, to 115.7 +/- 12.1 (SE) ng/ml (P less than 0.02) when the agent was combined with propranolol.",Pharmacokinetic interaction between nifedipine and propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[ng] / [ml],73.9,199403,DB01115,Nifedipine
,3371839,Cmax,"An elevation of the mean Cmax was found, from 73.9 +/- 14.1 when nifedipine was taken alone, to 115.7 +/- 12.1 (SE) ng/ml (P less than 0.02) when the agent was combined with propranolol.",Pharmacokinetic interaction between nifedipine and propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[ng] / [ml],115.7,199404,DB01115,Nifedipine
,3371839,AUC0----infinity,"The AUC0----infinity increased as well, from 287.1 +/- 33.5 to 363.0 +/- 54.3 (SE) (micrograms.hr)/l (P less than 0.01), indicating an increase in bioavailability.",Pharmacokinetic interaction between nifedipine and propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[hr·μg] / [l],287.1,199405,DB01115,Nifedipine
,3371839,AUC0----infinity,"The AUC0----infinity increased as well, from 287.1 +/- 33.5 to 363.0 +/- 54.3 (SE) (micrograms.hr)/l (P less than 0.01), indicating an increase in bioavailability.",Pharmacokinetic interaction between nifedipine and propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[hr·μg] / [l],363.0,199406,DB01115,Nifedipine
,8200723,Cmax,"No effects on heart rate, blood pressure or behaviour were observed with these doses at average Cmax levels ranging between 4.74 and 33.53 ng/ml and with a Tmax ranging from 2 to 6 h depending on the dose.",Pharmacokinetics and electroencephalographic effects of darodipine 50-200 mg modified release (MR) acute oral administration: dose-finding study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200723/),[ng] / [ml],4.74 and 33.53,201021,DB01115,Nifedipine
,8200723,Tmax,"No effects on heart rate, blood pressure or behaviour were observed with these doses at average Cmax levels ranging between 4.74 and 33.53 ng/ml and with a Tmax ranging from 2 to 6 h depending on the dose.",Pharmacokinetics and electroencephalographic effects of darodipine 50-200 mg modified release (MR) acute oral administration: dose-finding study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8200723/),h,2 to 6,201022,DB01115,Nifedipine
,2723112,ka,Nifedipine plasma levels rose rapidly (ka = 8.46 +/- 1.96 h-1) reaching a maximum concentration of 145 +/- 23 ng/ml in 0.61 +/- 0.07 h.,Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),1/[h],8.46,201665,DB01115,Nifedipine
,2723112,maximum concentration,Nifedipine plasma levels rose rapidly (ka = 8.46 +/- 1.96 h-1) reaching a maximum concentration of 145 +/- 23 ng/ml in 0.61 +/- 0.07 h.,Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),[ng] / [ml],145,201666,DB01115,Nifedipine
,2723112,alpha,"Plasma levels then decayed with a distribution phase (alpha = 1.98 +/- 0.40 h-1, t1/2 alpha = 0.46 +/- 0.06 h) and a terminal elimination phase (beta = 0.17 +/- 0.03 h-1, t1/2 beta = 4.98 +/- 0.55 h).",Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),1/[h],1.98,201667,DB01115,Nifedipine
,2723112,t1/2 alpha,"Plasma levels then decayed with a distribution phase (alpha = 1.98 +/- 0.40 h-1, t1/2 alpha = 0.46 +/- 0.06 h) and a terminal elimination phase (beta = 0.17 +/- 0.03 h-1, t1/2 beta = 4.98 +/- 0.55 h).",Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),h,0.46,201668,DB01115,Nifedipine
,2723112,terminal elimination phase (beta,"Plasma levels then decayed with a distribution phase (alpha = 1.98 +/- 0.40 h-1, t1/2 alpha = 0.46 +/- 0.06 h) and a terminal elimination phase (beta = 0.17 +/- 0.03 h-1, t1/2 beta = 4.98 +/- 0.55 h).",Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),1/[h],0.17,201669,DB01115,Nifedipine
,2723112,t1/2 beta,"Plasma levels then decayed with a distribution phase (alpha = 1.98 +/- 0.40 h-1, t1/2 alpha = 0.46 +/- 0.06 h) and a terminal elimination phase (beta = 0.17 +/- 0.03 h-1, t1/2 beta = 4.98 +/- 0.55 h).",Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),h,4.98,201670,DB01115,Nifedipine
,2723112,AUC,AUC was 384 +/- 41 ng h/ml.,Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),[h·ng] / [ml],384,201671,DB01115,Nifedipine
higher,2723112,ka/alpha relationship,"Ten subjects presented plasma concentration-time curves in which the distribution phase was clearly distinguishable, having a ka/alpha relationship higher than 1.5.",Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),,1.5,201672,DB01115,Nifedipine
lower,2723112,ka/alpha,"For the other two subjects, the distribution phase was not apparent and ka/alpha was lower than 1.5.",Pharmacokinetics of oral nifedipine: relevance of the distribution phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723112/),,1.5,201673,DB01115,Nifedipine
,3378388,apparent oral clearance (dose/AUC),"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],66,201963,DB01115,Nifedipine
,3378388,apparent oral clearance (dose/AUC),"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],33,201964,DB01115,Nifedipine
,3378388,elimination half-life,"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),h,4.0,201965,DB01115,Nifedipine
,3378388,elimination half-life,"After single doses of nifedipine, cimetidine decreased apparent oral clearance (dose/AUC) from 66 +/- 32 L/hr to 33 +/- 14 L/hr (p less than 0.01); elimination half-life increased from 4.0 +/- 2.2 to 4.9 +/- 2.9 hours (p less than 0.07).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),h,4.9,201966,DB01115,Nifedipine
,3378388,apparent oral clearance,"During nifedipine multiple-dose administration, cimetidine decreased the apparent oral clearance from 76 +/- 39 to 43 +/- 20 L/hr (p less than 0.01).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],76,201967,DB01115,Nifedipine
,3378388,apparent oral clearance,"During nifedipine multiple-dose administration, cimetidine decreased the apparent oral clearance from 76 +/- 39 to 43 +/- 20 L/hr (p less than 0.01).",Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[l] / [h],43,201968,DB01115,Nifedipine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],18,201969,DB01115,Nifedipine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],9,201970,DB01115,Nifedipine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],18,201971,DB01115,Nifedipine
,3378388,heart rate,Blood pressure responses were not altered by cimetidine but heart rate increased more (18 +/- 9 vs 9 +/- 9 beats/min supine; 18 +/- 13 vs 13 +/- 14 beats/min standing).,Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378388/),[beats] / [min],13,201972,DB01115,Nifedipine
,4096742,peak plasma concentrations,Mean peak plasma concentrations of 121.2 +/- 47.3 and 104.5 +/- 32.9 ng/ml were reached approximately 0.5 h p.a.,[Bioavailability of new nifedipine preparations in man. 2. Bioequivalence of nifedipine in the form of soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096742/),[ng] / [ml],121.2,203000,DB01115,Nifedipine
,4096742,peak plasma concentrations,Mean peak plasma concentrations of 121.2 +/- 47.3 and 104.5 +/- 32.9 ng/ml were reached approximately 0.5 h p.a.,[Bioavailability of new nifedipine preparations in man. 2. Bioequivalence of nifedipine in the form of soft gelatin capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096742/),[ng] / [ml],104.5,203001,DB01115,Nifedipine
,3203042,area under the plasma concentration-time curves (AUC),2. The area under the plasma concentration-time curves (AUC) for nifedipine demonstrated a skewed but not a bimodal distribution (mean 154 ng ml-1 h; range 54-306 ng ml-1h).,The pharmacokinetics of oral nifedipine--a population study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203042/),[h·ng] / [ml],154,203076,DB01115,Nifedipine
,3793948,maximum serum concentration (Cmax),"The mean (+/- SEM) maximum serum concentration (Cmax) after dose normalization, and the time to Cmax (tmax) were 115 +/- 7 ng/mL and 0.72 +/- 0.13 hr, respectively.",Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),[ng] / [ml],115,203311,DB01115,Nifedipine
,3793948,time to Cmax (tmax),"The mean (+/- SEM) maximum serum concentration (Cmax) after dose normalization, and the time to Cmax (tmax) were 115 +/- 7 ng/mL and 0.72 +/- 0.13 hr, respectively.",Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),h,0.72,203312,DB01115,Nifedipine
,3793948,area under the plasma concentration-time curve,The mean area under the plasma concentration-time curve per 10-mg dose was 304 +/- 34 hr-ng/mL.,Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),[hr-ng] / [ml],304,203313,DB01115,Nifedipine
,3793948,elimination rate constant,"The average elimination rate constant was 0.205 +/- 0.016 hr, and the harmonic mean elimination half-life was 3.4 hr (range, 2.5-4.9 hr).",Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),h,0.205,203314,DB01115,Nifedipine
,3793948,elimination half-life,"The average elimination rate constant was 0.205 +/- 0.016 hr, and the harmonic mean elimination half-life was 3.4 hr (range, 2.5-4.9 hr).",Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),h,3.4,203315,DB01115,Nifedipine
,3793948,Cardiac output,"Cardiac output was increased (1.1-2.8 L/min, P less than .05), and calculated total systemic resistance (3.8-6.3 mm Hg/L/min, P less than .05) was decreased for the entire dosing interval after nifedipine dosing.",Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),[l] / [min],1.1-2.8,203316,DB01115,Nifedipine
,3793948,total systemic resistance,"Cardiac output was increased (1.1-2.8 L/min, P less than .05), and calculated total systemic resistance (3.8-6.3 mm Hg/L/min, P less than .05) was decreased for the entire dosing interval after nifedipine dosing.",Pharmacokinetics and pharmacodynamics of nifedipine in patients at steady state. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793948/),[hg·mm] / [l·min],3.8-6.3,203317,DB01115,Nifedipine
,3203043,systemic clearance,"2. After high-dose nisoldipine, systemic clearance was 0.99 +/- 0.16 1 min-1, volume of distribution was 5.8 +/- 1.5 1 kg-1 and elimination half-life was 10.7 +/- 2.4 h.",The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203043/),[1] / [min],0.99,203761,DB01115,Nifedipine
,3203043,volume of distribution,"2. After high-dose nisoldipine, systemic clearance was 0.99 +/- 0.16 1 min-1, volume of distribution was 5.8 +/- 1.5 1 kg-1 and elimination half-life was 10.7 +/- 2.4 h.",The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203043/),[1] / [kg],5.8,203762,DB01115,Nifedipine
,3203043,elimination half-life,"2. After high-dose nisoldipine, systemic clearance was 0.99 +/- 0.16 1 min-1, volume of distribution was 5.8 +/- 1.5 1 kg-1 and elimination half-life was 10.7 +/- 2.4 h.",The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203043/),h,10.7,203763,DB01115,Nifedipine
,2467133,elimination half-life,"After i.v. amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs. 48 +/- 8 h; mean +/- SD).",Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467133/),h,64,203993,DB01115,Nifedipine
,2467133,elimination half-life,"After i.v. amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs. 48 +/- 8 h; mean +/- SD).",Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467133/),h,48,203994,DB01115,Nifedipine
,3709609,Plasma clearance,"Plasma clearance ranged from 5-12 ml/min/kg, and appeared lower than previously reported volunteer data.","Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709609/),[ml] / [kg·min],5-12,204216,DB01115,Nifedipine
,12959295,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) for nifedipine with grapefruit juice (mean 320 ng ml(-1) h) was increased significantly (P < 0.01) compared with the AUC when nifedipine was given alone (mean 218 ng ml(-1) h).,"Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959295/),[h·ng] / [ml],320,205792,DB01115,Nifedipine
,12959295,AUC,The area under the plasma concentration-time curve (AUC) for nifedipine with grapefruit juice (mean 320 ng ml(-1) h) was increased significantly (P < 0.01) compared with the AUC when nifedipine was given alone (mean 218 ng ml(-1) h).,"Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959295/),[h·ng] / [ml],218,205793,DB01115,Nifedipine
,12959295,time to peak plasma concentration,The time to peak plasma concentration for nifedipine with grapefruit juice (1.5 h) was also increased (P < 0.05) compared with control (0.5 h) suggesting delayed absorption.,"Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959295/),h,1.5,205794,DB01115,Nifedipine
,12959295,time to peak plasma concentration,The time to peak plasma concentration for nifedipine with grapefruit juice (1.5 h) was also increased (P < 0.05) compared with control (0.5 h) suggesting delayed absorption.,"Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959295/),h,0.5,205795,DB01115,Nifedipine
,12959295,time to peak nifedipine concentration,Although quercetin delayed the time to peak nifedipine concentration (1.3 h) it did not alter the AUC of either the parent drug (mean 209 ng ml(-1) h) or its first-pass metabolite.,"Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959295/),h,1.3,205796,DB01115,Nifedipine
,12959295,AUC,Although quercetin delayed the time to peak nifedipine concentration (1.3 h) it did not alter the AUC of either the parent drug (mean 209 ng ml(-1) h) or its first-pass metabolite.,"Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959295/),[h·ng] / [ml],209,205797,DB01115,Nifedipine
,1739628,area under the plasma concentration curve (AUC0-00),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h·μM,7.87,206086,DB01115,Nifedipine
,1739628,area under the plasma concentration curve (AUC0-00),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h,7.97,206087,DB01115,Nifedipine
,1739628,area under the plasma concentration curve (AUC0-00),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h·μM,4.97,206088,DB01115,Nifedipine
,1739628,plasma half-life (beta),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h,7.97,206089,DB01115,Nifedipine
,1739628,plasma half-life (beta),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h·μM,4.97,206090,DB01115,Nifedipine
,1739628,plasma half-life (beta),"Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively.",A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1739628/),h,14.0,206091,DB01115,Nifedipine
,9226591,relative bioavailability,The mean relative bioavailability of nifedipine following pre-treatment with rifampicin 1200 mg was 35.8% (P < 0.0001).,The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226591/),%,35.8,210635,DB01115,Nifedipine
,9226591,elimination half life (t1/2),"The mean elimination half life (t1/2) of nifedipine decreased from 2.62 to 1.03 h (P < 0.0001); and, the total clearance (ClT) increased from 17.33 to 50.17 ml min-1 kg-1 (P < 0.0001).",The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226591/),h,2,210636,DB01115,Nifedipine
,9226591,total clearance (ClT),"The mean elimination half life (t1/2) of nifedipine decreased from 2.62 to 1.03 h (P < 0.0001); and, the total clearance (ClT) increased from 17.33 to 50.17 ml min-1 kg-1 (P < 0.0001).",The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226591/),[ml] / [kg·min],17.33 to 50.17,210637,DB01115,Nifedipine
,18271884,concentrations,"Steady-state nifedipine concentrations (micrograms/l, mean +/- SE) were 54 +/- 6 (all doses, n = 31), 38 +/- 8 (60 mg/day, n = 13), and 92 +/- 12 (150 mg/day, n = 7) (P < 0.002).",Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18271884/),[μg] / [l],54,211176,DB01115,Nifedipine
,18271884,concentrations,"Steady-state nifedipine concentrations (micrograms/l, mean +/- SE) were 54 +/- 6 (all doses, n = 31), 38 +/- 8 (60 mg/day, n = 13), and 92 +/- 12 (150 mg/day, n = 7) (P < 0.002).",Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18271884/),[μg] / [l],38,211177,DB01115,Nifedipine
,18271884,concentrations,"Steady-state nifedipine concentrations (micrograms/l, mean +/- SE) were 54 +/- 6 (all doses, n = 31), 38 +/- 8 (60 mg/day, n = 13), and 92 +/- 12 (150 mg/day, n = 7) (P < 0.002).",Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18271884/),[μg] / [l],92,211178,DB01115,Nifedipine
,18271884,elimination half-lives,Umbilical cord and maternal concentrations both declined in a ln-linear regression with elimination half-lives of 20.4 and 17.4 hours.,Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18271884/),h,20.4,211179,DB01115,Nifedipine
,18271884,elimination half-lives,Umbilical cord and maternal concentrations both declined in a ln-linear regression with elimination half-lives of 20.4 and 17.4 hours.,Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18271884/),h,17.4,211180,DB01115,Nifedipine
,3358895,plasma clearance,2. Following 2.5 mg of nifedipine i.v. the plasma clearance of nifedipine was 348 +/- 83 (s.d.) ml min-1 in the elderly compared with 519 +/- 125 ml min-1 in the young (P less than 0.05) and the AUC in the elderly was significantly greater at 125 +/- 28 ng ml-1 h compared with 83.9 +/- 19 ng ml-1 h (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[ml] / [min],348,212181,DB01115,Nifedipine
,3358895,plasma clearance,2. Following 2.5 mg of nifedipine i.v. the plasma clearance of nifedipine was 348 +/- 83 (s.d.) ml min-1 in the elderly compared with 519 +/- 125 ml min-1 in the young (P less than 0.05) and the AUC in the elderly was significantly greater at 125 +/- 28 ng ml-1 h compared with 83.9 +/- 19 ng ml-1 h (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[ml] / [min],519,212182,DB01115,Nifedipine
,3358895,AUC,2. Following 2.5 mg of nifedipine i.v. the plasma clearance of nifedipine was 348 +/- 83 (s.d.) ml min-1 in the elderly compared with 519 +/- 125 ml min-1 in the young (P less than 0.05) and the AUC in the elderly was significantly greater at 125 +/- 28 ng ml-1 h compared with 83.9 +/- 19 ng ml-1 h (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[h·ng] / [ml],125,212183,DB01115,Nifedipine
,3358895,AUC,2. Following 2.5 mg of nifedipine i.v. the plasma clearance of nifedipine was 348 +/- 83 (s.d.) ml min-1 in the elderly compared with 519 +/- 125 ml min-1 in the young (P less than 0.05) and the AUC in the elderly was significantly greater at 125 +/- 28 ng ml-1 h compared with 83.9 +/- 19 ng ml-1 h (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[h·ng] / [ml],83.9,212184,DB01115,Nifedipine
,3358895,AUC,3. Following 10 mg oral sustained release nifedipine the AUC was 281 +/- 64 ng ml-1 h in the elderly compared with 136 +/- 56 ng ml-1 h in the young (P less than 0.002) and Cmax in the elderly was significantly greater at 36.8 +/- 11.8 ng ml-1 compared with 22.3 +/- 5.8 ng ml-1 (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[h·ng] / [ml],281,212185,DB01115,Nifedipine
,3358895,AUC,3. Following 10 mg oral sustained release nifedipine the AUC was 281 +/- 64 ng ml-1 h in the elderly compared with 136 +/- 56 ng ml-1 h in the young (P less than 0.002) and Cmax in the elderly was significantly greater at 36.8 +/- 11.8 ng ml-1 compared with 22.3 +/- 5.8 ng ml-1 (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[h·ng] / [ml],136,212186,DB01115,Nifedipine
,3358895,Cmax,3. Following 10 mg oral sustained release nifedipine the AUC was 281 +/- 64 ng ml-1 h in the elderly compared with 136 +/- 56 ng ml-1 h in the young (P less than 0.002) and Cmax in the elderly was significantly greater at 36.8 +/- 11.8 ng ml-1 compared with 22.3 +/- 5.8 ng ml-1 (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[ng] / [ml],36.8,212187,DB01115,Nifedipine
,3358895,Cmax,3. Following 10 mg oral sustained release nifedipine the AUC was 281 +/- 64 ng ml-1 h in the elderly compared with 136 +/- 56 ng ml-1 h in the young (P less than 0.002) and Cmax in the elderly was significantly greater at 36.8 +/- 11.8 ng ml-1 compared with 22.3 +/- 5.8 ng ml-1 (P less than 0.05).,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),[ng] / [ml],22.3,212188,DB01115,Nifedipine
,3358895,bioavailability,The trend towards an increased bioavailability in elderly subjects (36%) was supported by a significantly lower nitropyridine metabolite/nifedipine ratio in the elderly.,Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),%,36,212189,DB01115,Nifedipine
,3358895,t1/2,"In the elderly t1/2 (oral) was significantly greater than in the young (elderly 6.7 +/- 2.2 h, young 3.8 +/- 1.4 h, P less than 0.05).",Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),h,6.7,212190,DB01115,Nifedipine
,3358895,t1/2,"In the elderly t1/2 (oral) was significantly greater than in the young (elderly 6.7 +/- 2.2 h, young 3.8 +/- 1.4 h, P less than 0.05).",Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358895/),h,3.8,212191,DB01115,Nifedipine
,22875663,half-life,The mean half-life of nifedipine was 1.68 ± 1.56 hours.,Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875663/),h,1.68,216211,DB01115,Nifedipine
,22875663,area under the curve from 0 to 6 hours,The area under the curve from 0 to 6 hours for the women receiving nifedipine every 6 hours was 207 ± 138 µg·h /L.,Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875663/),[h·μg] / [l],207,216212,DB01115,Nifedipine
,22875663,Oral clearance,"Oral clearance was different between high expressers and low expressers (232.0 ± 37.8 µg/mL versus 85.6 ± 45.0 µg/mL, respectively; p = 0.007).",Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875663/),[μg] / [ml],232.0,216213,DB01115,Nifedipine
,22875663,Oral clearance,"Oral clearance was different between high expressers and low expressers (232.0 ± 37.8 µg/mL versus 85.6 ± 45.0 µg/mL, respectively; p = 0.007).",Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22875663/),[μg] / [ml],85.6,216214,DB01115,Nifedipine
,31526504,50% inhibitory concentration (IC50),Kaempferol reduced a 50% inhibitory concentration (IC50) of 8.6 μmol·L-1 on CYP3A4 enzyme activity.,Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31526504/),[μM] / [l],8.6,216589,DB01115,Nifedipine
,23463334,dissolution rate,"When the above SD granules were coated with ethylcellolulose (EC10, 45 and 100cp), the dissolution rate extended from 16 to 20 h.",Formulation and pharmacokinetic evaluation of once-daily sustained-released system of nifedipine with solid dispersion and coating techniques. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463334/),h,16 to 20,218347,DB01115,Nifedipine
,19085951,area under the curve from time zero to the last sampling time (AUC(0-t)),"The results showed that the area under the curve from time zero to the last sampling time (AUC(0-t)) of m-nifedipine, MN9201, MN9202 and MN9203 was 45.1 +/- 13.6, 51.7 +/- 15.2, 70 +/- 16 and 62 +/- 12.4 micromol/l*min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),[μM] / [l·min],45.1,218674,DB01115,Nifedipine
,19085951,area under the curve from time zero to the last sampling time (AUC(0-t)),"The results showed that the area under the curve from time zero to the last sampling time (AUC(0-t)) of m-nifedipine, MN9201, MN9202 and MN9203 was 45.1 +/- 13.6, 51.7 +/- 15.2, 70 +/- 16 and 62 +/- 12.4 micromol/l*min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),[μM] / [l·min],51.7,218675,DB01115,Nifedipine
,19085951,area under the curve from time zero to the last sampling time (AUC(0-t)),"The results showed that the area under the curve from time zero to the last sampling time (AUC(0-t)) of m-nifedipine, MN9201, MN9202 and MN9203 was 45.1 +/- 13.6, 51.7 +/- 15.2, 70 +/- 16 and 62 +/- 12.4 micromol/l*min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),[μM] / [l·min],70,218676,DB01115,Nifedipine
,19085951,area under the curve from time zero to the last sampling time (AUC(0-t)),"The results showed that the area under the curve from time zero to the last sampling time (AUC(0-t)) of m-nifedipine, MN9201, MN9202 and MN9203 was 45.1 +/- 13.6, 51.7 +/- 15.2, 70 +/- 16 and 62 +/- 12.4 micromol/l*min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),[μM] / [l·min],62,218677,DB01115,Nifedipine
,19085951,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 98 +/- 24, 129 +/- 55, 190 +/- 21 and 92 +/- 25 min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),min,98,218678,DB01115,Nifedipine
,19085951,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 98 +/- 24, 129 +/- 55, 190 +/- 21 and 92 +/- 25 min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),min,129,218679,DB01115,Nifedipine
,19085951,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 98 +/- 24, 129 +/- 55, 190 +/- 21 and 92 +/- 25 min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),min,190,218680,DB01115,Nifedipine
,19085951,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 98 +/- 24, 129 +/- 55, 190 +/- 21 and 92 +/- 25 min, respectively.",Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19085951/),min,92,218681,DB01115,Nifedipine
,2524389,elimination half-life,"The elimination half-life was of the order of 50 h, similar to previously reported values and did not vary with renal function.",Pharmacokinetics of amlodipine in renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2524389/),h,50,219535,DB01115,Nifedipine
,1283185,absolute bioavailability,Nilvadipine is absorbed rapidly and completely and its absolute bioavailability is about 14-19% because of its high first-pass metabolism.,Pharmacokinetics of nilvadipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283185/),%,14-19,219902,DB01115,Nifedipine
,1283185,terminal elimination half-life,Slow tissue redistribution is probably the reason for the terminal elimination half-life of 15-20 h.,Pharmacokinetics of nilvadipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283185/),h,15-20,219903,DB01115,Nifedipine
,31467909,flow rate,The flow rate was 0.3 mL/min.,A High Throughput HPLC-MS/MS Method for Antihypertensive Drugs Determination in Plasma and Its Application on Pharmacokinetic Interaction Study with Shuxuetong Injection in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31467909/),[ml] / [min],0.3,224280,DB01115,Nifedipine
,3440039,peak plasma concentrations,Approximately 0.5 h p.a. mean peak plasma concentrations of about 110-120 ng/ml were reached; the mean terminal half-live was 1.5 h.,[Biotransformation and bioequivalence of a new nifedipine preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440039/),[ng] / [ml],110-120,225540,DB01115,Nifedipine
,3440039,terminal half-live,Approximately 0.5 h p.a. mean peak plasma concentrations of about 110-120 ng/ml were reached; the mean terminal half-live was 1.5 h.,[Biotransformation and bioequivalence of a new nifedipine preparation]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440039/),h,1.5,225541,DB01115,Nifedipine
,2724140,apparent ethanol Vmax,"The apparent ethanol Vmax and volume of distribution were 1.85 +/- 0.25 mg/min and 723 +/- 91 ml/kg (mean +/- S.D.), respectively.",Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724140/),[mg] / [min],1.85,225684,DB01115,Nifedipine
,2724140,volume of distribution,"The apparent ethanol Vmax and volume of distribution were 1.85 +/- 0.25 mg/min and 723 +/- 91 ml/kg (mean +/- S.D.), respectively.",Characterization of the pharmacokinetic interaction between nifedipine and ethanol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724140/),[ml] / [kg],723,225685,DB01115,Nifedipine
,7849332,initial whole blood concentrations,Patients received cyclosporine 3-4 mg/kg by continuous infusion for 5 days followed by cyclosporine 10 mg/kg/d po to maintain initial whole blood concentrations of 300-400 ng/mL.,Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ng] / [ml],300-400,226740,DB01115,Nifedipine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.1,226741,DB01115,Nifedipine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],3.7,226742,DB01115,Nifedipine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],6.4,226743,DB01115,Nifedipine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.2,226744,DB01115,Nifedipine
,18343242,AUC(0-last),"Geometric mean of AUC(0-last)(test, 504.21 h x ng/mL; reference, 361.28 h x ng/mL) was significantly higher for the test product, with a point estimate of 140% and a corresponding 90% CI of 121% to 161%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[h·ng] / [ml],504.21,231330,DB01115,Nifedipine
,18343242,AUC(0-last),"Geometric mean of AUC(0-last)(test, 504.21 h x ng/mL; reference, 361.28 h x ng/mL) was significantly higher for the test product, with a point estimate of 140% and a corresponding 90% CI of 121% to 161%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[h·ng] / [ml],361.28,231331,DB01115,Nifedipine
,18343242,Cmax,"For the comparison of Cmax values, geometric means were: test, 76.46 ng/mL; reference, 19.20 ng/mL, with a point estimate of 398% and a CI of 316% to 503%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[ng] / [ml],76.46,231332,DB01115,Nifedipine
,18343242,Cmax,"For the comparison of Cmax values, geometric means were: test, 76.46 ng/mL; reference, 19.20 ng/mL, with a point estimate of 398% and a CI of 316% to 503%.",Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18343242/),[ng] / [ml],19.20,231333,DB01115,Nifedipine
,1688989,total body clearance (Cl),"Diltiazem induced a marked increment of the area under the plasma concentration-time curve (AUC) for nifedipine by a mean of 140% and reduced the total body clearance (Cl) from 0.0043 +/- 0.0019 to 0.0017 +/- 0.0006 ml/min/kg (p less than 0.05, mean +/- SD).",Effects of diltiazem on the pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),[ml] / [kg·min],0.0043,232333,DB01115,Nifedipine
,1688989,total body clearance (Cl),"Diltiazem induced a marked increment of the area under the plasma concentration-time curve (AUC) for nifedipine by a mean of 140% and reduced the total body clearance (Cl) from 0.0043 +/- 0.0019 to 0.0017 +/- 0.0006 ml/min/kg (p less than 0.05, mean +/- SD).",Effects of diltiazem on the pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),[ml] / [kg·min],0.0017,232334,DB01115,Nifedipine
,1688989,biological half-life (t1/2),The biological half-life (t1/2) of nifedipine was prolonged from 2.46 +/- 0.65 to 3.21 +/- 0.92 h (p less than 0.05) without any changes in indocyanine green (ICG) clearance.,Effects of diltiazem on the pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),h,2.46,232335,DB01115,Nifedipine
,1688989,biological half-life (t1/2),The biological half-life (t1/2) of nifedipine was prolonged from 2.46 +/- 0.65 to 3.21 +/- 0.92 h (p less than 0.05) without any changes in indocyanine green (ICG) clearance.,Effects of diltiazem on the pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688989/),h,3.21,232336,DB01115,Nifedipine
,18093252,time of peak nifedipine concentrations,"Plasma NE was higher in the Coracten- (480 +/- 38.3 pg ml(-1)) than N-GITS-treated patients (343 +/- 75.0 pg ml(-1)) at the time of peak nifedipine concentrations (4 and 5 h, respectively) and their change from baseline was significantly (P = 0.0046) different.",Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18093252/),h,4,233599,DB01115,Nifedipine
,18093252,time of peak nifedipine concentrations,"Plasma NE was higher in the Coracten- (480 +/- 38.3 pg ml(-1)) than N-GITS-treated patients (343 +/- 75.0 pg ml(-1)) at the time of peak nifedipine concentrations (4 and 5 h, respectively) and their change from baseline was significantly (P = 0.0046) different.",Formulation of long-acting nifedipine tablets influences the heart rate and sympathetic nervous system response in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18093252/),h,5,233600,DB01115,Nifedipine
,8527268,area under the plasma concentration-time curve (AUC),"3. The administration of grapefruit juice did not alter the pharmacokinetics of intravenous nifedipine, but resulted in a significantly increased area under the plasma concentration-time curve (AUC) (191 +/- 59 c.f. 301 +/- 95 ng ml-1 h, P < 0.05) and bioavailability (0.63 +/- 0.18 c.f. 0.86 +/- 0.15, P < 0.05) following oral nifedipine.",Factors affecting the absolute bioavailability of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),[h·ng] / [ml],191,238501,DB01115,Nifedipine
,8527268,area under the plasma concentration-time curve (AUC),"3. The administration of grapefruit juice did not alter the pharmacokinetics of intravenous nifedipine, but resulted in a significantly increased area under the plasma concentration-time curve (AUC) (191 +/- 59 c.f. 301 +/- 95 ng ml-1 h, P < 0.05) and bioavailability (0.63 +/- 0.18 c.f. 0.86 +/- 0.15, P < 0.05) following oral nifedipine.",Factors affecting the absolute bioavailability of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),[h·ng] / [ml],301,238502,DB01115,Nifedipine
,8527268,bioavailability,"3. The administration of grapefruit juice did not alter the pharmacokinetics of intravenous nifedipine, but resulted in a significantly increased area under the plasma concentration-time curve (AUC) (191 +/- 59 c.f. 301 +/- 95 ng ml-1 h, P < 0.05) and bioavailability (0.63 +/- 0.18 c.f. 0.86 +/- 0.15, P < 0.05) following oral nifedipine.",Factors affecting the absolute bioavailability of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),,0.63,238503,DB01115,Nifedipine
,8527268,bioavailability,"3. The administration of grapefruit juice did not alter the pharmacokinetics of intravenous nifedipine, but resulted in a significantly increased area under the plasma concentration-time curve (AUC) (191 +/- 59 c.f. 301 +/- 95 ng ml-1 h, P < 0.05) and bioavailability (0.63 +/- 0.18 c.f. 0.86 +/- 0.15, P < 0.05) following oral nifedipine.",Factors affecting the absolute bioavailability of nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),,0.86,238504,DB01115,Nifedipine
,8527268,AUC,"4. The AUC of nifedipine after intravenous administration was significantly higher in South Asian subjects than in Caucasians (146 +/- 39 c.f. 74 +/- 18 ng ml-1 h, P < 0.002).",Factors affecting the absolute bioavailability of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),[h·ng] / [ml],146,238505,DB01115,Nifedipine
,8527268,AUC,"4. The AUC of nifedipine after intravenous administration was significantly higher in South Asian subjects than in Caucasians (146 +/- 39 c.f. 74 +/- 18 ng ml-1 h, P < 0.002).",Factors affecting the absolute bioavailability of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),[h·ng] / [ml],74,238506,DB01115,Nifedipine
,8527268,half-life,"The half-life was markedly prolonged in South Asians (4.1 +/- 1.9 c.f. 1.7 +/- 0.5 h, P < 0.002).",Factors affecting the absolute bioavailability of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),h,4.1,238507,DB01115,Nifedipine
,8527268,half-life,"The half-life was markedly prolonged in South Asians (4.1 +/- 1.9 c.f. 1.7 +/- 0.5 h, P < 0.002).",Factors affecting the absolute bioavailability of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527268/),h,1.7,238508,DB01115,Nifedipine
,22579001,Km,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),μM,114.35,239835,DB01115,Nifedipine
,22579001,Vmax,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),[μM] / [g·min],23.13,239836,DB01115,Nifedipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,82.6,239837,DB01115,Nifedipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,72,239838,DB01115,Nifedipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,95,239839,DB01115,Nifedipine
,6085388,maximum concentration (Cmax),"On day 1, the maximum concentration (Cmax) in the normals was 4.67 +/- 2.60 ng/ml and in the hepatic patients 16.87 +/- 9.42 ng/ml.",Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),[ng] / [ml],4.67,240542,DB01115,Nifedipine
,6085388,maximum concentration (Cmax),"On day 1, the maximum concentration (Cmax) in the normals was 4.67 +/- 2.60 ng/ml and in the hepatic patients 16.87 +/- 9.42 ng/ml.",Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),[ng] / [ml],16.87,240543,DB01115,Nifedipine
,6085388,elimination half-life,The elimination half-life was only slightly prolonged from 15.29 +/- 7.25 h in the normals to 19.57 +/- 4.28 h in the hepatic impairment group.,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),h,15.29,240544,DB01115,Nifedipine
,6085388,elimination half-life,The elimination half-life was only slightly prolonged from 15.29 +/- 7.25 h in the normals to 19.57 +/- 4.28 h in the hepatic impairment group.,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),h,19.57,240545,DB01115,Nifedipine
,6085388,area under the concentration-time curve,This resulted in a marked increase in the area under the concentration-time curve from 28.71 +/- 28.92 ng . h/ml for the normals to 119.56 +/- 34.39 ng .,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),[h·ng] / [ml],28.71,240546,DB01115,Nifedipine
,6085388,area under the concentration-time curve,This resulted in a marked increase in the area under the concentration-time curve from 28.71 +/- 28.92 ng . h/ml for the normals to 119.56 +/- 34.39 ng .,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),ng,119.56,240547,DB01115,Nifedipine
,3368504,peak concentration,"The peak concentration of nifedipine in brain obtained after 10 min was 37 micrograms/g wet weight tissue, the half-life was 75 min.",Single-dose kinetics of nifedipine in rat plasma and brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368504/),[μg] / [g],37,241495,DB01115,Nifedipine
,3368504,half-life,"The peak concentration of nifedipine in brain obtained after 10 min was 37 micrograms/g wet weight tissue, the half-life was 75 min.",Single-dose kinetics of nifedipine in rat plasma and brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3368504/),min,75,241496,DB01115,Nifedipine
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,10.8,242191,DB01115,Nifedipine
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,9.9,242192,DB01115,Nifedipine
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242193,DB01115,Nifedipine
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242194,DB01115,Nifedipine
,1896255,maximum plasma concentration,"The mean (+/- SD) maximum plasma concentration and the time to maximum plasma concentration were 243.4 +/- 194.5 nmol/L and 1.0 +/- 0.8 h, respectively.",Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1896255/),[nM] / [l],243.4,243106,DB01115,Nifedipine
,1896255,time to maximum plasma concentration,"The mean (+/- SD) maximum plasma concentration and the time to maximum plasma concentration were 243.4 +/- 194.5 nmol/L and 1.0 +/- 0.8 h, respectively.",Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1896255/),h,1.0,243107,DB01115,Nifedipine
,1896255,area under the plasma concentration-time curve,The mean area under the plasma concentration-time curve was 761 +/- 509 nmol.h/L.,Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1896255/),[h·nM] / [l],761,243108,DB01115,Nifedipine
,1896255,elimination rate constant,"The mean elimination rate constant and t1/2 were 0.456 +/- 0.194 h-1 and 1.8 +/- 0.8 h, respectively.",Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1896255/),1/[h],0.456,243109,DB01115,Nifedipine
,1896255,t1/2,"The mean elimination rate constant and t1/2 were 0.456 +/- 0.194 h-1 and 1.8 +/- 0.8 h, respectively.",Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1896255/),h,1.8,243110,DB01115,Nifedipine
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.04,244288,DB01115,Nifedipine
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.64,244289,DB01115,Nifedipine
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.02,244290,DB01115,Nifedipine
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],44.40,244291,DB01115,Nifedipine
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],45.66,244292,DB01115,Nifedipine
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],46.87,244293,DB01115,Nifedipine
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.601,244294,DB01115,Nifedipine
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.591,244295,DB01115,Nifedipine
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.602,244296,DB01115,Nifedipine
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.32,244297,DB01115,Nifedipine
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.50,244298,DB01115,Nifedipine
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],42.10,244299,DB01115,Nifedipine
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],43.77,244300,DB01115,Nifedipine
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.451,244301,DB01115,Nifedipine
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.483,244302,DB01115,Nifedipine
,7711994,Cmax,"Plasma concentrations rose more rapidly after CAP than after SRT, Cmax being 131 +/- 39 and 40 +/- 7 ng/ml and tmax being 0.5 +/- 0.07 and 1.8 +/- 0.4 h, respectively.",Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711994/),[ng] / [ml],131,244737,DB01115,Nifedipine
,7711994,Cmax,"Plasma concentrations rose more rapidly after CAP than after SRT, Cmax being 131 +/- 39 and 40 +/- 7 ng/ml and tmax being 0.5 +/- 0.07 and 1.8 +/- 0.4 h, respectively.",Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711994/),[ng] / [ml],40,244738,DB01115,Nifedipine
,7711994,tmax,"Plasma concentrations rose more rapidly after CAP than after SRT, Cmax being 131 +/- 39 and 40 +/- 7 ng/ml and tmax being 0.5 +/- 0.07 and 1.8 +/- 0.4 h, respectively.",Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711994/),h,0.5,244739,DB01115,Nifedipine
,7711994,tmax,"Plasma concentrations rose more rapidly after CAP than after SRT, Cmax being 131 +/- 39 and 40 +/- 7 ng/ml and tmax being 0.5 +/- 0.07 and 1.8 +/- 0.4 h, respectively.",Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711994/),h,1.8,244740,DB01115,Nifedipine
,10719906,relative recoveries,The relative recoveries of nifedipine from plasma ranged from 91.0-107.3% whereas extraction recoveries were 88.6-93.3%.,Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719906/),%,91.0-107.3,246019,DB01115,Nifedipine
,10719906,extraction recoveries,The relative recoveries of nifedipine from plasma ranged from 91.0-107.3% whereas extraction recoveries were 88.6-93.3%.,Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719906/),%,88.6-93.3,246020,DB01115,Nifedipine
,7921534,maximal concentration,"Nifedipine pharmacokinetics showed wide interindividual variation, for instance maximal concentration varied from 10-90 ng/ml, elimination half-life from 2-9 hours, etc.",Nifedipine kinetics and dynamics in hypertensive patients: a new approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7921534/),[ng] / [ml],10-90,247200,DB01115,Nifedipine
,7921534,elimination half-life,"Nifedipine pharmacokinetics showed wide interindividual variation, for instance maximal concentration varied from 10-90 ng/ml, elimination half-life from 2-9 hours, etc.",Nifedipine kinetics and dynamics in hypertensive patients: a new approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7921534/),h,2-9,247201,DB01115,Nifedipine
more,7921534,elimination half-life,Group A was characterized by small maximal nifedipine concentrations and its fast elimination; in group C nifedipine concentration reached high level in plasma and elimination half-life was more than 5.5 hours; in group B intermediate variants of nifedipine concentration profiles were separated.,Nifedipine kinetics and dynamics in hypertensive patients: a new approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7921534/),h,5.5,247202,DB01115,Nifedipine
,2467132,elimination half-life,The principal findings were that the mean elimination half-life was 48 h and that peak plasma drug concentrations were not observed until 7 h after dosing.,A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467132/),h,48,247345,DB01115,Nifedipine
,2467132,terminal elimination half-life,"The terminal elimination half-life of 48 h in the elderly was significantly longer than that of 35 h in the young subjects and there was a correspondingly greater area under the curve in the elderly, by approximately 50%.",A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467132/),h,48,247346,DB01115,Nifedipine
,2467132,terminal elimination half-life,"The terminal elimination half-life of 48 h in the elderly was significantly longer than that of 35 h in the young subjects and there was a correspondingly greater area under the curve in the elderly, by approximately 50%.",A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467132/),h,35,247347,DB01115,Nifedipine
,2600195,elimination half-life,"The mean elimination half-life of nifedipine prolonged significantly following diltiazem (2.54 hours on placebo vs 3.40 hours on 30 mg diltiazem and 3.47 on 90 mg diltiazem, both P less than .01).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),h,2.54,249688,DB01115,Nifedipine
,2600195,elimination half-life,"The mean elimination half-life of nifedipine prolonged significantly following diltiazem (2.54 hours on placebo vs 3.40 hours on 30 mg diltiazem and 3.47 on 90 mg diltiazem, both P less than .01).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),h,3.40,249689,DB01115,Nifedipine
,2600195,elimination half-life,"The mean elimination half-life of nifedipine prolonged significantly following diltiazem (2.54 hours on placebo vs 3.40 hours on 30 mg diltiazem and 3.47 on 90 mg diltiazem, both P less than .01).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),,3.47,249690,DB01115,Nifedipine
,2600195,AUC,"The mean AUC of nifedipine increased during diltiazem (1726.6 nmol X hr/ml on placebo vs 3838.0 on 30 mg diltiazem, and 5370.0 on 90 mg diltiazem, both P less than .05, 30 mg vs 90 mg, 0.1 less than P less than .05).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),[h·nM] / [ml],1726.6,249691,DB01115,Nifedipine
,2600195,AUC,"The mean AUC of nifedipine increased during diltiazem (1726.6 nmol X hr/ml on placebo vs 3838.0 on 30 mg diltiazem, and 5370.0 on 90 mg diltiazem, both P less than .05, 30 mg vs 90 mg, 0.1 less than P less than .05).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),[h·nM] / [ml],3838.0,249692,DB01115,Nifedipine
,2600195,AUC,"The mean AUC of nifedipine increased during diltiazem (1726.6 nmol X hr/ml on placebo vs 3838.0 on 30 mg diltiazem, and 5370.0 on 90 mg diltiazem, both P less than .05, 30 mg vs 90 mg, 0.1 less than P less than .05).",Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600195/),[h·nM] / [ml],5370.0,249693,DB01115,Nifedipine
,8894514,oral clearance,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),[l] / [min],1.5,249747,DB01115,Nifedipine
,8894514,oral clearance,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),[l] / [min],20.9,249748,DB01115,Nifedipine
,8894514,bioavailability,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,41.2,249749,DB01115,Nifedipine
,8894514,bioavailability,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,5.3,249750,DB01115,Nifedipine
,8894514,hepatic extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,47.4,249751,DB01115,Nifedipine
,8894514,hepatic extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,67.4,249752,DB01115,Nifedipine
,8894514,extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,21.8,249753,DB01115,Nifedipine
,8894514,extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,75.8,249754,DB01115,Nifedipine
,3609449,concentration,"Mean nifedipine concentration in the blood peaked at 52.4 ng/ml, 1 h after administration and, after 7 h, was still 14.3 ng/ml which is higher than the minimum plasma concentration required for hypotensive effects to occur.",Rectal administration of nifedipine: haemodynamic effects and pharmacokinetics in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609449/),[ng] / [ml],52.4,251559,DB01115,Nifedipine
,3609449,concentration,"Mean nifedipine concentration in the blood peaked at 52.4 ng/ml, 1 h after administration and, after 7 h, was still 14.3 ng/ml which is higher than the minimum plasma concentration required for hypotensive effects to occur.",Rectal administration of nifedipine: haemodynamic effects and pharmacokinetics in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609449/),ng,14,251560,DB01115,Nifedipine
,25151141,drug-loaded amount,"The drug concentration, drug-loaded amount, and entrapment efficiency of mPEG-b-PCL-nifedipine micelles were (69.39 ± 4.33) μg mL(-1), (3.35 ± 0.21)%, and (8.67 ± 0.54)%, respectively.",Study on the preparation of nifedipine-loaded oral copolymer micelles and its pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25151141/),%,3.35,252141,DB01115,Nifedipine
,25151141,entrapment efficiency,"The drug concentration, drug-loaded amount, and entrapment efficiency of mPEG-b-PCL-nifedipine micelles were (69.39 ± 4.33) μg mL(-1), (3.35 ± 0.21)%, and (8.67 ± 0.54)%, respectively.",Study on the preparation of nifedipine-loaded oral copolymer micelles and its pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25151141/),%,8.67,252142,DB01115,Nifedipine
,25151141,relative bioavailability,"The micelles were globular shaped with a narrow size distribution and a mean diameter of (34.8 ± 3.2) nm, and the relative bioavailability of the micelles we developed was 246.20% when compared with the tablets available in the market.",Study on the preparation of nifedipine-loaded oral copolymer micelles and its pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25151141/),%,246.20,252143,DB01115,Nifedipine
,3987180,elimination t1/2,"After intravenous nifedipine infusion, the elimination t1/2 was 106 +/- 24 minutes in controls and increased gradually across the groups to 230 +/- 94 minutes in the group with severe renal impairment.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),min,106,253059,DB01115,Nifedipine
,3987180,elimination t1/2,"After intravenous nifedipine infusion, the elimination t1/2 was 106 +/- 24 minutes in controls and increased gradually across the groups to 230 +/- 94 minutes in the group with severe renal impairment.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),min,230,253060,DB01115,Nifedipine
,3987180,volume of distribution at steady state,"In these same groups, the volume of distribution at steady state was 0.78 +/- 0.23 and 1.47 +/- 0.24 L/kg, but total systemic clearance did not differ.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),[l] / [kg],0.78,253061,DB01115,Nifedipine
,3987180,volume of distribution at steady state,"In these same groups, the volume of distribution at steady state was 0.78 +/- 0.23 and 1.47 +/- 0.24 L/kg, but total systemic clearance did not differ.",Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987180/),[l] / [kg],1.47,253062,DB01115,Nifedipine
,2792174,systemic clearance,The systemic clearance of nifedipine after a single i.v.-dose was higher in subjects with renal insufficiency (854 ml/min) than in those with normal renal function (468 ml/min).,Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792174/),[ml] / [min],854,253118,DB01115,Nifedipine
,2792174,systemic clearance,The systemic clearance of nifedipine after a single i.v.-dose was higher in subjects with renal insufficiency (854 ml/min) than in those with normal renal function (468 ml/min).,Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792174/),[ml] / [min],468,253119,DB01115,Nifedipine
,2792174,AUC,After the single oral dose the AUC (6100 ng.min.ml-1) and maximum plasma concentration (75.0 ng.,Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792174/),[min·ng] / [ml],6100,253120,DB01115,Nifedipine
,2792174,maximum plasma concentration,After the single oral dose the AUC (6100 ng.min.ml-1) and maximum plasma concentration (75.0 ng.,Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792174/),ng,75.0,253121,DB01115,Nifedipine
,2792174,plasma protein binding,The plasma protein binding of nifedipine averaged 95.5% in normal subjects and 94.8% in patients with renal failure.,Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792174/),%,95.5,253122,DB01115,Nifedipine
,2792174,plasma protein binding,The plasma protein binding of nifedipine averaged 95.5% in normal subjects and 94.8% in patients with renal failure.,Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792174/),%,94.8,253123,DB01115,Nifedipine
> or =,10665942,AUC,An AUC > or = 4158 ng/ml per h was the best predictor for the presence of hypertrichosis.,Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10665942/),[ng] / [h·ml],4158,253196,DB01115,Nifedipine
> or =,10665942,Cmax,A Cmax > or = 878 ng/ml was the best predictor for the appearance of tremor.,Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10665942/),[ng] / [ml],878,253197,DB01115,Nifedipine
,3720176,elimination t1/2,"After intravenous nifedipine patients had a longer elimination t1/2 (420 +/- 254 vs. 111 +/- 22 minutes; P less than 0.01), a greater volume of distribution (1.29 +/- 0.60 vs. 0.97 +/- 0.42 L/kg), and a lower systemic clearance (233 +/- 109 vs. 588 +/- 140 ml/min; P less than 0.001).",Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),min,420,253557,DB01115,Nifedipine
,3720176,elimination t1/2,"After intravenous nifedipine patients had a longer elimination t1/2 (420 +/- 254 vs. 111 +/- 22 minutes; P less than 0.01), a greater volume of distribution (1.29 +/- 0.60 vs. 0.97 +/- 0.42 L/kg), and a lower systemic clearance (233 +/- 109 vs. 588 +/- 140 ml/min; P less than 0.001).",Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),min,111,253558,DB01115,Nifedipine
,3720176,volume of distribution,"After intravenous nifedipine patients had a longer elimination t1/2 (420 +/- 254 vs. 111 +/- 22 minutes; P less than 0.01), a greater volume of distribution (1.29 +/- 0.60 vs. 0.97 +/- 0.42 L/kg), and a lower systemic clearance (233 +/- 109 vs. 588 +/- 140 ml/min; P less than 0.001).",Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),[l] / [kg],1.29,253559,DB01115,Nifedipine
,3720176,volume of distribution,"After intravenous nifedipine patients had a longer elimination t1/2 (420 +/- 254 vs. 111 +/- 22 minutes; P less than 0.01), a greater volume of distribution (1.29 +/- 0.60 vs. 0.97 +/- 0.42 L/kg), and a lower systemic clearance (233 +/- 109 vs. 588 +/- 140 ml/min; P less than 0.001).",Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),[l] / [kg],0.97,253560,DB01115,Nifedipine
,3720176,systemic clearance,"After intravenous nifedipine patients had a longer elimination t1/2 (420 +/- 254 vs. 111 +/- 22 minutes; P less than 0.01), a greater volume of distribution (1.29 +/- 0.60 vs. 0.97 +/- 0.42 L/kg), and a lower systemic clearance (233 +/- 109 vs. 588 +/- 140 ml/min; P less than 0.001).",Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),[ml] / [min],233,253561,DB01115,Nifedipine
,3720176,systemic clearance,"After intravenous nifedipine patients had a longer elimination t1/2 (420 +/- 254 vs. 111 +/- 22 minutes; P less than 0.01), a greater volume of distribution (1.29 +/- 0.60 vs. 0.97 +/- 0.42 L/kg), and a lower systemic clearance (233 +/- 109 vs. 588 +/- 140 ml/min; P less than 0.001).",Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),[ml] / [min],588,253562,DB01115,Nifedipine
,3720176,systemic availability,After oral nifedipine systemic availability was much higher in patients (90.5% +/- 26.2% vs. 51.1% +/- 17.1%; P less than 0.01) and maximal in patients with a portacaval shunt.,Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),%,90.5,253563,DB01115,Nifedipine
,3720176,systemic availability,After oral nifedipine systemic availability was much higher in patients (90.5% +/- 26.2% vs. 51.1% +/- 17.1%; P less than 0.01) and maximal in patients with a portacaval shunt.,Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720176/),%,51.1,253564,DB01115,Nifedipine
,8595082,AUC0- tau ss (T,"The main pharmacokinetic parameters (mean +/- standard deviation) used for the bioequivalence decision at steady state were AUC0- tau ss (T: 351.4 +/- 161.0 ng.ml-1.h; R: 345.5 +/- 146.8 ng.ml-1.h), Cmaxss (T: 67.3 +/- 29.5 ng.ml-1; 66.9 +/- 33.0 ng.",Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595082/),[h·ng] / [ml],351.4,256148,DB01115,Nifedipine
,8595082,R,"The main pharmacokinetic parameters (mean +/- standard deviation) used for the bioequivalence decision at steady state were AUC0- tau ss (T: 351.4 +/- 161.0 ng.ml-1.h; R: 345.5 +/- 146.8 ng.ml-1.h), Cmaxss (T: 67.3 +/- 29.5 ng.ml-1; 66.9 +/- 33.0 ng.",Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595082/),[h·ng] / [ml],345.5,256149,DB01115,Nifedipine
,8595082,Cmaxss (T,"The main pharmacokinetic parameters (mean +/- standard deviation) used for the bioequivalence decision at steady state were AUC0- tau ss (T: 351.4 +/- 161.0 ng.ml-1.h; R: 345.5 +/- 146.8 ng.ml-1.h), Cmaxss (T: 67.3 +/- 29.5 ng.ml-1; 66.9 +/- 33.0 ng.",Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595082/),[ng] / [ml],67.3,256150,DB01115,Nifedipine
,8595082,Cmaxss (T,"The main pharmacokinetic parameters (mean +/- standard deviation) used for the bioequivalence decision at steady state were AUC0- tau ss (T: 351.4 +/- 161.0 ng.ml-1.h; R: 345.5 +/- 146.8 ng.ml-1.h), Cmaxss (T: 67.3 +/- 29.5 ng.ml-1; 66.9 +/- 33.0 ng.",Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595082/),ng,66.9,256151,DB01115,Nifedipine
,8595082,T,ml-1) and HVDss (T: 3.8 +/- 1.3 h; R: 4.2 +/- 1.8 h).,Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595082/),h,3.8,256152,DB01115,Nifedipine
,8595082,R,ml-1) and HVDss (T: 3.8 +/- 1.3 h; R: 4.2 +/- 1.8 h).,Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595082/),h,4.2,256153,DB01115,Nifedipine
,8592872,terminal half-lives,"2. After intravenous dosing, plasma concentrations of barnidipine hydrochloride declined bi-exponentially with the terminal half-lives of 0.6 h in the rat and 4.1 h in the dog.","Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592872/),h,0.6,256342,DB01115,Nifedipine
,8592872,terminal half-lives,"2. After intravenous dosing, plasma concentrations of barnidipine hydrochloride declined bi-exponentially with the terminal half-lives of 0.6 h in the rat and 4.1 h in the dog.","Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592872/),h,4.1,256343,DB01115,Nifedipine
,8592872,blood clearance,"The blood clearance was 5.2 l/h/kg in the rat and 3.3 l/h/kg in the dog, and was comparable with hepatic blood flow in both species.","Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592872/),[l] / [h·kg],5.2,256344,DB01115,Nifedipine
,8592872,blood clearance,"The blood clearance was 5.2 l/h/kg in the rat and 3.3 l/h/kg in the dog, and was comparable with hepatic blood flow in both species.","Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592872/),[l] / [h·kg],3.3,256345,DB01115,Nifedipine
,8592872,absolute bioavailability,"4. The absolute bioavailability was low (11-18% in the rat and 6-9% in the dog), suggesting a marked first-pass metabolism.","Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592872/),%,11-18,256346,DB01115,Nifedipine
,8592872,absolute bioavailability,"4. The absolute bioavailability was low (11-18% in the rat and 6-9% in the dog), suggesting a marked first-pass metabolism.","Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592872/),%,6-9,256347,DB01115,Nifedipine
,3437063,elimination half-life,There was a fourfold increase in the elimination half-life (434 +/- 74 minutes in the cirrhotics compared with 102 +/- 11 minutes in the healthy subjects).,Pharmacokinetics of nifedipine after oral administration in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437063/),min,434,256819,DB01115,Nifedipine
,3437063,elimination half-life,There was a fourfold increase in the elimination half-life (434 +/- 74 minutes in the cirrhotics compared with 102 +/- 11 minutes in the healthy subjects).,Pharmacokinetics of nifedipine after oral administration in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3437063/),min,102,256820,DB01115,Nifedipine
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,40 to 60,259217,DB01115,Nifedipine
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,10-20,259218,DB01115,Nifedipine
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,15-30,259219,DB01115,Nifedipine
,3937500,volumes of distribution,"Protein binding is high but does not interfere in the distribution; the volumes of distribution of bepridil, diltiazem and verapamil are large (4-5 l/kg); those of nifedipine and nicardipine are smaller (l l/kg).",[Clinical pharmacology of calcium inhibitors]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),[l] / [kg],4-5,259220,DB01115,Nifedipine
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),h,1 to 5,259221,DB01115,Nifedipine
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),d,2 to 3,259222,DB01115,Nifedipine
,3707812,apparent t1/2,The geometric mean apparent t1/2 for the slow release preparation was 6.3 +/- 2.0 h.,The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707812/),h,6.3,259726,DB01115,Nifedipine
,3707812,bioavailability,"In the six volunteers, the mean bioavailability was 46% (range 29-86%), the mean CL was 588.0 +/- 67.1 ml min-1, the mean apparent V was 160.1 +/- 61.7 l.",The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707812/),%,46,259727,DB01115,Nifedipine
,3707812,CL,"In the six volunteers, the mean bioavailability was 46% (range 29-86%), the mean CL was 588.0 +/- 67.1 ml min-1, the mean apparent V was 160.1 +/- 61.7 l.",The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707812/),[ml] / [min],588.0,259728,DB01115,Nifedipine
,3707812,apparent V,"In the six volunteers, the mean bioavailability was 46% (range 29-86%), the mean CL was 588.0 +/- 67.1 ml min-1, the mean apparent V was 160.1 +/- 61.7 l.",The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3707812/),l,160.1,259729,DB01115,Nifedipine
,8824695,maximum plasma concentration (Cmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),[ng] / [ml],8.0,260580,DB01115,Nifedipine
,8824695,maximum plasma concentration (Cmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),[ng] / [ml],4.8,260581,DB01115,Nifedipine
,8824695,time to reach maximal concentration (tmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),min,45,260582,DB01115,Nifedipine
,8824695,time to reach maximal concentration (tmax),"When compared with Caucasians, Southern Asians achieved higher maximum plasma concentration (Cmax) (8.0 +/- 2.6 vs 4.8 +/- 1.9 ng ml-1; the 95% confidence interval (CI) of the mean difference was 0.76 to 5.7; P < 0.01) and had a shorter time to reach maximal concentration (tmax) (45 min (range 30-75) vs 90 min (range 60-145); the 95% CI of the mean difference was -69 to -20; P < 0.002).",Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824695/),min,90,260583,DB01115,Nifedipine
,6527979,Bioavailability,Bioavailability ranged from 15-45% approximately over the dose range 10-40 mg.,Pharmacokinetics of nicardipine following oral and intravenous administration in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527979/),%,15-45,261771,DB01115,Nifedipine
,2435999,total systemic plasma clearance,"At the first intravenous nifedipine infusion a total systemic plasma clearance of 671 +/- 240 ml/min (mean +/- SD), an elimination half-life of 95 +/- 36 min, and a volume of distribution of 60.2 +/- 11.9 L were found.",Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),[ml] / [min],671,263636,DB01115,Nifedipine
,2435999,elimination half-life,"At the first intravenous nifedipine infusion a total systemic plasma clearance of 671 +/- 240 ml/min (mean +/- SD), an elimination half-life of 95 +/- 36 min, and a volume of distribution of 60.2 +/- 11.9 L were found.",Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),min,95,263637,DB01115,Nifedipine
,2435999,volume of distribution,"At the first intravenous nifedipine infusion a total systemic plasma clearance of 671 +/- 240 ml/min (mean +/- SD), an elimination half-life of 95 +/- 36 min, and a volume of distribution of 60.2 +/- 11.9 L were found.",Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),l,60.2,263638,DB01115,Nifedipine
,2435999,Protein unbound fraction,Protein unbound fraction of nifedipine amounted to 4.6 +/- 0.3%.,Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),%,4.6,263639,DB01115,Nifedipine
,2435999,plasma half-life,During oral nifedipine treatment the mean plasma half-life was 5.8 +/- 1.0 h; trough concentration was 11.3 +/- 4.1 ng/ml and peak concentrations were 36.8 +/- 14.3 ng/ml.,Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),h,5.8,263640,DB01115,Nifedipine
,2435999,trough concentration,During oral nifedipine treatment the mean plasma half-life was 5.8 +/- 1.0 h; trough concentration was 11.3 +/- 4.1 ng/ml and peak concentrations were 36.8 +/- 14.3 ng/ml.,Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),[ng] / [ml],11.3,263641,DB01115,Nifedipine
,2435999,peak concentrations,During oral nifedipine treatment the mean plasma half-life was 5.8 +/- 1.0 h; trough concentration was 11.3 +/- 4.1 ng/ml and peak concentrations were 36.8 +/- 14.3 ng/ml.,Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2435999/),[ng] / [ml],36.8,263642,DB01115,Nifedipine
,22886904,flow rate,"The chromatographic resolution was achieved on a Hypurity Advance C(18) column using an isocratic mobile phase consisting of 5 mm ammonium acetate-acetonitrile (15:85, v/v) at flow rate of 1.0 mL/min.",Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22886904/),[ml] / [min],1.0,264261,DB01115,Nifedipine
,22886904,total run time of analysis,"The total run time of analysis was 2 min and elution of NF, AT and IS occurred at 0.79, 1.04 and 0.76 min, respectively.",Sensitive LC-MS/MS-ESI method for simultaneous determination of nifedipine and atenolol in human plasma and its application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22886904/),min,2,264262,DB01115,Nifedipine
,4017422,time to peak concentration,"Given as an oral solution, felodipine is rapidly (mean time to peak concentration 64 minutes; range 30 to 90 minutes) and completely absorbed.",Felodipine kinetics in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),min,64,264399,DB01115,Nifedipine
,4017422,t1/2,"The t1/2 for the initial phase was 6.4 minutes (range 1.7 to 10.4 minutes) and felodipine was distributed to a volume of 0.6 L/kg (range 0.4 to 0.9 L/kg), which approximately corresponds to the total body water.",Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),min,6.4,264400,DB01115,Nifedipine
,4017422,volume,"The t1/2 for the initial phase was 6.4 minutes (range 1.7 to 10.4 minutes) and felodipine was distributed to a volume of 0.6 L/kg (range 0.4 to 0.9 L/kg), which approximately corresponds to the total body water.",Felodipine kinetics in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),[l] / [kg],0.6,264401,DB01115,Nifedipine
,4017422,t1/2,The second distribution phase reached pseudoequilibrium with a t1/2 of 1.6 hours (range 1.3 to 2.2 hours).,Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,1.6,264402,DB01115,Nifedipine
,4017422,volume of distribution,The volume of distribution at the end of this phase was 9.7 L/kg (range 6.0 to 18.2 L/kg).,Felodipine kinetics in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),[l] / [kg],9.7,264403,DB01115,Nifedipine
,4017422,terminal,The terminal phase had t1/2 of 10.2 hours (range 6.7 to 20.7 hours).,Felodipine kinetics in healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,10.2,264404,DB01115,Nifedipine
,4017422,t1/2,The terminal phase had t1/2 of 10.2 hours (range 6.7 to 20.7 hours).,Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,10.2,264405,DB01115,Nifedipine
,4017422,Total body clearance,Total body clearance of felodipine was 1.2 L/min (range 0.9 to 1.6 L/min).,Felodipine kinetics in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),[l] / [min],1.2,264406,DB01115,Nifedipine
,4017422,t1/2,"The rate of excretion by the kidneys had a biphasic pattern, with t1/2 values of 4 and 18 hours.",Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,4,264407,DB01115,Nifedipine
,4017422,t1/2,"The rate of excretion by the kidneys had a biphasic pattern, with t1/2 values of 4 and 18 hours.",Felodipine kinetics in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017422/),h,18,264408,DB01115,Nifedipine
,2900404,oral bioavailability,"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,15,266162,DB01115,Nifedipine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],1.6,266163,DB01115,Nifedipine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],8.9,266164,DB01115,Nifedipine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],2.0,266165,DB01115,Nifedipine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],30.0,266166,DB01115,Nifedipine
,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,6.6,266167,DB01115,Nifedipine
less,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,1,266168,DB01115,Nifedipine
,2943898,elimination half-life,"One compound, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5- methoxycarbonyl-6-methyl-1,4-dihydropyridine (17, amlodipine) was found to be comparable in potency to nifedipine and to have an elimination half-life of 30 h in dogs.",Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943898/),h,30,268060,DB01115,Nifedipine
,2943898,Oral bioavailability,"Oral bioavailability approached 100%, and hemodynamic responses were gradual in onset and long-lasting in effect.",Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2943898/),%,100,268061,DB01115,Nifedipine
,11923060,ratio of C(max),The mean ratio of C(max) was 235% comparing CORAL with Adalat OROS under these conditions.,Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11923060/),,235,269602,DB01115,Nifedipine
,21495269,flow rate,"The mobile phase was consisted of acetonitrile-5 mM ammonium acetate (52:48, v/v), delivered at flow rate of 1 mL/min.",Bioequivalence of nifedipine softgel and capsule in healthy Chinese volunteers by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21495269/),[ml] / [min],1,271762,DB01115,Nifedipine
,4041333,peak plasma concentrations,"In eight patients, during the interdialytic period, peak plasma concentrations of nifedipine (29-332 ng/ml) were reached 0.5-1.0 h after administration of a single 10 mg oral dose.",Haemodialysis does not affect the pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),[ng] / [ml],29-332,273989,DB01115,Nifedipine
,4041333,Elimination half-life,Elimination half-life and oral plasma clearance were respectively 2.6 +/- 0.5 h and 1 176 +/- 412 ml/min.,Haemodialysis does not affect the pharmacokinetics of nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),h,2.6,273990,DB01115,Nifedipine
,4041333,oral plasma clearance,Elimination half-life and oral plasma clearance were respectively 2.6 +/- 0.5 h and 1 176 +/- 412 ml/min.,Haemodialysis does not affect the pharmacokinetics of nifedipine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),[ml] / [min],1 176,273991,DB01115,Nifedipine
,4041333,plasma protein binding,Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/- 0.3% vs 94.4 +/- 0.1%) but not affected by haemodialysis.,Haemodialysis does not affect the pharmacokinetics of nifedipine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),%,88.8,273992,DB01115,Nifedipine
,4041333,plasma protein binding,Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/- 0.3% vs 94.4 +/- 0.1%) but not affected by haemodialysis.,Haemodialysis does not affect the pharmacokinetics of nifedipine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),%,94.4,273993,DB01115,Nifedipine
,4041333,extraction ratio,Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/- 0.8% and 2.8 +/- 0.9 ml/min.,Haemodialysis does not affect the pharmacokinetics of nifedipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),%,2.3,273994,DB01115,Nifedipine
,4041333,clearance,Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/- 0.8% and 2.8 +/- 0.9 ml/min.,Haemodialysis does not affect the pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041333/),[ml] / [min],2.8,273995,DB01115,Nifedipine
